var title_f39_21_40272="Pathologic skin picking face";
var content_f39_21_40272=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F66802&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F66802&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 488px\">",
"   <div class=\"ttl\">",
"    Psychogenic excoriations of the face",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 468px; height: 296px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Excoriations and sharply demarcated superficial ulcerations on the face of a woman with pathologic skin picking.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f39_21_40272=[""].join("\n");
var outline_f39_21_40272=null;
var title_f39_21_40273="Diascopy";
var content_f39_21_40273=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ALLRG%2F60497&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ALLRG%2F60497&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Diascopy of urticarial vasculitis skin lesion",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 357px; height: 540px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    (1) Lesion of urticarial vasculitis on the neck. (2) Diascopy causes erythematous halo to disappear, revealing clinically inapparent purpura.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Dahl MV. Clinical pearl: diascopy helps diagnose urticarial vasculitis. J Am Acad Dermatol 1994; 30:481. Copyright &copy; 1994 American Academy of Dermatology.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f39_21_40273=[""].join("\n");
var outline_f39_21_40273=null;
var title_f39_21_40274="Necrobiosis lipoidica 3";
var content_f39_21_40274=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F63574&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F63574&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Necrobiosis lipoidica",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 420px; height: 365px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Yellow-red or yellow-brown plaques with atrophy and telangiectasias are consistent with necrobiosis lipoidica.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Berg, D, Worzala, K. Atlas of Adult Physical Diagnosis. Lippincott Williams &amp; Wilkins, Philadelphia 2006. Copyright &copy; 2006 Lippincott Williams &amp; Wilkins.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f39_21_40274=[""].join("\n");
var outline_f39_21_40274=null;
var title_f39_21_40275="Lindane: Pediatric drug information";
var content_f39_21_40275=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Lindane: Pediatric drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_general\" href=\"mobipreview.htm?36/34/37412?source=see_link\">",
"    see \"Lindane: Drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_patient\" href=\"mobipreview.htm?36/37/37461?source=see_link\">",
"    see \"Lindane: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"block black-box-warn drugH1Div\" id=\"F5709012\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     ALERT: U.S. Boxed Warning",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     The FDA-approved labeling includes a boxed warning. See Warnings/Precautions section for a concise summary of this information.  For verbatim wording of the boxed warning, consult the product labeling or",
"     <a href=\"file://www.fda.gov\" target=\"_blank\">",
"      www.fda.gov",
"     </a>",
"     .",
"    </p>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F188883\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Hexit&trade;;",
"     </li>",
"     <li>",
"      PMS-Lindane",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list_set htclist drugH1Div drugBrandNames\" id=\"F1048263\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Therapeutic Category",
"    </span>",
"    <ul>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Antiparasitic Agent, Topical",
"      </span>",
"     </li>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Pediculocide",
"      </span>",
"     </li>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Scabicidal Agent",
"      </span>",
"     </li>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Shampoos",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block dos drugH1Div\" id=\"F1048258\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Usual",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?36/34/37412?source=see_link\">",
"      see \"Lindane: Drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Children and Adults: Topical:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Pediculosis: 15-30 mL of shampoo is applied and lathered for 4 minutes; in children 6 years: &le;30 mL is sufficient volume for one application; in older pediatric patients and adults: ~30-60 mL is sufficient volume for one application (maximum dose: 60 mL); rinse hair thoroughly and comb with a fine tooth comb to remove nits; repeat treatment in 7 days if lice or nits are still present",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Pediculosis of the eyelashes: Do not treat with lindane; instead, apply an occlusive ophthalmic ointment like petrolatum to the eyelid margins twice daily for 10 days",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Scabies: Apply a thin layer of lotion and massage it on skin from the neck to the toes (head to toe in infants).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Infants: Wash off 6 hours after application",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Children: Wash off 6-8 hours after application",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Adults: Bathe and remove drug 8-12 hours after application",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <b>",
"      Do not reapply sooner than 1 week later if live mites appear",
"     </b>",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F188864\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Lotion, topical: 1% (60 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Shampoo, topical: 1% (60 mL)",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F188850\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes",
"    </p>",
"   </div>",
"   <div class=\"block meg drugH1Div\" id=\"F7874687\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Guide",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     An FDA-approved patient medication guide, which is available with the product information and as follows, must be dispensed with this medication:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;\">",
"     Lindane lotion:",
"     <a href=\"file://www.fda.gov/downloads/Drugs/DrugSafety/UCM133687.pdf\" target=\"_blank\">",
"      file://www.fda.gov/downloads/Drugs/DrugSafety/UCM133687.pdf",
"     </a>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Lindane shampoo:",
"     <a href=\"file://www.fda.gov/downloads/Drugs/DrugSafety/UCM133688.pdf\" target=\"_blank\">",
"      file://www.fda.gov/downloads/Drugs/DrugSafety/UCM133688.pdf",
"     </a>",
"     .",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F1048266\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     For topical use only; do not apply to face; avoid getting in eyes; do",
"     <b>",
"      not",
"     </b>",
"     apply lotion immediately after a hot, soapy bath; lotion should be applied to dry, cool skin",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Before applying lindane shampoo, wash hair with a plain shampoo, then dry",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F1048265\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Alternative treatment of scabies (",
"     <i>",
"      Sarcoptes scabiei",
"     </i>",
"     ),",
"     <i>",
"      Pediculus capitis",
"     </i>",
"     (head lice), and",
"     <i>",
"      Pediculus pubis",
"     </i>",
"     (crab lice); (the AAP and CDC consider permethrin 5% to be the scabicide of choice due to its safety and efficacy profile; many clinicians no longer recommend lindane as initial therapy for pediculosis due to reports of resistance and neurotoxicity)",
"    </p>",
"   </div>",
"   <div class=\"block arm drugH1Div\" id=\"F188922\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Cardiovascular: Cardiac arrhythmia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Central nervous system: Ataxia, dizziness, headache, pain, restlessness, seizure",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Dermatologic: Alopecia, contact dermatitis, eczematous eruptions, pruritus, skin and adipose tissue may act as repositories, urticaria",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Gastrointestinal: Nausea, vomiting",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Hematologic: Aplastic anemia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Hepatic: Hepatitis",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Local: Burning, stinging",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Paresthesia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Renal: Hematuria",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Respiratory: Pulmonary edema",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F1048269\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to lindane or any component; premature neonates; pregnant or lactating women; acutely inflamed skin or raw, weeping surfaces",
"    </p>",
"   </div>",
"   <div class=\"block pre drugH1Div\" id=\"F1048257\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Precautions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Cover hands to prevent accidental lindane ingestion from thumbsucking;",
"     <b>",
"      consider alternative therapy for the treatment of scabies in infants and young children &lt;2 years of age (ie, permethrin)",
"     </b>",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F1048256\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hazardous agent; use appropriate precautions for handling and disposal. May be associated with severe neurologic toxicities (contraindicated in premature infants and uncontrolled seizure disorders)",
"     <b>",
"      [U.S. Boxed Warning]",
"     </b>",
"     . Seizures and death have been reported with use; use with caution in infants, small children, patients &lt;50 kg, or patients with a history of seizures; use caution with conditions which may increase risk of seizures or medications which decrease seizure threshold. Avoid contact with the face, eyes, mucous membranes, and urethral meatus.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13299605\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F188859\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:0em;display:inline\">",
"     There are no known significant interactions.",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F188860\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F188872\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     There are no well-controlled studies in pregnant women.",
"    </p>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F1048255\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Directly absorbed by parasites and ova through the exoskeleton; stimulates the nervous system resulting in seizures and death of parasitic arthropods",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F1048268\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacokinetics (Adult data unless noted)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Absorption: Topical: Up to 13% absorbed systemically (absorption is greater when applied to damaged skin, face, scalp, neck, or scrotum)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Distribution: Stored in body fat and accumulates in the brain; skin and adipose tissue may act as repositories",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Metabolism: By the liver",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life, children: 17-22 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Time to peak serum concentration: Children: Topical: 6 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Elimination: In urine and feces",
"    </p>",
"   </div>",
"   <div class=\"block pai drugH1Div\" id=\"F1048261\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Patient Information",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_patient\" href=\"mobipreview.htm?36/37/37461?source=see_link\">",
"      see \"Lindane: Patient drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Read the patient Medication Guide that you receive with each prescription and refill of lindane. Clothing and bedding should be washed in hot water or by dry cleaning to kill the scabies mite; combs and brushes may be washed with lindane shampoo then thoroughly rinsed with water",
"    </p>",
"   </div>",
"   <div class=\"block adi drugH1Div\" id=\"F1048270\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Additional Information",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excessive absorption may result in overdose with signs and symptoms which include nausea, vomiting, seizures, headaches, arrhythmias, apnea, pulmonary edema, hematuria, hepatitis, coma, and even death",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Eichenfield LF, Honig PJ, &ldquo;Blistering Disorders in Childhood,&rdquo;",
"      <i>",
"       Pediatr Clin North Am",
"      </i>",
"      , 1991, 38(4):959-76.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?39/21/40275/abstract-text/1651468/pubmed\" id=\"1651468\" target=\"_blank\">",
"        1651468",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Hogan DJ, Schachner L, Tanglertsampan C, &ldquo;Diagnosis and Treatment of Childhood Scabies and Pediculosis,&rdquo;",
"      <i>",
"       Pediatr Clin North Am",
"      </i>",
"      , 1991, 38(4):941-57.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?39/21/40275/abstract-text/1870912 /pubmed\" id=\"1870912 \" target=\"_blank\">",
"        1870912",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Pramanik AK and Hansen RC, &ldquo;Transcutaneous Gamma Benzene Hexachloride Absorption and Toxicity in Infants and Children,&rdquo;",
"      <i>",
"       Arch Dermatol",
"      </i>",
"      , 1979, 115(10):1224-5.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?39/21/40275/abstract-text/92217/pubmed\" id=\"92217\" target=\"_blank\">",
"        92217",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 12554 Version 33.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1002-61.234.146.186-2A6F391156-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f39_21_40275=[""].join("\n");
var outline_f39_21_40275=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5709012\">",
"      ALERT: U.S. Boxed Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F188883\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1048263\">",
"      Therapeutic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1048258\">",
"      Dosing: Usual",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F188864\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F188850\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7874687\">",
"      Medication Guide",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1048266\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1048265\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F188922\">",
"      Adverse Reactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1048269\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1048257\">",
"      Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1048256\">",
"      Warnings",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13299605\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F188859\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F188860\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F188872\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1048255\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1048268\">",
"      Pharmacokinetics (Adult data unless noted)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1048261\">",
"      Patient Information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1048270\">",
"      Additional Information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_PED/12554\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_PED/12554|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?36/34/37412?source=related_link\">",
"      Lindane: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"mobipreview.htm?36/37/37461?source=related_link\">",
"      Lindane: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f39_21_40276="Senna: Drug information";
var content_f39_21_40276=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Senna: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"mobipreview.htm?27/51/28468?source=see_link\">",
"    see \"Senna: Patient drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?41/1/42003?source=see_link\">",
"    see \"Senna: Pediatric drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F220473\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Black Draught&reg; [OTC];",
"     </li>",
"     <li>",
"      Evac-U-Gen&reg; [OTC];",
"     </li>",
"     <li>",
"      ex-lax&reg; Maximum Strength [OTC];",
"     </li>",
"     <li>",
"      ex-lax&reg; [OTC];",
"     </li>",
"     <li>",
"      Fleet&reg; Pedia-Lax&trade; Quick Dissolve [OTC];",
"     </li>",
"     <li>",
"      Fletcher's&reg; [OTC];",
"     </li>",
"     <li>",
"      Geri-kot [OTC];",
"     </li>",
"     <li>",
"      Little Tummys&reg; Laxative [OTC];",
"     </li>",
"     <li>",
"      Perdiem&reg; Overnight Relief [OTC];",
"     </li>",
"     <li>",
"      Senexon&reg; [OTC];",
"     </li>",
"     <li>",
"      Senna-Lax [OTC];",
"     </li>",
"     <li>",
"      SennaGen [OTC];",
"     </li>",
"     <li>",
"      Senokot&reg; [OTC]",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F220481\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Laxative, Stimulant",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F220474\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Bowel evacuation:",
"     </b>",
"     Oral: OTC labeling: Usual dose: Sennosides 130 mg between 2-4 PM the afternoon of the day prior to procedure",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Constipation:",
"     </b>",
"     Oral: OTC ranges: Sennosides 15 mg once daily (maximum: 70-100 mg/day, divided twice daily)",
"    </p>",
"   </div>",
"   <div class=\"block dop drugH1Div\" id=\"F220478\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Pediatric",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?41/1/42003?source=see_link\">",
"      see \"Senna: Pediatric drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Bowel evacuation:",
"     </b>",
"     OTC labeling: Children &ge;12 years: Refer to adult dosing.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Constipation:",
"     </b>",
"     OTC ranges: Children:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     2-6 years:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     <i>",
"      Sennosides:",
"     </i>",
"     Initial: 3.75 mg once daily (maximum: 15 mg/day, divided twice daily)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     <i>",
"      Senna concentrate:",
"     </i>",
"     33.3 mg/mL: 5-10 mL up to twice daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     6-12 years:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     <i>",
"      Sennosides:",
"     </i>",
"     Initial:  8.6 mg once daily  (maximum: 50 mg/day, divided twice daily)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     <i>",
"      Senna concentrate:",
"     </i>",
"     33.3 mg/mL: 10-30 mL up to twice daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &ge;12 years: Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F220475\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F220464\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.  [DSC] = Discontinued product",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Liquid, oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Senexon&reg;: Sennosides 8.8 mg/5 mL (237 mL) [contains propylene glycol; chocolate flavor]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Liquid, oral [concentrate]:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Fletcher's&reg;: Senna concentrate 33.3 mg/mL (75 mL) [ethanol free; contains sodium benzoate; rootbeer flavor]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Liquid, oral [concentrate/drops]:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Little Tummys&reg; Laxative: Sennosides 8.8 mg/mL (30 mL) [dye free, ethanol free; contains propylene glycol, soya lecithin; chocolate flavor]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Strip, orally disintegrating, oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Fleet&reg; Pedia-Lax&trade; Quick Dissolve: Sennosides 8.6 mg (12s) [grape flavor]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Syrup, oral: Sennosides 8.8 mg/5 mL (237 mL, 240 mL [DSC])",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, oral: Sennosides 8.6 mg, Sennosides 15 mg, Sennosides 25 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     ex-lax&reg;: Sennosides USP 15 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     ex-lax&reg; Maximum Strength: Sennosides USP 25 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Geri-kot: Sennosides 8.6 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Perdiem&reg; Overnight Relief: Sennosides USP 15 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Senexon&reg;: Sennosides 8.6 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Senna-Lax: Sennosides 8.6 mg [contains calcium 50 mg/tablet]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     SennaGen: Sennosides 8.6 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Senokot&reg;: Sennosides 8.6 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, chewable, oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Black Draught&reg;: Sennosides 10 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Evac-U-Gen&reg;: Sennosides 10 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     ex-lax&reg;: Sennosides USP 15 mg [chocolate flavor]",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F220454\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F220467\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Oral: Once daily doses should be taken at bedtime. Granules may be eaten plain, sprinkled on food, or mixed in liquids",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F220465\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Short-term treatment of constipation; evacuate the colon for bowel or rectal examinations",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F220487\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Perdiem&reg; may be confused with Pyridium&reg;",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Senexon&reg; may be confused with Cenestin&reg;",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Senokot&reg; may be confused with Depakote&reg;",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F220479\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Frequency not defined: Abdominal cramps, diarrhea, nausea, vomiting",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F220469\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Per Commission E: Intestinal obstruction, acute intestinal inflammation (eg, Crohn's disease), colitis ulcerosa, appendicitis, abdominal pain of unknown origin",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F220457\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Other warnings/precautions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Self-medication (OTC use): Not recommended for use in patients experiencing stomach pain, nausea, vomiting, or a sudden change in bowel movements which lasts &gt;2 weeks. Not recommended for OTC use in children &lt;2 years of age.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13300035\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F6222897\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:0em;display:inline\">",
"     There are no known significant interactions.",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F14079765\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;\">",
"     An increased risk of congenital abnormalities was not observed following maternal use of senna during pregnancy (Acs, 2009). Short-term use of senna is generally considered safe during pregnancy (Mahadevan, 2006).",
"    </p>",
"   </div>",
"   <div class=\"block brc drugH1Div\" id=\"F14079766\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Breast-Feeding Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Maternal use of senna is considered compatible with breast-feeding (Mahadevan, 2006).",
"    </p>",
"   </div>",
"   <div class=\"block dic drugH1Div\" id=\"F220471\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dietary Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Liquid may be administered with fruit juice or milk to mask taste.",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F6487656\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Capsules",
"     </b>",
"     (Senna Prompt Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     9-500 mg (90): $9.30",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Chewable",
"     </b>",
"     (Black Draught Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     10 mg (30): $9.60",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Chewable",
"     </b>",
"     (Ex-Lax Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     15 mg (24): $4.07",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Syrup",
"     </b>",
"     (Senna Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     176 mg/5 mL (15 mL): $1.90",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (Evac-U-Gen Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     8.6 mg (80): $16.63",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (Ex-Lax Maximum Strength Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     25 mg (24): $5.33",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (Ex-Lax Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     15 mg (8): $1.98",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (Perdiem Overnight Relief Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     15 mg (60): $8.78",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (Senna Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     187 mg (100): $3.84",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (SennaCon Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     8.6 mg (100): $1.44",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (Senokot Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     8.6 mg (100): $21.04",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (Senokot To Go Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     8.6 mg (4): $1.18",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (Senokot XTRA Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     17.2 mg (12): $5.56",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F5539927\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Agiolax (MX);",
"     </li>",
"     <li>",
"      Bekunis (GR);",
"     </li>",
"     <li>",
"      Bekunis Krauter (DE);",
"     </li>",
"     <li>",
"      Bekunis Senna (AU);",
"     </li>",
"     <li>",
"      Sennalax (ZA);",
"     </li>",
"     <li>",
"      Senokot (GB, HK, IE, PH, SG)",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Acs N, B&aacute;nhidy F, Puh&oacute; EH, et al, \"Senna Treatment in Pregnant Women and Congenital Abnormalities in Their Offspring - A Population-Based Case-Control Study,\"",
"      <i>",
"       Reprod Toxicol",
"      </i>",
"      , 2009, 28(1):100-4.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?39/21/40276/abstract-text/19491001/pubmed\" id=\"19491001\" target=\"_blank\">",
"        19491001",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Mahadevan U and Kane S, \"American Gastroenterological Association Institute Medical Position Statement on the Use of Gastrointestinal Medications in Pregnancy,\"",
"      <i>",
"       Gastroenterology",
"      </i>",
"      , 2006, 131(1):278-82.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?39/21/40276/abstract-text/16831610/pubmed\" id=\"16831610\" target=\"_blank\">",
"        16831610",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 10260 Version 34.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-61.55.141.10-6DAE62D42F-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f39_21_40276=[""].join("\n");
var outline_f39_21_40276=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F220473\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F220481\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F220474\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F220478\">",
"      Dosing: Pediatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F220475\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F220464\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F220454\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F220467\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F220465\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F220487\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F220479\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F220469\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F220457\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13300035\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6222897\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14079765\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14079766\">",
"      Breast-Feeding Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F220471\">",
"      Dietary Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6487656\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5539927\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/10260\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/10260|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"mobipreview.htm?27/51/28468?source=related_link\">",
"      Senna: Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?41/1/42003?source=related_link\">",
"      Senna: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f39_21_40277="Adenocarcinoma colon Endosc";
var content_f39_21_40277=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F74346&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=4\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F74346&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=4\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic2\" style=\"width: 1146px;\">",
"  <div class=\"figure\" style=\"width: 576px\">",
"   <div class=\"ttl\">",
"    Adenocarcinoma of the colon",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 556px; height: 183px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Adenocarcinoma of the colon may have a variety of appearances on endoscopy. Panel A: a typical exophytic mass; Panel B: a friable polypoid mass; Panel C: circumferential adenocarcinoma.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of James B McGee, MD.",
"    </div>",
"   </div>",
"  </div>",
"  <div class=\"figure\" style=\"width: 450px\">",
"   <div class=\"ttl\">",
"    Normal sigmoid colon",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 216px; height: 216px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Endoscopic appearance of the normal sigmoid colonic mucosa. The fine vasculature is easily visible, and the surface is shiny and smooth. The folds are of normal thickness.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of James B McGee, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f39_21_40277=[""].join("\n");
var outline_f39_21_40277=null;
var title_f39_21_40278="Placenta adherens and trapped placenta";
var content_f39_21_40278=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F65797&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F65797&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 558px\">",
"   <div class=\"ttl\">",
"    Placenta adherens and trapped placenta",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 538px; height: 639px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Ultrasound pictures (sagital midline view) of placenta adherens and a trapped placenta.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f39_21_40278=[""].join("\n");
var outline_f39_21_40278=null;
var title_f39_21_40279="Isoniazid: Drug information";
var content_f39_21_40279=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Isoniazid: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"mobipreview.htm?8/5/8277?source=see_link\">",
"    see \"Isoniazid: Patient drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?37/24/38278?source=see_link\">",
"    see \"Isoniazid: Pediatric drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"block black-box-warn drugH1Div\" id=\"F5708956\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     ALERT: U.S. Boxed Warning",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     The FDA-approved labeling includes a boxed warning. See Warnings/Precautions section for a concise summary of this information.  For verbatim wording of the boxed warning, consult the product labeling or",
"     <a href=\"file://www.fda.gov\" target=\"_blank\">",
"      www.fda.gov",
"     </a>",
"     .",
"    </p>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F184784\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Isotamine&reg;;",
"     </li>",
"     <li>",
"      PMS-Isoniazid",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F184824\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Antitubercular Agent",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F184787\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Recommendations often change due to resistant strains and newly-developed information; consult",
"     <i>",
"      MMWR",
"     </i>",
"     for current CDC recommendations. Intramuscular injection is available for patients who are unable to either take or absorb oral therapy.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Nontuberculous mycobacterium",
"     </b>",
"     <b>",
"      <i>",
"       (M. kansasii)",
"      </i>",
"     </b>",
"     <b>",
"      (unlabeled use):",
"     </b>",
"     Oral, I.M.: 5 mg/kg/day (maximum: 300 mg/day) for duration to include 12 months of culture-negative sputum; typically used in combination with ethambutol and rifampin",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Treatment of latent tuberculosis infection (LTBI):",
"     </b>",
"     Oral, I.M.: CDC recommendations: 5 mg/kg (maximum: 300 mg/dose) once daily or 15 mg/kg (maximum: 900 mg/dose) twice weekly by directly observed therapy (DOT) for 6-9 months in patients who do not have HIV infection (9 months is optimal, 6 months may be considered to reduce costs of therapy) and 9 months in patients who have HIV infection. Extend to 12 months of therapy if interruptions in treatment occur (",
"     <i>",
"      MMWR",
"     </i>",
"     , 2000).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Treatment of active TB infection (drug susceptible):",
"     </b>",
"     Oral, I.M.:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Daily therapy: CDC recommendations: 5 mg/kg/day once daily (usual dose: 300 mg/day) (",
"     <i>",
"      MMWR",
"     </i>",
"     , 2003)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Directly observed therapy (DOT): CDC recommendations: 15 mg/kg (maximum: 900 mg/dose) twice weekly or 3 times/week;",
"     <b>",
"      Note:",
"     </b>",
"     CDC guidelines state that once-weekly therapy (15 mg/kg/dose) may be considered, but only after the first 2 months of initial therapy in HIV-negative patients, and only in combination with rifapentine (",
"     <i>",
"      MMWR",
"     </i>",
"     , 2003).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Note:",
"     </b>",
"     Treatment may be defined by the number of doses administered (eg, &ldquo;six-month&rdquo; therapy involves 182 doses of INH and rifampin, and 56 doses of pyrazinamide). Six months is the shortest interval of time over which these doses may be administered, assuming no interruption of therapy.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Note:",
"     </b>",
"     Concomitant administration of 10-50 mg/day pyridoxine is recommended in malnourished patients or those prone to neuropathy (eg, alcoholics, patients with diabetes)",
"    </p>",
"   </div>",
"   <div class=\"block dop drugH1Div\" id=\"F184805\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Pediatric",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?37/24/38278?source=see_link\">",
"      see \"Isoniazid: Pediatric drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Recommendations often change due to resistant strains and newly-developed information; consult",
"     <i>",
"      MMWR",
"     </i>",
"     for current CDC recommendations. Intramuscular injection is available for patients who are unable to either take or absorb oral therapy.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Treatment of latent TB infection (LTBI):",
"     </b>",
"     Infants and Children: Oral, I.M.:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Daily therapy: CDC recommendations: 10-20 mg/kg/day once daily (maximum: 300 mg/dose) (",
"     <i>",
"      MMWR",
"     </i>",
"     , 2000); Manufacturer&rsquo;s labeling: 10 mg/kg/day once daily (maximum: 300 mg/dose)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Directly observed therapy (DOT): CDC recommendations: 20-40 mg/kg (maximum: 900 mg/dose) twice weekly for 9 months (",
"     <i>",
"      MMWR",
"     </i>",
"     , 2000); Manufacturer&rsquo;s labeling: 20-30 mg/kg twice weekly (maximum: 900 mg/dose)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Treatment of active TB infection:",
"     </b>",
"     Infants and Children: Oral, I.M.:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Daily therapy: CDC recommendations: 10-15 mg/kg/day once daily (maximum: 300 mg/day) (",
"     <i>",
"      MMWR",
"     </i>",
"     , 2003)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Directly observed therapy (DOT): CDC recommendations: 20-30 mg/kg (maximum: 900 mg/dose) twice weekly (",
"     <i>",
"      MMWR",
"     </i>",
"     , 2003); Manufacturer&rsquo;s labeling: 20-40 mg/kg (maximum: 900 mg/dose) twice weekly or 3 times/week",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F184788\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block dor drugH1Div\" id=\"F184789\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Renal Impairment",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     No adjustment necessary",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Hemodialysis: Dialyzable (50% to 100%); administer dose postdialysis",
"    </p>",
"   </div>",
"   <div class=\"block doh drugH1Div\" id=\"F184790\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Hepatic Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No adjustment required, however, use with caution, may accumulate and additional liver damage may occur in patients with pre-existing liver disease. For ALT or AST &gt;3 times the ULN: discontinue or temporarily withhold treatment. Treatment with isoniazid for latent tuberculosis infection should be deferred in patients with acute hepatic diseases.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F184755\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Injection, solution: 100 mg/mL (10 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Solution, oral: 50 mg/5 mL (473 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, oral: 100 mg, 300 mg",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F184739\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F803140\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Should be administered 1 hour before or 2 hours after meals on an empty stomach.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F184759\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Treatment of susceptible tuberculosis infections; treatment of latent tuberculosis infection (LTBI)",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F3271336\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      International issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Hydra [Japan] may be confused with Hydrea brand name for hydroxyurea [U.S., Canada, and multiple international markets]",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F184822\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Frequency not defined.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Cardiovascular: Hypertension, palpitation, tachycardia, vasculitis",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Central nervous system: Depression, dizziness, encephalopathy, fever, lethargy, memory impairment, psychosis, seizure, slurred speech, toxic encephalopathy",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Dermatologic: Flushing, rash (morbilliform, maculopapular, pruritic, or exfoliative)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Endocrine &amp; metabolic: Gynecomastia, hyperglycemia, metabolic acidosis, pellagra, pyridoxine deficiency",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Gastrointestinal: Anorexia, epigastric distress, nausea, stomach pain, vomiting",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Hematologic: Agranulocytosis, anemia (sideroblastic, hemolytic, or aplastic), eosinophilia,  thrombocytopenia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Hepatic: LFTs mildly increased (10% to 20%), hyperbilirubinemia, bilirubinuria, jaundice, hepatic dysfunction, hepatitis (may involve progressive liver damage; risk increases with age; 2.3% in patients &gt;50 years)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Arthralgia, hyper-reflexia, paresthesia, peripheral neuropathy (dose-related incidence, 10% to 20% incidence with 10 mg/kg/day), weakness",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Ocular: Blurred vision, loss of vision, optic neuritis and atrophy",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Miscellaneous: Lupus-like syndrome, lymphadenopathy, rheumatic syndrome",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F184763\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to isoniazid or any component of the formulation; acute liver disease; previous history of hepatic damage during isoniazid therapy; previous severe adverse reaction (drug fever, chills, arthritis) to isoniazid",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F184743\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hepatitis:",
"     <b>",
"      [U.S. Boxed Warning]: Severe and sometimes fatal hepatitis may occur; usually occurs within the first 3 months of treatment, although may develop even after many months of treatment.",
"     </b>",
"     The risk of developing hepatitis is age-related, although isoniazid-induced hepatotoxicity has been reported in children; daily ethanol consumption may also increase the risk. Patients must report any prodromal symptoms of hepatitis, such as fatigue, weakness, malaise, anorexia, nausea, abdominal pain, jaundice, or vomiting. Patients should be instructed to immediately discontinue therapy if any of these symptoms occur, even if a clinical evaluation has yet to be conducted.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Peripheral neuropathies: Pyridoxine (10-50 mg/day) is recommended in individuals at risk for development of peripheral neuropathies (eg, HIV infection, nutritional deficiency, diabetes, pregnancy).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hepatic impairment: Use with caution in patients with hepatic impairment. Treatment with isoniazid for latent tuberculosis infection should be deferred in patients with acute hepatic diseases.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Renal impairment: Use with caution in patients with severe renal impairment.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Other warnings/precautions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Appropriate use: Multidrug regimens should be utilized for the treatment of active tuberculosis to prevent the emergence of drug resistance.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Ophthalmic  exams: Periodic ophthalmic examinations are recommended even when usual symptoms do not occur.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F184818\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Substrate",
"     </b>",
"     of CYP2E1 (major);",
"     <b>",
"      Note:",
"     </b>",
"     Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential;",
"     <b>",
"      Inhibits",
"     </b>",
"     CYP1A2 (weak), CYP2A6 (moderate), CYP2C19 (strong), CYP2C9 (weak), CYP2D6 (moderate), CYP2E1 (moderate), CYP3A4 (weak);",
"     <b>",
"      Induces",
"     </b>",
"     CYP2E1 (weak/moderate)",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F184748\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Acetaminophen: Isoniazid may enhance the adverse/toxic effect of Acetaminophen.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antacids: May decrease the absorption of Isoniazid.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     ARIPiprazole: CYP3A4 Inhibitors (Weak) may increase the serum concentration of ARIPiprazole.  Management: Monitor for increased aripiprazole pharmacologic effects. Aripiprazole dose adjustments may or may not be required based on concomitant therapy and/or indication. Consult full interaction monograph for specific recommendations.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     ARIPiprazole: CYP2D6 Inhibitors (Moderate) may increase the serum concentration of ARIPiprazole.  Management: Monitor for increased aripiprazole pharmacologic effects. Aripiprazole dose adjustments may or may not be required based on concomitant therapy and/or indication. Consult full interaction monograph for specific recommendations.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Benzodiazepines (metabolized by oxidation): Isoniazid may decrease the metabolism of Benzodiazepines (metabolized by oxidation).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CarBAMazepine: Isoniazid may decrease the metabolism of CarBAMazepine.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Chlorzoxazone: Isoniazid may decrease the metabolism of Chlorzoxazone.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Citalopram: CYP2C19 Inhibitors (Strong) may increase the serum concentration of Citalopram.  Management: Limit citalopram dose to a maximum of 20 mg/day if used with a strong CYP2C19 inhibitor.  Patients using this combination should be monitored closely for evidence of citalopram toxicity (e.g., serotonin syndrome, QT prolongation, etc.).",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Clopidogrel: CYP2C19 Inhibitors (Strong) may decrease serum concentrations of the active metabolite(s) of Clopidogrel.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Codeine: CYP2D6 Inhibitors (Moderate) may diminish the therapeutic effect of Codeine. These CYP2D6 inhibitors may prevent the metabolic conversion of codeine to its active metabolite morphine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Corticosteroids (Systemic): May decrease the serum concentration of Isoniazid.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CycloSERINE: Isoniazid may enhance the adverse/toxic effect of CycloSERINE. Specifically, CNS toxicity may be enhanced.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP2A6 Substrates: CYP2A6 Inhibitors (Moderate) may decrease the metabolism of CYP2A6 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP2C19 Substrates: CYP2C19 Inhibitors (Strong) may decrease the metabolism of CYP2C19 Substrates.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP2D6 Substrates: CYP2D6 Inhibitors (Moderate) may decrease the metabolism of CYP2D6 Substrates.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Tamoxifen.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP2E1 Substrates: CYP2E1 Inhibitors (Moderate) may decrease the metabolism of CYP2E1 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cyproterone: May decrease the serum concentration of CYP2E1 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Disulfiram: May enhance the adverse/toxic effect of Isoniazid. Disulfiram may increase the serum concentration of Isoniazid.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ethionamide: May increase the serum concentration of Isoniazid.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Fesoterodine: CYP2D6 Inhibitors may increase serum concentrations of the active metabolite(s) of Fesoterodine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Fosphenytoin: Isoniazid may increase the serum concentration of Fosphenytoin.  Management: Consider alternatives. If concomitant therapy cannot be avoided, monitor for increased phenytoin concentrations/effects with isoniazid initiation/dose increase, or decreased concentrations/effects with isoniazid discontinuation/dose decrease.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Itraconazole: Isoniazid may decrease the serum concentration of Itraconazole.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ketoconazole (Systemic): Isoniazid may decrease the serum concentration of Ketoconazole (Systemic).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lomitapide: CYP3A4 Inhibitors (Weak) may increase the serum concentration of Lomitapide.  Management: Limit the maximum adult dose of lomitapide to 30 mg daily when used in combination with any weak CYP3A4 inhibitor.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Metoprolol: CYP2D6 Inhibitors may increase the serum concentration of Metoprolol.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Nebivolol: CYP2D6 Inhibitors (Moderate) may increase the serum concentration of Nebivolol.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Phenytoin: Isoniazid may increase the serum concentration of Phenytoin.  Management: Consider alternatives. If concomitant therapy cannot be avoided, monitor for increased phenytoin concentrations/effects with isoniazid initiation/dose increase, or decreased concentrations/effects with isoniazid discontinuation/dose decrease.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pimozide: CYP3A4 Inhibitors (Weak) may increase the serum concentration of Pimozide.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Propafenone: May increase the serum concentration of CYP2D6 Inhibitors (Moderate).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Rifamycin Derivatives: May enhance the hepatotoxic effect of Isoniazid. Even so, this is a frequently employed combination regimen.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tamoxifen: CYP2D6 Inhibitors (Moderate) may decrease serum concentrations of the active metabolite(s) of Tamoxifen. Specifically, CYP2D6 inhibitors may decrease the metabolic formation of highly potent active metabolites.  Management: Consider alternatives with less of an inhibitory effect on CYP2D6 activity when possible.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Theophylline Derivatives: Isoniazid may increase the serum concentration of Theophylline Derivatives.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Dyphylline.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Thioridazine: CYP2D6 Inhibitors may decrease the metabolism of Thioridazine.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     TraMADol: CYP2D6 Inhibitors (Moderate) may diminish the therapeutic effect of TraMADol. These CYP2D6 inhibitors may prevent the metabolic conversion of tramadol to its active metabolite that accounts for much of its opioid-like effects.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block foi drugH1Div\" id=\"F184779\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Ethanol/Nutrition/Herb Interactions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Ethanol: Ethanol increases the risk of hepatitis. Management: Avoid ethanol.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Food: Serum levels may be decreased if taken with food. Has some ability to inhibit tyramine metabolism; several case reports of mild reactions (flushing, palpitations) after ingestion of cheese (with or without wine). Reactions resembling allergic symptoms following ingestion of fish high in histamine content have been reported. Isoniazid decreases folic acid absorption. Isoniazid alters pyridoxine metabolism. Management: Take on an empty stomach 1 hour before or 2 hours after a meal, increase dietary intake of folate, niacin, and magnesium. Avoid tyramine-containing foods (eg, aged or matured cheese, air-dried or cured meats including sausages and salamis; fava or broad bean pods, tap/draft beers, Marmite concentrate, sauerkraut, soy sauce, and other soybean condiments). Food&rsquo;s freshness is also an important concern; improperly stored or spoiled food can create an environment in which tyramine concentrations may increase. Avoid histamine-containing foods.",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F184751\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F184767\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Isoniazid was found to be embryocidal in animal studies; teratogenic effects were not noted. Isoniazid crosses the human placenta. Due to the risk of tuberculosis to the fetus, treatment is recommended when the probability of maternal disease is moderate to high. The CDC recommends isoniazid as part of the initial treatment regimen (CDC, 2003). Pyridoxine supplementation is recommended (25 mg/day).",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F184794\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Enters breast milk/compatible",
"    </p>",
"   </div>",
"   <div class=\"block brc drugH1Div\" id=\"F184768\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Breast-Feeding Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Small amounts of isoniazid are excreted in breast milk. However, women with tuberculosis should not be discouraged from breast-feeding. Pyridoxine supplementation is recommended for the mother and infant.",
"    </p>",
"   </div>",
"   <div class=\"block dic drugH1Div\" id=\"F184769\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dietary Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Should be taken 1 hour before or 2 hours after meals on an empty stomach; increase dietary intake of folate, niacin, magnesium. Avoid tyramine-containing foods; some examples include aged or matured cheese, air-dried or cured meats (including sausages and salamis), fava or broad bean pods, tap/draft beers, Marmite concentrate, sauerkraut, soy sauce and other soybean condiments. Avoid histamine-containing foods.",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F184766\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution",
"     </b>",
"     (Isoniazid Injection)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     100 mg/mL (10 mL): $352.06",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Syrup",
"     </b>",
"     (Isoniazid Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     50 mg/5 mL (473 mL): $75.60",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (Isoniazid Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     100 mg (100): $9.83",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     300 mg (100): $15.10",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F184753\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Baseline and periodic (more frequently in patients with higher risk for hepatitis) liver function tests (ALT and AST); sputum cultures monthly (until 2 consecutive negative cultures reported); monitoring for prodromal signs of hepatitis",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     LTBI therapy: American Thoracic Society/Centers for Disease Control (ATS/CDC) recommendations: Monthly clinical evaluation, including brief physical exam for adverse events. Baseline serum AST or ALT and bilirubin should be considered for patients at higher risk for adverse events (eg, history of liver disease, chronic ethanol use, HIV-infected patients, women who are pregnant or postpartum &le;3 months, older adults with concomitant medications or diseases). Routine, periodic monitoring is recommended for any patient with an abnormal baseline or at increased risk for hepatotoxicity.",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F184770\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Antimic (TH);",
"     </li>",
"     <li>",
"      Cemidon (ES);",
"     </li>",
"     <li>",
"      Curazid Forte (PH);",
"     </li>",
"     <li>",
"      Dardex (ES);",
"     </li>",
"     <li>",
"      Dianicotyl (GR);",
"     </li>",
"     <li>",
"      Diazid (JP);",
"     </li>",
"     <li>",
"      Eutizon (HR);",
"     </li>",
"     <li>",
"      Fimazid (ES);",
"     </li>",
"     <li>",
"      Fluodrazin (BR);",
"     </li>",
"     <li>",
"      Hidrafasa (ES);",
"     </li>",
"     <li>",
"      Hidranison (ES);",
"     </li>",
"     <li>",
"      Hidrasolco (ES);",
"     </li>",
"     <li>",
"      Hidrazida (ES, PT);",
"     </li>",
"     <li>",
"      INH Agepha (AT);",
"     </li>",
"     <li>",
"      INH Lannacher (AT);",
"     </li>",
"     <li>",
"      INH Waldheim (AT);",
"     </li>",
"     <li>",
"      Iscotin (TW);",
"     </li>",
"     <li>",
"      Iso-Dexter (ES);",
"     </li>",
"     <li>",
"      Isokin (IN);",
"     </li>",
"     <li>",
"      Isonex (ID, IN);",
"     </li>",
"     <li>",
"      Isoniac (AR);",
"     </li>",
"     <li>",
"      Isoniazid (AU, NZ);",
"     </li>",
"     <li>",
"      Isoniazid Atlantic (HK);",
"     </li>",
"     <li>",
"      Isoniazid &rdquo;Dak&rdquo; (DK);",
"     </li>",
"     <li>",
"      Isoniazid &rdquo;Oba&rdquo; (DK);",
"     </li>",
"     <li>",
"      Isoniazide Drank FNA (NL);",
"     </li>",
"     <li>",
"      Isoniazidum (PL);",
"     </li>",
"     <li>",
"      Isonicid (HN);",
"     </li>",
"     <li>",
"      Isozid (DE);",
"     </li>",
"     <li>",
"      Kridan Simple (ES);",
"     </li>",
"     <li>",
"      Lefos (ES);",
"     </li>",
"     <li>",
"      Nicotibine (BE, IL, LU);",
"     </li>",
"     <li>",
"      Nicozid (IT);",
"     </li>",
"     <li>",
"      Nidrazid (CZ);",
"     </li>",
"     <li>",
"      Nydrazide (PK);",
"     </li>",
"     <li>",
"      Pycazide (GB);",
"     </li>",
"     <li>",
"      Pyreazid (ES);",
"     </li>",
"     <li>",
"      Rimicid (BG);",
"     </li>",
"     <li>",
"      Rimifon (CH, ES, FR, GB);",
"     </li>",
"     <li>",
"      Sheng Jun (CL);",
"     </li>",
"     <li>",
"      Solonex (CO);",
"     </li>",
"     <li>",
"      Tebilon (AT);",
"     </li>",
"     <li>",
"      Tibinide (SE);",
"     </li>",
"     <li>",
"      Tubilysin (FI);",
"     </li>",
"     <li>",
"      Valifol (MX);",
"     </li>",
"     <li>",
"      Yuhan-Zid (KP)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F184742\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Unknown, but may include the inhibition of mycolic acid synthesis resulting in disruption of the bacterial cell wall",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F184762\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Absorption: Rapid and complete; rate can be slowed with food",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Distribution: All body tissues and fluids including CSF; crosses placenta; enters breast milk",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Protein binding: 10% to 15%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Metabolism: Hepatic with decay rate determined genetically by acetylation phenotype",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life elimination: Fast acetylators: 30-100 minutes; Slow acetylators: 2-5 hours; may be prolonged with hepatic or severe renal impairment",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Time to peak, serum: 1-2 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Excretion: Urine (75% to 95%); feces; saliva",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Ad Hoc Committee of the Scientific Assembly on Microbiology, Tuberculosis, and Pulmonary Infections, &ldquo;Treatment of Tuberculosis and Tuberculosis Infection in Adults and Children,&rdquo;",
"      <i>",
"       Clin Infect Dis",
"      </i>",
"      , 1995, 21:9-27.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      American Academy of Pediatrics, Committee on Infectious Diseases, &ldquo;Chemotherapy for Tuberculosis in Infants and Children,&rdquo;",
"      <i>",
"       Pediatrics",
"      </i>",
"      , 1992, 89(1):161-5.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?39/21/40279/abstract-text/1728006/pubmed\" id=\"1728006\" target=\"_blank\">",
"        1728006",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Aronoff GR, Bennett WM, Berns JS, et al,",
"      <i>",
"       Drug Prescribing in Renal Failure: Dosing Guidelines for Adults and Children",
"      </i>",
"      , 5th ed. Philadelphia, PA: American College of Physicians; 2007.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Askgaard DS, Wilcke T, and Dossing M, &ldquo;Hepatotoxicity Caused by the Combined Action of Isoniazid and Rifampicin,&rdquo;",
"      <i>",
"       Thorax",
"      </i>",
"      , 1995, 50(2):213-4.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?39/21/40279/abstract-text/7701468/pubmed\" id=\"7701468\" target=\"_blank\">",
"        7701468",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Bass JB Jr, Farer LS, Hopewell PC, et al, &ldquo;Treatment of Tuberculosis and Tuberculosis Infection in Adults and Children,&rdquo;",
"      <i>",
"       Am J Respir Crit Care Med",
"      </i>",
"      , 1994, 149(5):1359-74.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?39/21/40279/abstract-text/8173779/pubmed\" id=\"8173779\" target=\"_blank\">",
"        8173779",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Blowey DL, Johnson D, and Verjee Z, &ldquo;Isoniazid-Associated Rhabdomyolysis,&rdquo;",
"      <i>",
"       Am J Emerg Med",
"      </i>",
"      , 1995, 13(5):543-4.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?39/21/40279/abstract-text/7662061/pubmed\" id=\"7662061\" target=\"_blank\">",
"        7662061",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Blumberg HM, Burman WJ, Chaisson RE, et al, &ldquo;American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America: Treatment of Tuberculosis,&rdquo;",
"      <i>",
"       Am J Respir Crit Care Med",
"      </i>",
"      , 2003, 167(4):603-62.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?39/21/40279/abstract-text/12588714/pubmed\" id=\"12588714\" target=\"_blank\">",
"        12588714",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Bredemann JA, Krechel SW, and Eggers GW Jr, &ldquo;Treatment of Refractory Seizures in Massive Isoniazid Overdose,&rdquo;",
"      <i>",
"       Anesth Analg",
"      </i>",
"      , 1990, 71(5):554-7.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?39/21/40279/abstract-text/2221419/pubmed\" id=\"2221419\" target=\"_blank\">",
"        2221419",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Brent J, Vo N, Kulig K, et al, &ldquo;Reversal of Prolonged Isoniazid-Induced Coma by Pyridoxine,&rdquo;",
"      <i>",
"       Arch Intern Med",
"      </i>",
"      , 1990, 150(8):1751-3.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?39/21/40279/abstract-text/2152443/pubmed\" id=\"2152443\" target=\"_blank\">",
"        2152443",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Brown CV, &ldquo;Acute Isoniazid Poisoning,&rdquo;",
"      <i>",
"       Am Rev Respir Dis",
"      </i>",
"      , 1972, 105(2):206-16.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?39/21/40279/abstract-text/5009799/pubmed\" id=\"5009799\" target=\"_blank\">",
"        5009799",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Centers for Disease Control and Prevention (CDC), &ldquo;Treatment of Tuberculosis,&rdquo;",
"      <i>",
"       MMWR Recomm Rep",
"      </i>",
"      , 2003, 52(RR11):1-77; published erratum appears in",
"      <i>",
"       MMWR Recomm Rep",
"      </i>",
"      , 2005, 53(51):1203.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?39/21/40279/abstract-text/12836625/pubmed\" id=\"12836625\" target=\"_blank\">",
"        12836625",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Centers for Disease Control and Prevention (CDC) and American Thoracic Society, &ldquo;Update: Adverse Event Data and Revised American Thoracic Society/CDC Recommendations Against the Use of Rifampin and Pyrazinamide for Treatment of Latent Tuberculosis Infection - United States, 2003,&rdquo;",
"      <i>",
"       MMWR Morb Mortal Wkly Rep",
"      </i>",
"      , 2003, 52(31):735-9. Available at",
"      <a href=\"file://www.cdc.gov/mmwr/preview/mmwrhtml/mm5231a4.htm\" target=\"_blank\">",
"       file://www.cdc.gov/mmwr/preview/mmwrhtml/mm5231a4.htm",
"      </a>",
"      .",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?39/21/40279/abstract-text/12904741/pubmed\" id=\"12904741\" target=\"_blank\">",
"        12904741",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Centers for Disease Control and Prevention (CDC), &ldquo;Severe Isoniazid-Associated Liver Injuries Among Persons Being Treated for Latent Tuberculosis Infection -- United States, 2004-08,&rdquo;",
"      <i>",
"       MMWR Morb Mortal Wkly Rep",
"      </i>",
"      , 2010, 59(8):224-9. Available at file://www.cdc.gov/mmwr/preview/mmwrhtml/mm5908a3.htm",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?39/21/40279/abstract-text/20203555/pubmed\" id=\"20203555\" target=\"_blank\">",
"        20203555",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Centers for Disease Control and Prevention (CDC), &ldquo;Targeted Tuberculin Testing and Treatment of Latent Tuberculosis Infection. American Thoracic Society and CDC Statement Committee,&rdquo;",
"      <i>",
"       MMWR Recomm Rep",
"      </i>",
"      , 2000, 49(RR-6):1-51.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?39/21/40279/abstract-text/10881762/pubmed\" id=\"10881762\" target=\"_blank\">",
"        10881762",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Frieden TR, Sterling TR, Munsiff SS, et al, &ldquo;Tubercolosis,&rdquo;",
"      <i>",
"       Lancet,",
"      </i>",
"      2003, 362(9387):887-99.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?39/21/40279/abstract-text/13678977/pubmed\" id=\"13678977\" target=\"_blank\">",
"        13678977",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Griffith DE, Aksamit T, Brown-Elliott BA, et al, &ldquo;An Official ATS/IDSA Statement: Diagnosis, Treatment, and Prevention of Nontuberculous Mycobacterial Diseases,&rdquo;",
"      <i>",
"       Am J Respir Crit Care Med",
"      </i>",
"      , 2007, 175(4):367-416.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?39/21/40279/abstract-text/17277290/pubmed\" id=\"17277290\" target=\"_blank\">",
"        17277290",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Havlir DV and Barnes PF, &ldquo;Tuberculosis in Patients With Human Immunodeficiency Virus Infection,&rdquo;",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 1999, 340(5):367-73.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?39/21/40279/abstract-text/9929528/pubmed\" id=\"9929528\" target=\"_blank\">",
"        9929528",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Iseman MD, &ldquo;Treatment of Multidrug-Resistant Tuberculosis,&rdquo;",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 1993, 329(11):784-91.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?39/21/40279/abstract-text/8350889/pubmed\" id=\"8350889\" target=\"_blank\">",
"        8350889",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Kergueris MF, Bourin M, and Larousse C, &ldquo;Pharmacokinetics of Isoniazid: Influence of Age,&rdquo;",
"      <i>",
"       Eur J Clin Pharmacol",
"      </i>",
"      , 1986, 30(3):335-40.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?39/21/40279/abstract-text/3732371/pubmed\" id=\"3732371\" target=\"_blank\">",
"        3732371",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Noble A, &ldquo;Antituberculous Therapy and Acute Liver Failure,&rdquo;",
"      <i>",
"       Lancet",
"      </i>",
"      , 1995, 345(8953):867.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      &ldquo;Prevention and Treatment of Tuberculosis Among Patients Infected With Human Immunodeficiency Virus: Principles of Therapy and Revised Recommendations. Centers for Disease Control and Prevention,&rdquo;",
"      <i>",
"       MMWR Recomm Rep",
"      </i>",
"      , 1998, 47(RR-20):1-58.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Rabassa AA, Trey G, Shukla U, et al, &ldquo;Isoniazid-Induced Acute Pancreatitis,&rdquo;",
"      <i>",
"       Ann Intern Med",
"      </i>",
"      , 1994, 121(6):433-4.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?39/21/40279/abstract-text/8053617/pubmed\" id=\"8053617\" target=\"_blank\">",
"        8053617",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Saukkonen JJ, Cohn DL, Jasmer RM, et al, &ldquo;An Official ATS Statement: Hepatotoxicity of Antituberculosis Therapy,&rdquo;",
"      <i>",
"       Am J Respir Crit Care Med",
"      </i>",
"      , 2006, 174(8):935-52.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?39/21/40279/abstract-text/17021358/pubmed\" id=\"17021358\" target=\"_blank\">",
"        17021358",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Scharman EJ and Rosencrane JG, &ldquo;Isoniazid Toxicity: A Survey of Pyridoxine Availability,&rdquo;",
"      <i>",
"       Am J Emerg Med",
"      </i>",
"      , 1994, 12(3):386-8.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Self TH, Chrisman CR, Baciewicz AM, et al, &ldquo;Isoniazid Drug and Food Interactions,&rdquo;",
"      <i>",
"       Am J Med Sci",
"      </i>",
"      , 1999, 317(5):304-11.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?39/21/40279/abstract-text/10334118/pubmed\" id=\"10334118\" target=\"_blank\">",
"        10334118",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Sharieff G and Shad JA, &ldquo;Early Recognition of Isoniazid Overdose,&rdquo;",
"      <i>",
"       Hosp Physician",
"      </i>",
"      , 1995, 31(5):22-2.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Sievers ML and Herrier RN, &ldquo;Treatment of Acute Isoniazid Toxicity,&rdquo;",
"      <i>",
"       Am J Hosp Pharm",
"      </i>",
"      , 1975, 32(2):202-6.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?39/21/40279/abstract-text/1136966/pubmed\" id=\"1136966\" target=\"_blank\">",
"        1136966",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Toutoungi M, Carroll RL, Enrico JF, et al, &ldquo;Cheese, Wine, and Isoniazid,&rdquo;",
"      <i>",
"       Lancet",
"      </i>",
"      , 1985. 2(8456):671.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      &ldquo;Treatment of Latent Tuberculosis Infection (LTBI), Last Updated: July, 2007.&rdquo; Available at",
"      <a href=\"file://www.cdc.gov/tb/pubs/tbfactsheets/treatmentLTBI.pdf\" target=\"_blank\">",
"       file://www.cdc.gov/tb/pubs/tbfactsheets/treatmentLTBI.pdf",
"      </a>",
"      . Last accessed September 18, 2007.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Wason S, LaCoutore PG, and Lovejoy FH Jr, &ldquo;Single High-Dose Pyridoxine Treatment for Isoniazid Overdose,&rdquo;",
"      <i>",
"       JAMA",
"      </i>",
"      , 1981, 246(10):1102-4.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?39/21/40279/abstract-text/7265398/pubmed\" id=\"7265398\" target=\"_blank\">",
"        7265398",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Yoshikawa TT, &ldquo;Tuberculosis in Aging Adults,&rdquo;",
"      <i>",
"       J Am Geriatr Soc",
"      </i>",
"      , 1992, 40(2):178-87.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?39/21/40279/abstract-text/1740604/pubmed\" id=\"1740604\" target=\"_blank\">",
"        1740604",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 8577 Version 45.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0602-201.77.166.39-C008A65255-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f39_21_40279=[""].join("\n");
var outline_f39_21_40279=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5708956\">",
"      ALERT: U.S. Boxed Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F184784\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F184824\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F184787\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F184805\">",
"      Dosing: Pediatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F184788\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F184789\">",
"      Dosing: Renal Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F184790\">",
"      Dosing: Hepatic Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F184755\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F184739\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F803140\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F184759\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3271336\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F184822\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F184763\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F184743\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F184818\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F184748\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F184779\">",
"      Ethanol/Nutrition/Herb Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F184751\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F184767\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F184794\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F184768\">",
"      Breast-Feeding Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F184769\">",
"      Dietary Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F184766\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F184753\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F184770\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F184742\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F184762\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/8577\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/8577|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"mobipreview.htm?8/5/8277?source=related_link\">",
"      Isoniazid: Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?37/24/38278?source=related_link\">",
"      Isoniazid: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f39_21_40280="Clinical features of amyotrophic lateral sclerosis and other forms of motor neuron disease";
var content_f39_21_40280=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Clinical features of amyotrophic lateral sclerosis and other forms of motor neuron disease",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?39/21/40280/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?39/21/40280/contributors\">",
"     Lauren B Elman, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?39/21/40280/contributors\">",
"     Leo McCluskey, MD, MBE",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?39/21/40280/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?39/21/40280/contributors\">",
"     Jeremy M Shefner, MD, PhD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?39/21/40280/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?39/21/40280/contributors\">",
"     John F Dashe, MD, PhD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?39/21/40280/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Feb 15, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Amyotrophic lateral sclerosis (ALS), first described by Charcot in the nineteenth century, is a relentlessly progressive, presently incurable, neurodegenerative disorder that causes muscle weakness, disability, and eventually death. ALS is also known as Lou Gehrig's disease, after the famous New York Yankee baseball player who was affected with the disorder [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/21/40280/abstract/1-3\">",
"     1-3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    ALS has an annual incidence of one to three cases per 100,000 people that is believed to be the same worldwide. There appears to be no ethnic or racial predisposition to ALS. Prior to the age of 65 or 70, the incidence of ALS is higher in men than in women, but thereafter the gender incidence is equal. ALS has an age distribution that peaks in the seventh to eight decade. However, ALS can occur in people in their twenties. ALS is most commonly sporadic. Genetic or familial ALS represents only 10 percent of all ALS. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?15/48/16138?source=see_link\">",
"     \"Familial amyotrophic lateral sclerosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    This topic will review the clinical features of ALS. The epidemiology, diagnosis, and differential diagnosis of ALS are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?22/57/23450?source=see_link\">",
"     \"Epidemiology and pathogenesis of amyotrophic lateral sclerosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?16/34/16938?source=see_link\">",
"     \"Diagnosis of amyotrophic lateral sclerosis and other forms of motor neuron disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     CLINICOPATHOLOGIC FEATURES",
"    </span>",
"    &nbsp;&mdash;&nbsp;The clinical hallmark of ALS is the combination of upper and lower motor neuron signs and symptoms.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The upper motor neuron findings of weakness with slowness, hyperreflexia, and spasticity result from degeneration of frontal motor neurons located in the motor strip (Brodman area 4) and their axons traversing the corona radiata, internal capsule, cerebral peduncles, pontine base, medullary pyramids, and the lateral corticospinal tracts of the spinal cord. At autopsy, the dorsolateral area of the spinal cord, the region containing the lateral corticospinal tract, is gliotic and hardened or sclerotic to palpation.",
"     </li>",
"     <li>",
"      The lower motor neuron findings of weakness, atrophy or amyotrophy, and fasciculations are a direct consequence of degeneration of lower motor neurons in the brainstem and spinal cord producing muscle denervation.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The neuropathology of ALS is characterized by pathologic inclusions within both upper and lower motor neurons and glia. Such inclusions also occur in nonmotor frontal and temporal cortical neurons and in more widespread areas of the brain not typically associated with classic ALS. Inclusions stain positively for ubiquitin; a large subset also stain positively for TAR DNA-binding protein (TDP-43) and smaller subsets stain for fused in sarcoma (FUS) protein and optineurin. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?22/57/23450?source=see_link&amp;anchor=H9#H9\">",
"     \"Epidemiology and pathogenesis of amyotrophic lateral sclerosis\", section on 'Intracellular inclusions'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The term \"amyotrophic lateral sclerosis\" is derived from the combination of the clinical examination finding of amyotrophy with the pathological finding of lateral sclerosis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/21/40280/abstract/2-7\">",
"     2-7",
"    </a>",
"    ]. While it was once presumed to be a pure motor disorder, it has become increasingly apparent that degeneration of other brain regions such as frontal and temporal cortical neurons may also occur as part of the clinicopathologic spectrum of ALS. (See",
"    <a class=\"local\" href=\"#H8\">",
"     'ALS-plus syndrome'",
"    </a>",
"    below and",
"    <a class=\"local\" href=\"#H13\">",
"     'Cognitive symptoms'",
"    </a>",
"    below and",
"    <a class=\"local\" href=\"#H14\">",
"     'Autonomic symptoms'",
"    </a>",
"    below and",
"    <a class=\"local\" href=\"#H15\">",
"     'Parkinsonism and supranuclear gaze palsy'",
"    </a>",
"    below and",
"    <a class=\"local\" href=\"#H16\">",
"     'Sensory symptoms'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     SPECTRUM OF MOTOR NEURON DISEASE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Amyotrophic lateral sclerosis (ALS) is one of multiple degenerative motor neuron diseases that are clinically defined, based on the involvement of upper",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    lower motor neurons [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/21/40280/abstract/1,2,8\">",
"     1,2,8",
"    </a>",
"    ]. Amyotrophic lateral sclerosis is the most common form of motor neuron disease and includes upper and lower motor neuron pathology.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Progressive muscular atrophy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Progressive muscular atrophy is a progressive lower motor neuron disorder. Some experts believe it represents a form of ALS [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/21/40280/abstract/9,10\">",
"     9,10",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    When the disease remains confined to the lower motor neuron, survival may be prolonged compared with classic ALS. In the largest study, 91 patients initially diagnosed with progressive muscular atrophy had a longer median survival than 871 patients with ALS (48 versus 36 months) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/21/40280/abstract/9\">",
"     9",
"    </a>",
"    ]. However, on Kaplan-Meier estimates, the survival curves of progressive muscular atrophy and ALS crossed at approximately 80 months. Thereafter, the estimated survival in progressive muscular atrophy was about the same as that of ALS. In an earlier series, 37 patients with progressive muscular atrophy had a median survival of 56 months [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/21/40280/abstract/11\">",
"     11",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Some individuals with progressive muscular atrophy never develop clinical upper motor neuron signs. Many, however, develop upper motor neuron signs later in their clinical course, at which point the disease is called lower motor neuron-onset ALS. In the series cited above, upper motor neuron signs developed in 20 of 91 patients (22 percent) initially diagnosed with progressive muscular atrophy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/21/40280/abstract/9\">",
"     9",
"    </a>",
"    ]. Typically, upper motor neuron involvement occurred within two years of symptom onset.",
"   </p>",
"   <p>",
"    At autopsy, patients with progressive muscular atrophy who never developed clinically apparent upper motor neuron signs frequently have upper motor neuron pathology, including corticospinal tract abnormalities and TDP-43 positive inclusions in motor cortex, in a pattern identical to that of ALS [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/21/40280/abstract/6,12\">",
"     6,12",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Primary lateral sclerosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Primary lateral sclerosis is a progressive isolated upper motor neuron disorder [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/21/40280/abstract/13\">",
"     13",
"    </a>",
"    ]. Compared with ALS, it is characterized by slower progression, lack of weight loss, and absence of lower motor neuron findings on examination or electromyography in the first four years after symptom onset [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/21/40280/abstract/14,15\">",
"     14,15",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Some individuals with primary lateral sclerosis never develop clinical lower motor neuron signs. Most, however, do develop lower motor neuron signs later in their clinical course. This is referred to as upper motor neuron-onset ALS. Reports of pathology in clinically defined primary lateral sclerosis are limited, but disease pathologically isolated to the upper motor neuron has been described [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/21/40280/abstract/16-19\">",
"     16-19",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In a retrospective study of 39 patients who were initially diagnosed with primary lateral sclerosis, pure upper motor neuron signs were present on initial evaluation in 29 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/21/40280/abstract/14\">",
"     14",
"    </a>",
"    ]. Over a mean 8.7 years of follow-up, pure upper motor neuron signs were retained in 16 patients who were classified as clinically pure primary lateral sclerosis, while electromyographic or clinical evidence of denervation and lower motor neuron disease developed in 13 patients who were classified as upper motor neuron-dominant ALS. The lower motor neuron findings developed by four years in 10 (77 percent) of the 13 patients with upper motor neuron-dominant ALS.",
"   </p>",
"   <p>",
"    In another retrospective series involving 661 patients with ALS and 43 with primary lateral sclerosis, spasticity at clinical presentation and absence of limb muscle wasting for at least three years were significantly more common in patients with primary lateral sclerosis than those with ALS [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/21/40280/abstract/20\">",
"     20",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Pure primary lateral sclerosis and upper motor neuron-dominant ALS appear to have a more benign prognosis than typical ALS [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/21/40280/abstract/13,20\">",
"     13,20",
"    </a>",
"    ]. Survival was longer and disease progression slower in patients classified as primary lateral sclerosis compared with ALS controls [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/21/40280/abstract/14\">",
"     14",
"    </a>",
"    ]. Survival for patients with upper motor neuron-dominant ALS was intermediate between that of primary lateral sclerosis and classic ALS.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Progressive bulbar palsy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Progressive bulbar palsy is a progressive upper and lower motor neuron disorder of cranial muscles. This condition may occasionally stay isolated to the bulbar segment, but more commonly, upper and lower motor neuron signs and symptoms spread to involve other segments. This is then referred to as bulbar-onset ALS. There have been no reports of specific pathology in progressive bulbar palsy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/21/40280/abstract/1-3,21\">",
"     1-3,21",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Flail arm syndrome",
"    </span>",
"    &nbsp;&mdash;&nbsp;The flail arm syndrome (also called brachial amyotrophic diplegia) is characterized by progressive lower motor neuron weakness and wasting that predominantly affects the proximal arm [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/21/40280/abstract/22-24\">",
"     22-24",
"    </a>",
"    ]. It usually begins proximally and spreads distally to the point where arm and hand function is severely impaired. It is often asymmetric. Patients presenting with the flail arm variant of ALS have a slower rate of progression both to the spread of signs and symptoms in other body segments and to development of respiratory muscle weakness [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/21/40280/abstract/25\">",
"     25",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28382562\">",
"    <span class=\"h2\">",
"     Flail leg syndrome",
"    </span>",
"    &nbsp;&mdash;&nbsp;The flail leg syndrome (also called the pseudopolyneuritic variant of",
"    <span class=\"nowrap\">",
"     ALS/motor",
"    </span>",
"    neuron disease) is characterized by progressive lower motor neuron weakness and wasting with onset in the distal leg [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/21/40280/abstract/25,26\">",
"     25,26",
"    </a>",
"    ]. Patients presenting with the flail leg syndrome have a slower rate of progression to involvement of other body segments and of the development of respiratory muscle weakness [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/21/40280/abstract/25\">",
"     25",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     ALS-plus syndrome",
"    </span>",
"    &nbsp;&mdash;&nbsp;Classically defined, ALS is considered a degenerative disorder of the upper and lower motor neurons, and does not include symptoms or signs outside of the voluntary motor system. However, some patients have all of the clinical features of ALS along with features of other disorders such as frontotemporal dementia, autonomic insufficiency, parkinsonism, supranuclear gaze paresis,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    sensory loss. Such patients are considered to have ALS-plus syndrome. In a case report, a patient with clinically definite ALS accompanied by a supranuclear gaze disorder and an extrapyramidal syndrome reminiscent of progressive supranuclear palsy demonstrated diffuse TDP-43 pathology at autopsy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/21/40280/abstract/27\">",
"     27",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     CLINICAL SYMPTOMS AND SIGNS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The loss of motor neurons results in the primary clinical symptoms and signs of ALS. These may produce impairment affecting limb (",
"    <a class=\"graphic graphic_table graphicRef72454 \" href=\"mobipreview.htm?24/58/25517\">",
"     table 1",
"    </a>",
"    ), bulbar (",
"    <a class=\"graphic graphic_table graphicRef75146 \" href=\"mobipreview.htm?33/2/33837\">",
"     table 2",
"    </a>",
"    ), axial (",
"    <a class=\"graphic graphic_table graphicRef67913 \" href=\"mobipreview.htm?9/60/10188\">",
"     table 3",
"    </a>",
"    ) and respiratory (",
"    <a class=\"graphic graphic_table graphicRef58537 \" href=\"mobipreview.htm?36/37/37467\">",
"     table 4",
"    </a>",
"    ) function.",
"   </p>",
"   <p>",
"    Differences in site and segment (cranial, cervical, thoracic, or lumbosacral) of onset, pattern and speed of spread, and the degree of upper",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    lower motor neuron dysfunction produce a disorder that is remarkably variable between individuals.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Initial presentation and patient complaints",
"    </span>",
"    &nbsp;&mdash;&nbsp;The initial clinical manifestation of ALS may occur in any body segment (bulbar, cervical, thoracic or lumbosacral) and may manifest as upper motor neuron (see",
"    <a class=\"local\" href=\"#H11\">",
"     'Upper motor neuron symptoms'",
"    </a>",
"    below) or lower motor neuron (see",
"    <a class=\"local\" href=\"#H12\">",
"     'Lower motor neuron symptoms'",
"    </a>",
"    below) symptoms or signs. Asymmetric limb weakness is the most common presentation of ALS (80 percent). Upper extremity onset is most often heralded by hand weakness but may begin in the shoulder girdle muscles. Lower extremity onset of ALS most often begins with weakness of foot dorsiflexion (foot drop), while proximal pelvic girdle onset is less common.",
"   </p>",
"   <p>",
"    Twenty percent of patients will have onset in the bulbar segment, which most often presents with either dysarthria or dysphagia.",
"   </p>",
"   <p>",
"    Less common patterns of ALS onset include respiratory muscle weakness (1 to 3 percent) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/21/40280/abstract/28\">",
"     28",
"    </a>",
"    ], generalized weakness in the limbs and bulbar muscles (1 to 9 percent), axial onset with head drop or truncal extension weakness, and weight loss with muscle atrophy, fasciculations, and cramps [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/21/40280/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Upper motor neuron symptoms",
"    </span>",
"    &nbsp;&mdash;&nbsp;Loss of upper motor neurons (UMNs) results in slowness of movement, incoordination and stiffness with relatively little overt weakness. Arm or hand UMN symptoms include poor dexterity with resulting difficulty performing activities of daily living. Leg UMN symptoms manifest as a spastic gait with poor balance and may include spontaneous leg flexor spasms and ankle clonus (",
"    <a class=\"graphic graphic_table graphicRef72454 \" href=\"mobipreview.htm?24/58/25517\">",
"     table 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Dysarthria and dysphagia are the most common bulbar UMN symptoms (",
"    <a class=\"graphic graphic_table graphicRef75146 \" href=\"mobipreview.htm?33/2/33837\">",
"     table 2",
"    </a>",
"    ). UMN or spastic dysarthria produces a characteristically strained vocal quality with slow speech. UMN dysphagia results from slow and discoordinated contraction of the swallowing muscles, which may lead to coughing and choking.",
"   </p>",
"   <p>",
"    Another frequent bulbar UMN symptom is the syndrome of the pseudobulbar affect. This is manifested as inappropriate laughing, crying, or yawning. This may occur as an early manifestation of ALS or may develop during the disease course. The observed affect is often mood incongruent or may be triggered by stimuli that would not have elicited such a response prior to the development of pseudobulbar affect. Patients also report difficulty with cessation of the laughing or crying once it has begun. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?32/26/33193?source=see_link&amp;anchor=H21#H21\">",
"     \"Symptom-based management of amyotrophic lateral sclerosis\", section on 'Pseudobulbar affect'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    UMN bulbar dysfunction may also result in laryngospasm. This is a short-lived (usually &lt;30 seconds) reflex closure of the larynx that most often occurs in response to aspiration of food particles or liquids, including saliva. The patient typically describes a squeezing feeling in the throat accompanied by impaired inspiration and difficulty speaking; there may be audible stridor.",
"   </p>",
"   <p>",
"    Additional manifestations of UMN bulbar dysfunction may include increased masseter tone and difficulty opening the mouth. When severe, this is referred to as trismus. At times there may be involuntary jaw clenching with biting of the sides of the tongue and cheeks.",
"   </p>",
"   <p>",
"    Axial UMN dysfunction may contribute to stiffness and imbalance (",
"    <a class=\"graphic graphic_table graphicRef67913 \" href=\"mobipreview.htm?9/60/10188\">",
"     table 3",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Lower motor neuron symptoms",
"    </span>",
"    &nbsp;&mdash;&nbsp;Loss of LMNs results in weakness, usually accompanied by atrophy (",
"    <a class=\"graphic graphic_movie graphicRef53274 \" href=\"mobipreview.htm?6/36/6735\">",
"     movie 1",
"    </a>",
"    ) and fasciculations (",
"    <a class=\"graphic graphic_movie graphicRef66062 \" href=\"mobipreview.htm?6/10/6318\">",
"     movie 2",
"    </a>",
"    and",
"    <a class=\"graphic graphic_movie graphicRef63510 \" href=\"mobipreview.htm?17/24/17806\">",
"     movie 3",
"    </a>",
"    ). Cramps are also common.",
"   </p>",
"   <p>",
"    Hand weakness causes difficulty manipulating small objects (buttons, zippers, coins) and using writing instruments (",
"    <a class=\"graphic graphic_table graphicRef72454 \" href=\"mobipreview.htm?24/58/25517\">",
"     table 1",
"    </a>",
"    ). Proximal arm weakness results in difficulty elevating the arm to the level of the mouth or above the head. This can produce difficulty with bathing, dressing, grooming and eating. Foot and ankle weakness results in tripping, a slapping gait, and falling. Proximal leg weakness results in difficulty arising from chairs, climbing stairs and getting off of the floor. Balance may also be adversely affected.",
"   </p>",
"   <p>",
"    Dysarthria and dysphagia can also result from LMN damage (",
"    <a class=\"graphic graphic_table graphicRef75146 \" href=\"mobipreview.htm?33/2/33837\">",
"     table 2",
"    </a>",
"    ). Dysarthria may result from weakness of the tongue, lips or palate. The speech is usually slurred and may have a nasal quality. Hoarseness may be caused by associated vocal cord weakness. Dysphagia results from tongue weakness with disruption of the oral phase of swallowing or from pharyngeal constrictor weakness with disruption of the pharyngeal phase of swallowing or both. Tongue weakness may lead to pocketing of food between the cheeks and gums. Pharyngeal weakness often manifests as coughing and choking on food, liquids or secretions such as saliva or mucus. Aspiration may result.",
"   </p>",
"   <p>",
"    LMN weakness of the upper face may produce incomplete eye closure (",
"    <a class=\"graphic graphic_table graphicRef75146 \" href=\"mobipreview.htm?33/2/33837\">",
"     table 2",
"    </a>",
"    ). In the lower face the result may be a poor lip seal that may contribute to drooling or sialorrhea particularly in patients with associated swallowing difficulty. LMN weakness of the masseter can cause difficulty chewing; when severe it may produce an inability to close the mouth. LMN weakness of the pterygoids may produce difficulty opening the mouth and moving the jaw from side to side. Severe masseter and pterygoid weakness may contribute to disarticulation of the temporomandibular joint.",
"   </p>",
"   <p>",
"    LMN weakness affecting the trunk and spine may produce difficulty holding up the head and difficulty maintaining an erect posture as well as abdominal protuberance (",
"    <a class=\"graphic graphic_table graphicRef67913 \" href=\"mobipreview.htm?9/60/10188\">",
"     table 3",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    LMN weakness of the diaphragm produces progressive dyspnea with decreasing amounts of effort culminating in dyspnea at rest and with talking along with reduced vocal volume (",
"    <a class=\"graphic graphic_table graphicRef58537 \" href=\"mobipreview.htm?36/37/37467\">",
"     table 4",
"    </a>",
"    ). Diaphragmatic weakness may also result in orthopnea and sleep disordered breathing.",
"   </p>",
"   <p>",
"    Extraocular motor neurons residing in the nuclei of the oculomotor (CN III), trochlear (CN IV) and abducens (CN VI) nerves are spared until very late in the disease course. Patients who choose long-term mechanical ventilation have a longer clinical course that can include progressive difficulty with ocular motility. This may culminate in the locked-in-state, a clinical condition characterized by inability to move any voluntary muscle. Such patients may be alert and awake but completely unable to communicate.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Cognitive symptoms",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is a well-established link between ALS and frontotemporal executive dysfunction that may precede or follow the onset of upper",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    lower motor neuron dysfunction [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/21/40280/abstract/29-36\">",
"     29-36",
"    </a>",
"    ]. The frequency of frontotemporal executive dysfunction in patients with ALS varies in previous reports from 28 percent to 100 percent. The three largest series found evidence of cognitive impairment in 35 to 51 percent of patients with ALS [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/21/40280/abstract/30,33,37\">",
"     30,33,37",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Nevertheless, most patients with ALS do not have overt dementia, and when present, cognitive impairment is typically subtle [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/21/40280/abstract/36\">",
"     36",
"    </a>",
"    ]. In the largest report, the proportion of patients with ALS who met criteria for frontotemporal dementia (FTD) was 15 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/21/40280/abstract/33\">",
"     33",
"    </a>",
"    ]. Retrospective data suggest that ALS with FTD may be associated with shorter survival than ALS with normal executive and behavioral function [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/21/40280/abstract/38\">",
"     38",
"    </a>",
"    ]. ALS with FTD may be a familial disorder. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?15/48/16138?source=see_link&amp;anchor=H1808661#H1808661\">",
"     \"Familial amyotrophic lateral sclerosis\", section on 'C9ORF72 gene'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The presentation of FTD may be dramatic and initially suggestive of a psychiatric disorder because of change in personality, impairment of judgment, and development of obsessional behaviors. It may also manifest as a disorder of language called primary progressive aphasia (also semantic aphasia or semantic dementia). Short-term memory and spatial abilities are usually spared early in the course. However, the precise clinical and neuropathologic features of ALS associated with dementia remain to be defined [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/21/40280/abstract/36,39,40\">",
"     36,39,40",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?12/20/12618?source=see_link\">",
"     \"Frontotemporal dementia: Clinical features and diagnosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Autonomic symptoms",
"    </span>",
"    &nbsp;&mdash;&nbsp;Autonomic symptoms may occur in ALS as the disease progresses, although this is not an initial manifestation of the disease. Constipation occurs frequently and is likely multifactorial. Delayed colonic motility has been demonstrated. Dysphagia for thin liquids related to pharyngeal muscle weakness may lead to dehydration that can exacerbate constipation. Symptoms of early satiety and bloating consistent with delayed gastric emptying also occur as the disease progresses [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/21/40280/abstract/41-43\">",
"     41-43",
"    </a>",
"    ]. Urinary urgency without incontinence is common, while incontinence is uncommon.",
"   </p>",
"   <p>",
"    Some patients complain of excessive sweating, but whether a disorder of sweating occurs in association with ALS is controversial [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/21/40280/abstract/44,45\">",
"     44,45",
"    </a>",
"    ]. Abnormal sympathetic activity with hyperhidrosis in early ALS and a reduction in sweat production as the disease progresses has been demonstrated in one study [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/21/40280/abstract/46\">",
"     46",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Cases of ALS associated with autonomic disturbances have been reported. As examples, an individual from a Japanese ALS 1 (SOD 1 Gly93Ser) kindred had prominent sensory impairment, urinary disturbance, and blood pressure fluctuation due to sympathetic hyperactivity [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/21/40280/abstract/47\">",
"     47",
"    </a>",
"    ]. Another individual with ALS and the locked-in-state related to a rare SOD1 mutation (Val118Leu) developed cardiac arrest following autonomic failure [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/21/40280/abstract/48\">",
"     48",
"    </a>",
"    ]. Neuropathology demonstrated widespread neurodegeneration including autonomic nuclei in the medulla and spinal cord.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Parkinsonism and supranuclear gaze palsy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Extrapyramidal symptoms and signs of parkinsonism may precede or follow the upper and lower motor neuron symptoms. These extrapyramidal features may include facial masking, tremor, bradykinesia, and postural instability.",
"   </p>",
"   <p>",
"    At times, a supranuclear gaze abnormality occurs that is similar to that seen in progressive supranuclear palsy. A case report of a man presenting with symptoms and signs of ALS along with clinical features resembling progressive supranuclear palsy included autopsy evidence of degeneration of upper and lower motor neurons, as well as widespread TDP-43 inclusion pathology that included the basal ganglia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/21/40280/abstract/49\">",
"     49",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Sensory symptoms",
"    </span>",
"    &nbsp;&mdash;&nbsp;Sensory symptoms may occur in 20 to 30 percent of patients with ALS, but the sensory examination is usually normal [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/21/40280/abstract/1,50\">",
"     1,50",
"    </a>",
"    ]. It is not uncommon for patients with ALS, particularly those with distal limb onset of symptoms, to complain of tingling paresthesias. When queried regarding sensory loss, these patients typically will deny loss of sensation, and physical examination does not detect objective sensory loss. At times, however, objective sensory loss may occur as part of an ALS-plus syndrome and may precede or follow motor symptoms. Electrophysiologic studies may demonstrate reduction of amplitudes on sensory nerve conduction and or slowing of dorsal column conduction on somatosensory evoked potential testing, even in patients without sensory findings on examination [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/21/40280/abstract/50-54\">",
"     50-54",
"    </a>",
"    ]. Autopsy may demonstrate evidence of degeneration within sensory pathways in individuals with and without sensory loss.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Clinical patterns of progression",
"    </span>",
"    &nbsp;&mdash;&nbsp;ALS is a relentlessly progressive disorder with a clinical course that is nearly always linear, with a relatively constant slope. While the rate of progression between individuals is variable, the history should reflect gradual and progressive worsening over time without intervening remissions or exacerbations.",
"   </p>",
"   <p>",
"    Symptoms initially spread within the segment of onset and then to other regions in a relatively predictable pattern [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/21/40280/abstract/1,18,55,56\">",
"     1,18,55,56",
"    </a>",
"    ]. In patients with unilateral arm onset the most common (about 60 to 70 percent of patients) pattern of spread is to the contralateral arm, then to the ipsilateral leg, then to the contralateral remaining leg, and then to the bulbar muscles. In patients with unilateral leg onset the most common (about 60 to 70 percent of patients) pattern of spread is to the contralateral leg, then to the ipsilateral arm, then to the contralateral arm, and then to bulbar muscles. In patients with bulbar onset the most common pattern of spread is to one arm and then to the contralateral arm [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/21/40280/abstract/1,18\">",
"     1,18",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Life threatening features",
"    </span>",
"    &nbsp;&mdash;&nbsp;The progressive course of ALS eventually produces one or both of the life-threatening aspects of the disease, neuromuscular respiratory failure and dysphagia. Respiratory muscle weakness may be the first manifestation of the disease but more commonly develops after months or years of progressive limb",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    bulbar muscle weakness.",
"   </p>",
"   <p>",
"    Progressive neuromuscular respiratory failure is the most common cause of death in ALS. In the United States, 5 to 10 percent of patients choose tracheostomy and permanent ventilation when respiratory compromise becomes severe.",
"   </p>",
"   <p>",
"    Similarly, progressive dysphagia may be one of the initial manifestations of the disease or may develop after months or years of progressive limb",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    other bulbar weakness. Dysphagia poses a risk for aspiration of food, liquids, or secretions with resultant pneumonia and may also lead to malnutrition and dehydration. These conditions can be minimized in patients who choose gastrostomy tube insertion and with aggressive management of secretions.",
"   </p>",
"   <p>",
"    The median survival from the time of diagnosis is three to five years. However, about ten percent of ALS patients can live 10 years or more. Survival beyond 20 years is possible but rare and in part depends on treatment decisions made by patients and their families.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?20/35/21041?source=see_link\">",
"       \"Patient information: Amyotrophic lateral sclerosis (ALS) (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The clinical hallmark of amyotrophic lateral sclerosis (ALS) is the combination of upper motor neuron and lower motor neuron signs and symptoms. Upper motor neuron findings of weakness, hyperreflexia, and spasticity result from degeneration of frontal motor neurons. The lower motor neuron findings of weakness, atrophy or amyotrophy, and fasciculations are a direct consequence of degeneration of lower motor neurons in the brainstem and spinal cord. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Clinicopathologic features'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      ALS is one of multiple degenerative motor neuron diseases that are clinically defined, based on the involvement of upper motor neurons and lower motor neurons. The spectrum of motor neuron disease includes progressive muscular atrophy, primary lateral sclerosis, and progressive bulbar palsy, all of which may be variants of ALS, or represent different patterns of evolution to ALS. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Spectrum of motor neuron disease'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Asymmetric limb weakness is the most common presentation of ALS (80 percent). Bulbar onset, usually manifested as dysarthria or dysphagia, is the next most common pattern (20 percent). However, differences in site and segment (cranial, cervical, thoracic, or lumbosacral) of onset, pattern and speed of spread, and the degree of upper and lower motor neuron dysfunction produce a disorder that is remarkably variable between individuals. (See",
"      <a class=\"local\" href=\"#H17\">",
"       'Clinical patterns of progression'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H11\">",
"       'Upper motor neuron symptoms'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H12\">",
"       'Lower motor neuron symptoms'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Cognitive impairment, typically related to frontotemporal executive dysfunction, may precede or follow the onset of upper motor neuron",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      lower motor neuron dysfunction in patients with ALS. Frontotemporal dementia may be associated with ALS in 15 to 50 percent of cases. (See",
"      <a class=\"local\" href=\"#H13\">",
"       'Cognitive symptoms'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Autonomic symptoms, parkinsonism, supranuclear gaze paresis,",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      sensory loss may occur as part of an ALS-plus syndrome. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'ALS-plus syndrome'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H14\">",
"       'Autonomic symptoms'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H15\">",
"       'Parkinsonism and supranuclear gaze palsy'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H16\">",
"       'Sensory symptoms'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      ALS is a relentlessly progressive disorder with a clinical course that is nearly always linear. Symptoms initially spread within the segment of onset and then to other regions in a relatively predictable pattern. The progressive course of ALS eventually produces one or both of the life-threatening aspects of the disease, neuromuscular respiratory failure and dysphagia. (See",
"      <a class=\"local\" href=\"#H17\">",
"       'Clinical patterns of progression'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H18\">",
"       'Life threatening features'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     Mitsumoto H, Chad DA, Pioro EP. Amyotrophic lateral sclerosis. In: Contemporary Neurology Series, 49, F.A. Davis Company, Philadelphia 1998.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/21/40280/abstract/2\">",
"      Rowland LP. Diagnosis of amyotrophic lateral sclerosis. J Neurol Sci 1998; 160 Suppl 1:S6.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/21/40280/abstract/3\">",
"      Rowland LP. What's in a name? Amyotrophic lateral sclerosis, motor neuron disease, and allelic heterogeneity. Ann Neurol 1998; 43:691.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/21/40280/abstract/4\">",
"      Hirano A. Neuropathology of ALS: an overview. Neurology 1996; 47:S63.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/21/40280/abstract/5\">",
"      Adamek D, Tomik B, Pich&oacute;r A, et al. The heterogeneity of neuropathological changes in amyotrophic lateral sclerosis. A review of own autopsy material. Folia Neuropathol 2002; 40:119.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/21/40280/abstract/6\">",
"      Ince PG, Evans J, Knopp M, et al. Corticospinal tract degeneration in the progressive muscular atrophy variant of ALS. Neurology 2003; 60:1252.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/21/40280/abstract/7\">",
"      Ince PG, Lowe J, Shaw PJ. Amyotrophic lateral sclerosis: current issues in classification, pathogenesis and molecular pathology. Neuropathol Appl Neurobiol 1998; 24:104.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/21/40280/abstract/8\">",
"      Rowland LP. Amyotrophic lateral sclerosis. Curr Opin Neurol 1994; 7:310.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/21/40280/abstract/9\">",
"      Kim WK, Liu X, Sandner J, et al. Study of 962 patients indicates progressive muscular atrophy is a form of ALS. Neurology 2009; 73:1686.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/21/40280/abstract/10\">",
"      Rowland LP. Progressive muscular atrophy and other lower motor neuron syndromes of adults. Muscle Nerve 2010; 41:161.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/21/40280/abstract/11\">",
"      Visser J, van den Berg-Vos RM, Franssen H, et al. Disease course and prognostic factors of progressive muscular atrophy. Arch Neurol 2007; 64:522.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/21/40280/abstract/12\">",
"      Tsuchiya K, Sano M, Shiotsu H, et al. Sporadic amyotrophic lateral sclerosis of long duration mimicking spinal progressive muscular atrophy exists: additional autopsy case with a clinical course of 19 years. Neuropathology 2004; 24:228.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/21/40280/abstract/13\">",
"      Singer MA, Statland JM, Wolfe GI, Barohn RJ. Primary lateral sclerosis. Muscle Nerve 2007; 35:291.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/21/40280/abstract/14\">",
"      Gordon PH, Cheng B, Katz IB, et al. The natural history of primary lateral sclerosis. Neurology 2006; 66:647.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/21/40280/abstract/15\">",
"      Gordon PH, Cheng B, Katz IB, et al. Clinical features that distinguish PLS, upper motor neuron-dominant ALS, and typical ALS. Neurology 2009; 72:1948.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/21/40280/abstract/16\">",
"      Heene R, Kolander D, Knisatschek H. [Chronic progressive spinobulbar spasticity (primary lateral sclerosis)]. Fortschr Neurol Psychiatr 1996; 64:192.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/21/40280/abstract/17\">",
"      Rowland LP. Primary lateral sclerosis: disease, syndrome, both or neither? J Neurol Sci 1999; 170:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/21/40280/abstract/18\">",
"      Amyotrophic lateral sclerosis and other motor neuron diseases. Adv Neurol 1991; 56:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/21/40280/abstract/19\">",
"      Tan CF, Kakita A, Piao YS, et al. Primary lateral sclerosis: a rare upper-motor-predominant form of amyotrophic lateral sclerosis often accompanied by frontotemporal lobar degeneration with ubiquitinated neuronal inclusions? Report of an autopsy case and a review of the literature. Acta Neuropathol 2003; 105:615.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/21/40280/abstract/20\">",
"      Tartaglia MC, Rowe A, Findlater K, et al. Differentiation between primary lateral sclerosis and amyotrophic lateral sclerosis: examination of symptoms and signs at disease onset and during follow-up. Arch Neurol 2007; 64:232.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/21/40280/abstract/21\">",
"      Donaghy M. Classification and clinical features of motor neurone diseases and motor neuropathies in adults. J Neurol 1999; 246:331.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/21/40280/abstract/22\">",
"      Hu MT, Ellis CM, Al-Chalabi A, et al. Flail arm syndrome: a distinctive variant of amyotrophic lateral sclerosis. J Neurol Neurosurg Psychiatry 1998; 65:950.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/21/40280/abstract/23\">",
"      Katz JS, Wolfe GI, Andersson PB, et al. Brachial amyotrophic diplegia: a slowly progressive motor neuron disorder. Neurology 1999; 53:1071.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/21/40280/abstract/24\">",
"      Couratier P, Truong C, Khalil M, et al. Clinical features of flail arm syndrome. Muscle Nerve 2000; 23:646.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/21/40280/abstract/25\">",
"      Wijesekera LC, Mathers S, Talman P, et al. Natural history and clinical features of the flail arm and flail leg ALS variants. Neurology 2009; 72:1087.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/21/40280/abstract/26\">",
"      Alem&agrave; G, Brusa A, Pastorino P, Sacco G. [On 3 cases of the pseudopolyneuritic form of amyotrophic lateral sclerosis. Anatomic and electromyographic study]. J Neurol Sci 1967; 4:241.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/21/40280/abstract/27\">",
"      McCluskey LF, Elman LB, Martinez-Lage M, et al. Amyotrophic lateral sclerosis-plus syndrome with TAR DNA-binding protein-43 pathology. Arch Neurol 2009; 66:121.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/21/40280/abstract/28\">",
"      Shoesmith CL, Findlater K, Rowe A, Strong MJ. Prognosis of amyotrophic lateral sclerosis with respiratory onset. J Neurol Neurosurg Psychiatry 2007; 78:629.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/21/40280/abstract/29\">",
"      Lomen-Hoerth C, Anderson T, Miller B. The overlap of amyotrophic lateral sclerosis and frontotemporal dementia. Neurology 2002; 59:1077.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/21/40280/abstract/30\">",
"      Lomen-Hoerth C, Murphy J, Langmore S, et al. Are amyotrophic lateral sclerosis patients cognitively normal? Neurology 2003; 60:1094.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/21/40280/abstract/31\">",
"      Lomen-Hoerth C. Characterization of amyotrophic lateral sclerosis and frontotemporal dementia. Dement Geriatr Cogn Disord 2004; 17:337.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/21/40280/abstract/32\">",
"      Strong MJ, Grace GM, Orange JB, et al. A prospective study of cognitive impairment in ALS. Neurology 1999; 53:1665.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/21/40280/abstract/33\">",
"      Ringholz GM, Appel SH, Bradshaw M, et al. Prevalence and patterns of cognitive impairment in sporadic ALS. Neurology 2005; 65:586.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/21/40280/abstract/34\">",
"      Rippon GA, Scarmeas N, Gordon PH, et al. An observational study of cognitive impairment in amyotrophic lateral sclerosis. Arch Neurol 2006; 63:345.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/21/40280/abstract/35\">",
"      Murphy J, Henry R, Lomen-Hoerth C. Establishing subtypes of the continuum of frontal lobe impairment in amyotrophic lateral sclerosis. Arch Neurol 2007; 64:330.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/21/40280/abstract/36\">",
"      Phukan J, Pender NP, Hardiman O. Cognitive impairment in amyotrophic lateral sclerosis. Lancet Neurol 2007; 6:994.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/21/40280/abstract/37\">",
"      Massman PJ, Sims J, Cooke N, et al. Prevalence and correlates of neuropsychological deficits in amyotrophic lateral sclerosis. J Neurol Neurosurg Psychiatry 1996; 61:450.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/21/40280/abstract/38\">",
"      Olney RK, Murphy J, Forshew D, et al. The effects of executive and behavioral dysfunction on the course of ALS. Neurology 2005; 65:1774.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/21/40280/abstract/39\">",
"      Yoshida M. Amyotrophic lateral sclerosis with dementia: the clinicopathological spectrum. Neuropathology 2004; 24:87.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/21/40280/abstract/40\">",
"      Kertesz A. A frontotemporal family bridge. Arch Neurol 2004; 61:318.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/21/40280/abstract/41\">",
"      Toepfer M, Folwaczny C, Klauser A, et al. Gastrointestinal dysfunction in amyotrophic lateral sclerosis. Amyotroph Lateral Scler Other Motor Neuron Disord 1999; 1:15.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/21/40280/abstract/42\">",
"      Toepfer M, Folwaczny C, Lochm&uuml;ller H, et al. Noninvasive (13)C-octanoic acid breath test shows delayed gastric emptying in patients with amyotrophic lateral sclerosis. Digestion 1999; 60:567.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/21/40280/abstract/43\">",
"      Toepfer M, Schroeder M, Klauser A, et al. Delayed colonic transit times in amyotrophic lateral sclerosis assessed with radio-opaque markers. Eur J Med Res 1997; 2:473.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/21/40280/abstract/44\">",
"      Kihara M, Takahashi A, Sugenoya J, et al. Sudomotor dysfunction in amyotrophic lateral sclerosis. Funct Neurol 1994; 9:193.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/21/40280/abstract/45\">",
"      Santos-Bento M, de Carvalho M, Evangelista T, Sales Lu&iacute;s ML. Sympathetic sudomotor function and amyotrophic lateral sclerosis. Amyotroph Lateral Scler Other Motor Neuron Disord 2001; 2:105.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/21/40280/abstract/46\">",
"      Beck M, Giess R, Magnus T, et al. Progressive sudomotor dysfunction in amyotrophic lateral sclerosis. J Neurol Neurosurg Psychiatry 2002; 73:68.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/21/40280/abstract/47\">",
"      Kawata A, Kato S, Hayashi H, Hirai S. Prominent sensory and autonomic disturbances in familial amyotrophic lateral sclerosis with a Gly93Ser mutation in the SOD1 gene. J Neurol Sci 1997; 153:82.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/21/40280/abstract/48\">",
"      Shimizu T, Kawata A, Kato S, et al. Autonomic failure in ALS with a novel SOD1 gene mutation. Neurology 2000; 54:1534.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/21/40280/abstract/49\">",
"      Geser F, Martinez-Lage M, Robinson J, et al. Clinical and pathological continuum of multisystem TDP-43 proteinopathies. Arch Neurol 2009; 66:180.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/21/40280/abstract/50\">",
"      Hammad M, Silva A, Glass J, et al. Clinical, electrophysiologic, and pathologic evidence for sensory abnormalities in ALS. Neurology 2007; 69:2236.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/21/40280/abstract/51\">",
"      Feller TG, Jones RE, Netsky MG. Amyotrophic lateral sclerosis and sensory changes. Va Med Mon (1918) 1966; 93:328.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/21/40280/abstract/52\">",
"      Isaacs JD, Dean AF, Shaw CE, et al. Amyotrophic lateral sclerosis with sensory neuropathy: part of a multisystem disorder? J Neurol Neurosurg Psychiatry 2007; 78:750.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/21/40280/abstract/53\">",
"      Pugdahl K, Fuglsang-Frederiksen A, de Carvalho M, et al. Generalised sensory system abnormalities in amyotrophic lateral sclerosis: a European multicentre study. J Neurol Neurosurg Psychiatry 2007; 78:746.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/21/40280/abstract/54\">",
"      Amoiridis G, Tsimoulis D, Ameridou I. Clinical, electrophysiologic, and pathologic evidence for sensory abnormalities in ALS. Neurology 2008; 71:779.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/21/40280/abstract/55\">",
"      Ravits J, Paul P, Jorg C. Focality of upper and lower motor neuron degeneration at the clinical onset of ALS. Neurology 2007; 68:1571.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/21/40280/abstract/56\">",
"      Ravits J, Laurie P, Fan Y, Moore DH. Implications of ALS focality: rostral-caudal distribution of lower motor neuron loss postmortem. Neurology 2007; 68:1576.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 5136 Version 6.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1104-85.214.214.87-D5DBC4741A-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f39_21_40280=[""].join("\n");
var outline_f39_21_40280=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H19\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      CLINICOPATHOLOGIC FEATURES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      SPECTRUM OF MOTOR NEURON DISEASE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Progressive muscular atrophy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Primary lateral sclerosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Progressive bulbar palsy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Flail arm syndrome",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H28382562\">",
"      Flail leg syndrome",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      ALS-plus syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      CLINICAL SYMPTOMS AND SIGNS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Initial presentation and patient complaints",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Upper motor neuron symptoms",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Lower motor neuron symptoms",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Cognitive symptoms",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Autonomic symptoms",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Parkinsonism and supranuclear gaze palsy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Sensory symptoms",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Clinical patterns of progression",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Life threatening features",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"NEURO/5136\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"NEURO/5136|MOV\">",
"      <a href=\"#\" title=\"MOVIES\">",
"       MOVIES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_movie\" href=\"mobipreview.htm?6/36/6735\" title=\"movie 1\">",
"      Arm and hand atrophy in ALS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_movie\" href=\"mobipreview.htm?6/10/6318\" title=\"movie 2\">",
"      Fasciculations deltoid and triceps ALS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_movie\" href=\"mobipreview.htm?17/24/17806\" title=\"movie 3\">",
"      Tongue atrophy and fasciculations in ALS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"NEURO/5136|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?24/58/25517\" title=\"table 1\">",
"      Limb signs symptoms ALS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?33/2/33837\" title=\"table 2\">",
"      Bulbar signs symptoms ALS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?9/60/10188\" title=\"table 3\">",
"      Axial signs symptoms ALS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?36/37/37467\" title=\"table 4\">",
"      Respiratory signs symptoms ALS",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?16/34/16938?source=related_link\">",
"      Diagnosis of amyotrophic lateral sclerosis and other forms of motor neuron disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?22/57/23450?source=related_link\">",
"      Epidemiology and pathogenesis of amyotrophic lateral sclerosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?15/48/16138?source=related_link\">",
"      Familial amyotrophic lateral sclerosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?12/20/12618?source=related_link\">",
"      Frontotemporal dementia: Clinical features and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?20/35/21041?source=related_link\">",
"      Patient information: Amyotrophic lateral sclerosis (ALS) (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?32/26/33193?source=related_link\">",
"      Symptom-based management of amyotrophic lateral sclerosis",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f39_21_40281="Etiology and evaluation of nocturnal enuresis in children";
var content_f39_21_40281=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Etiology and evaluation of nocturnal enuresis in children",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?39/21/40281/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?39/21/40281/contributors\">",
"     Naiwen D Tu, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?39/21/40281/contributors\">",
"     Laurence S Baskin, MD, FAAP",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?39/21/40281/contributors\">",
"     Anne M Arnhym, CPNP",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?39/21/40281/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?39/21/40281/contributors\">",
"     Jan E Drutz, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?39/21/40281/contributors\">",
"     Carolyn Bridgemohan, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?39/21/40281/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?39/21/40281/contributors\">",
"     Mary M Torchia, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?39/21/40281/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Dec 4, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Urinary incontinence is a common problem in children. At five years of age, 15 percent of children are incompletely continent of urine. Most of these children have isolated nocturnal enuresis (monosymptomatic nocturnal enuresis).",
"   </p>",
"   <p>",
"    An overview of the causes and evaluation of nocturnal enuresis in children will be presented here. The management of nocturnal enuresis and bladder dysfunction are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?7/0/7178?source=see_link\">",
"     \"Management of nocturnal enuresis in children\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?28/7/28793?source=see_link\">",
"     \"Etiology and clinical features of bladder dysfunction in children\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?24/50/25384?source=see_link\">",
"     \"Evaluation and diagnosis of bladder dysfunction in children\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?40/51/41785?source=see_link\">",
"     \"Management of bladder dysfunction in children\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H540528631\">",
"    <span class=\"h1\">",
"     TERMINOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The International Children&rsquo;s Continence Society (ICCS) has developed standardized terminology for lower urinary tract function and malfunction in children [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/21/40281/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <strong>",
"     Enuresis",
"    </strong>",
"    (synonymous with intermittent nocturnal incontinence) refers to discrete episodes of urinary incontinence during sleep in children &ge;5 years of age [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/21/40281/abstract/1\">",
"     1",
"    </a>",
"    ]. Enuresis is divided into monosymptomatic and non-monosymptomatic forms.",
"   </p>",
"   <p>",
"    <strong>",
"     Monosymptomatic enuresis",
"    </strong>",
"    is defined as enuresis in children without any other lower urinary tract symptoms and without a history of bladder dysfunction [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/21/40281/abstract/1\">",
"     1",
"    </a>",
"    ]. Monosymptomatic nocturnal enuresis usually is divided into primary and secondary forms. Children who have never achieved a satisfactory period of nighttime dryness have",
"    <strong>",
"     primary enuresis",
"    </strong>",
"    . An estimated 80 percent of children with nocturnal enuresis have this form. Children who develop enuresis after a dry period of at least six months have",
"    <strong>",
"     secondary enuresis",
"    </strong>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/21/40281/abstract/2\">",
"     2",
"    </a>",
"    ]. Secondary enuresis often is ascribed to an unusually stressful event (eg, parental divorce, birth of a sibling) at a time of vulnerability in a child's life. However, the exact cause of secondary enuresis remains unknown.",
"   </p>",
"   <p>",
"    <strong>",
"     Non-monosymptomatic",
"    </strong>",
"    enuresis is defined as enuresis in children with other lower urinary tract symptoms, including [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/21/40281/abstract/1\">",
"     1",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Consistently increased (&ge;8",
"      <span class=\"nowrap\">",
"       times/day)",
"      </span>",
"      or decreased (&le;3",
"      <span class=\"nowrap\">",
"       times/day)",
"      </span>",
"      voiding frequency",
"     </li>",
"     <li>",
"      Daytime incontinence",
"     </li>",
"     <li>",
"      Urgency",
"     </li>",
"     <li>",
"      Hesitancy (difficulty initiating voiding)",
"     </li>",
"     <li>",
"      Straining (application of abdominal pressure to initiate and maintain voiding)",
"     </li>",
"     <li>",
"      A weak stream",
"     </li>",
"     <li>",
"      Intermittency (micturition occurs in several discrete spurts)",
"     </li>",
"     <li>",
"      Holding maneuvers (strategies used to postpone voiding)",
"     </li>",
"     <li>",
"      A feeling of incomplete emptying",
"     </li>",
"     <li>",
"      Post-micturation dribble",
"     </li>",
"     <li>",
"      Genital or lower urinary tract pain",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The pathogenesis, evaluation, and treatment of monosymptomatic nocturnal enuresis and non-monosymptomatic nocturnal enuresis overlap [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/21/40281/abstract/3\">",
"     3",
"    </a>",
"    ]. Approximately 20 percent of children who have nighttime wetting also have significant daytime symptoms [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/21/40281/abstract/4\">",
"     4",
"    </a>",
"    ]. Patients who have nocturnal enuresis with daytime symptoms are described as having",
"    <strong>",
"     bladder dysfunction",
"    </strong>",
"    (also called complex or complicated enuresis). The daytime symptoms may be limited to urgency and frequency, but often include incontinence. Urologic (eg, detrusor instability, recurrent urinary tract infection) and neurologic disorders (eg, spinal dysraphism) are more common among children with daytime symptoms than those with monosymptomatic enuresis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/21/40281/abstract/5\">",
"     5",
"    </a>",
"    ]. Approximately 15 percent of children with nighttime wetting also have troublesome encopresis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/21/40281/abstract/5\">",
"     5",
"    </a>",
"    ]. Children who have associated urinary and bowel symptoms often are described as having bowel and bladder dysfunction (BBD).",
"   </p>",
"   <p>",
"    This topic review will focus on the causes and evaluation of monosymptomatic enuresis in children. Bladder dysfunction is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?28/7/28793?source=see_link\">",
"     \"Etiology and clinical features of bladder dysfunction in children\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?24/50/25384?source=see_link\">",
"     \"Evaluation and diagnosis of bladder dysfunction in children\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?40/51/41785?source=see_link\">",
"     \"Management of bladder dysfunction in children\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY AND NATURAL HISTORY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Monosymptomatic nocturnal enuresis is common in children. The prevalence varies according to age (",
"    <a class=\"graphic graphic_figure graphicRef58087 \" href=\"mobipreview.htm?39/7/40061\">",
"     figure 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/21/40281/abstract/6-8\">",
"     6-8",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      5 years: 16 percent",
"     </li>",
"     <li>",
"      6 years: 13 percent",
"     </li>",
"     <li>",
"      7 years: 10 percent",
"     </li>",
"     <li>",
"      8 years: 7 percent",
"     </li>",
"     <li>",
"      10 years: 5 percent",
"     </li>",
"     <li>",
"      12 to 14 years: 2 to 3 percent",
"     </li>",
"     <li>",
"      &ge;15 years: 1 to 2 percent",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Monosymptomatic nocturnal enuresis is twice as common among boys as girls. It resolves spontaneously at a rate of approximately 15 percent per year [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/21/40281/abstract/9,10\">",
"     9,10",
"    </a>",
"    ]. The longer the enuresis persists, the lower the probability that it will spontaneously resolve [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/21/40281/abstract/7,9\">",
"     7,9",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     BLADDER MATURATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Normal bladder function depends upon a complex interrelationship between autonomic and somatic nerves, which are integrated at various sites in the spinal cord, brainstem, midbrain, and higher cortical centers (",
"    <a class=\"graphic graphic_figure graphicRef65433 \" href=\"mobipreview.htm?10/55/11125\">",
"     figure 2",
"    </a>",
"    ). The complex coordination permits urine storage at low pressure with high outlet resistance and voiding with low outlet resistance and sustained detrusor (bladder wall muscle) contraction.",
"   </p>",
"   <p>",
"    At birth, bladder function is thought to be coordinated through the lower spinal cord",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    primitive brain centers. Voiding at this stage is efficient but uncontrolled: uninhibited contraction is caused by progressive and sustained bladder filling. Voiding in the newborn also may be initiated by neurologically stimulating activities, such as feeding, bathing, tickling, etc.",
"   </p>",
"   <p>",
"    During the first three years of life, bladder capacity increases disproportionately relative to body surface area. By four years of age, most children void five to six times per day [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/21/40281/abstract/11,12\">",
"     11,12",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Development of bladder control appears to follow a progressive maturation whereby the child first becomes aware of bladder filling, then develops the ability to suppress detrusor contractions voluntarily and, finally, learns to coordinate sphincter and detrusor function. These skills usually are achieved, at least during the day, by approximately four years of age. Nighttime bladder control is achieved months to years after daytime control, but is not expected until five to seven years of age [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/21/40281/abstract/13,14\">",
"     13,14",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Incomplete development of bladder control results in more complex wetting problems that almost always are associated with daytime incontinence. These include bladder dysfunction, overactive bladder, underactive bladder, recurrent urinary tract infections, and some cases of vesicoureteral reflux. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?28/7/28793?source=see_link&amp;anchor=H6#H6\">",
"     \"Etiology and clinical features of bladder dysfunction in children\", section on 'Daytime urinary incontinence'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?28/7/28793?source=see_link&amp;anchor=H14#H14\">",
"     \"Etiology and clinical features of bladder dysfunction in children\", section on 'Associated conditions'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     CAUSES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Monosymptomatic nocturnal enuresis may result from one or a combination of several possible factors in a given child [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/21/40281/abstract/15-17\">",
"     15-17",
"    </a>",
"    ]. The major pathogenetic mechanisms include nocturnal polyuria, detrusor overactivity, and disturbed sleep [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/21/40281/abstract/3\">",
"     3",
"    </a>",
"    ]. Other factors that are believed to contribute include maturational delay, genetics, and abnormal secretion of antidiuretic hormone (ADH, vasopressin). Psychologic and behavioral abnormalities appear to be a result, rather than a cause, of enuresis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/21/40281/abstract/18-20\">",
"     18-20",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H611494174\">",
"     'Associated conditions'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Maturational delay",
"    </span>",
"    &nbsp;&mdash;&nbsp;In almost all cases, monosymptomatic nocturnal enuresis resolves spontaneously (",
"    <a class=\"graphic graphic_figure graphicRef58087 \" href=\"mobipreview.htm?39/7/40061\">",
"     figure 1",
"    </a>",
"    ). This observation suggests that delayed maturation of a normal developmental process plays a role in nocturnal enuresis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/21/40281/abstract/21-23\">",
"     21-23",
"    </a>",
"    ]. Some studies have demonstrated an increased incidence of delayed language and gross motor development and slowed motor performance among children with enuresis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/21/40281/abstract/24,25\">",
"     24,25",
"    </a>",
"    ]. The hypothesis that there is a difference in the central nervous system maturation in children with primary enuresis compared with controls is supported by neurophysiologic data [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/21/40281/abstract/26-28\">",
"     26-28",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Enuretic episodes are associated with characteristic urodynamic and electroencephalographic (EEG) findings. Many children who have enuresis are noted to have progressive maturation of bladder stability in conjunction with EEG findings that suggest increased central nervous system recognition of bladder fullness and the ultimate ability to suppress the onset of bladder contraction [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/21/40281/abstract/28\">",
"     28",
"    </a>",
"    ]. These findings support the hypothesis that delayed maturation of bladder control plays a role in monosymptomatic nocturnal enuresis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Genetics",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is a genetic tendency toward nocturnal enuresis. The concordance among monozygotic twins is almost twice that among dizygotic twins (68 versus 36 percent) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/21/40281/abstract/29\">",
"     29",
"    </a>",
"    ]. When one or both parents have a history of prolonged nighttime wetting, approximately one-half and three-quarters, respectively, of the offspring are affected [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/21/40281/abstract/30\">",
"     30",
"    </a>",
"    ]. On the other hand, when neither parent has a history of nocturnal enuresis, only 15 percent of offspring are affected. An autosomal dominant form of primary nocturnal enuresis with a penetrance greater than 90 percent has been identified in Danish families and linked to a locus on chromosome 13q13-q14.3 (MIM %600631) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/21/40281/abstract/31\">",
"     31",
"    </a>",
"    ]. Additional genetic loci for enuresis have been identified on chromosomes 12q13-q21 (MIM %600808) and 22q11 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/21/40281/abstract/32\">",
"     32",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Parents who experienced nocturnal enuresis as children may derive some reassurance from the knowledge of the role of genetics in enuresis, which may help them to understand that their child's problem will resolve as their own did. However, data from genetic studies have not yet been helpful in the development of treatment strategies.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Small bladder capacity",
"    </span>",
"    &nbsp;&mdash;&nbsp;At birth, bladder volume is approximately 60 mL; bladder volume increases with age at a relatively steady rate of approximately 30 mL per year. Normal bladder capacity (in ounces) can be estimated by adding 2 to the child's age in years, until 10 years of age [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/21/40281/abstract/33\">",
"     33",
"    </a>",
"    ]. Children with nocturnal enuresis, even those who do not have daytime symptoms, have been noted to have a smaller bladder capacity than age-matched children who do not have nocturnal enuresis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/21/40281/abstract/34-38\">",
"     34-38",
"    </a>",
"    ]. Clinical findings suggestive of reduced bladder capacity include urinary frequency, and associated constipation or cystitis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/21/40281/abstract/39\">",
"     39",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The reduced bladder capacity appears to be functional rather than anatomical. This was illustrated by a study in which bladder capacity was measured in the awake state as well as under general anesthesia in children with nocturnal enuresis, and compared with functional bladder capacity among controls [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/21/40281/abstract/40\">",
"     40",
"    </a>",
"    ]. Compared with control children, the average volume of urine voided by enuretic children in the awake state was reduced: 135 versus 180, 165 versus 240, and 180 versus 360 among children aged four to six years, seven to eight years, and 9 to 11 years, respectively. However, the average bladder volume measured during general anesthesia in the enuretic children was 206 mL, 229 mL, and 283 mL in the respective age groups.",
"   </p>",
"   <p>",
"    In another study, the maximal endurable bladder capacity during the daytime was similar between children with enuresis and controls [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/21/40281/abstract/41\">",
"     41",
"    </a>",
"    ]. However, among children with enuresis, the maximal voided volume during the night was significantly smaller than the maximal daytime bladder capacity, suggesting that inability to hold urine during sleep plays a role in nocturnal enuresis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Nocturnal polyuria",
"    </span>",
"    &nbsp;&mdash;&nbsp;Increased nighttime urine output appears to play an important role in nocturnal enuresis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/21/40281/abstract/3,42,43\">",
"     3,42,43",
"    </a>",
"    ]. Mechanisms for increased nighttime urine output may include increased fluid intake before bedtime [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/21/40281/abstract/39\">",
"     39",
"    </a>",
"    ], reduced response to antidiuretic hormone (ADH, vasopressin), and decreased secretion of ADH [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/21/40281/abstract/44-48\">",
"     44-48",
"    </a>",
"    ]. Clinical findings suggestive of or associated with nocturnal polyuria include majority of fluid intake during the late afternoon and evening; soaking of or through absorbent underpants; and large-volume first morning void despite nocturnal enuresis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/21/40281/abstract/39\">",
"     39",
"    </a>",
"    ]",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H634204340\">",
"    <span class=\"h3\">",
"     Role of ADH",
"    </span>",
"    &nbsp;&mdash;&nbsp;In children who do not have enuresis, urine output decreases during the night because the secretion of ADH and other regulatory hormones follows a circadian pattern, with increased secretion at night [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/21/40281/abstract/49-51\">",
"     49-51",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The relationship between ADH secretion and nighttime urinary flow rates remains controversial. Abnormalities in ADH secretion appear to play a role in at least some patients with nocturnal enuresis. However, whether these abnormalities are primary or secondary (eg, to bladder capacity or maturational delay) is not clear.",
"   </p>",
"   <p>",
"    Various observations regarding ADH secretion in enuretic children have been used to explain nocturnal enuresis:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Initial studies in enuretic children suggested that they had a blunted response to vasopressin compared with age-matched controls. It was postulated that this abnormality might permit urinary flow rates at night sufficiently high to exceed bladder capacity, resulting in enuresis. Subsequent studies failed to reproduce this observation.",
"     </li>",
"     <li>",
"      Other studies have indicated that children with nocturnal enuresis have decreased nocturnal secretion of ADH [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/21/40281/abstract/44-48\">",
"       44-48",
"      </a>",
"      ], which also would cause increased nocturnal urine output. One of the reasons may be small bladder capacity, since ADH secretion is thought to increase with bladder distension [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/21/40281/abstract/52\">",
"       52",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Neither of these observations (blunted response to ADH or decreased nocturnal secretion of ADH) explains why the children do not wake to void. However, the observations that the urine osmolality of enuretic and nonenuretic children is similar, and that early morning osmolality tends to increase with age, suggest that the ADH secretion response may be a maturational one [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/21/40281/abstract/53\">",
"     53",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H5\">",
"     'Maturational delay'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Detrusor overactivity",
"    </span>",
"    &nbsp;&mdash;&nbsp;Urodynamic testing in children who have daytime incontinence demonstrates a variety of significant functional detrusor abnormalities. In contrast, no clear pattern of urodynamic abnormality has been demonstrated in children with primary monosymptomatic nocturnal enuresis. Nonetheless, bladder dysfunction should be considered in children who have refractory monosymptomatic primary nocturnal enuresis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/21/40281/abstract/54\">",
"     54",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?28/7/28793?source=see_link&amp;anchor=H6#H6\">",
"     \"Etiology and clinical features of bladder dysfunction in children\", section on 'Daytime urinary incontinence'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Most studies suggest that the incidence of uninhibited bladder activity in children with primary monosymptomatic nocturnal enuresis is similar to the incidence of uninhibited activity in normal children (between 3 and 5 percent) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/21/40281/abstract/55-57\">",
"     55-57",
"    </a>",
"    ]. However, children with monosymptomatic nocturnal enuresis may have a defect in the circadian rhythm of detrusor inhibition [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/21/40281/abstract/58\">",
"     58",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    When urodynamic studies are performed during sleep, the only difference between enuretic and non-enuretic children is the increased rate of bladder contractions that occur in association with the enuretic episode [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/21/40281/abstract/59\">",
"     59",
"    </a>",
"    ]. In addition, urodynamic studies during sleep demonstrate a relationship between nocturnal enuresis and pelvic floor activity. When pelvic floor activity increased in association with detrusor contractions, wetting was usually avoided, and the patient would often awaken subsequently to void. In contrast, when pelvic floor activity did not increase, the detrusor contraction usually was associated with a wetting episode [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/21/40281/abstract/60,61\">",
"     60,61",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Disturbed sleep",
"    </span>",
"    &nbsp;&mdash;&nbsp;Whether abnormally deep sleep contributes to enuresis is controversial. Parents often describe their children with enuresis as excessively deep sleepers [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/21/40281/abstract/62,63\">",
"     62,63",
"    </a>",
"    ]. This may be a bias of observation, since parents rarely attempt to wake non-enuretic children. Nonetheless, in one sleep laboratory study of 33 boys aged 7 to 12 years (15 with enuresis and 18 age-matched controls), attempts at arousal were more often successful in control subjects than in boys with enuresis (40 versus 9 percent) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/21/40281/abstract/64\">",
"     64",
"    </a>",
"    ]. Excessively deep sleep also appears to contribute to nocturnal enuresis in adolescents and adults [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/21/40281/abstract/65\">",
"     65",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Another sleep study found that children with severe and refractory enuresis (&ge;5 wet",
"    <span class=\"nowrap\">",
"     nights/week)",
"    </span>",
"    slept more lightly than controls but did not wake before voiding [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/21/40281/abstract/66\">",
"     66",
"    </a>",
"    ]. Enuretic subjects had frequent cortical arousals but inability to waken completely. The cortical arousals were associated with unstable bladder contractions, suggesting to the authors that the arousal center may be paradoxically suppressed by signals from the bladder.",
"   </p>",
"   <p>",
"    Other sleep studies show that sleep patterns among children with and without enuresis are similar [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/21/40281/abstract/67,68\">",
"     67,68",
"    </a>",
"    ]. These studies indicate that enuretic episodes may occur at random throughout the night, but primarily during nonrapid eye movement (non-REM) sleep [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/21/40281/abstract/69\">",
"     69",
"    </a>",
"    ]. However, some children wet during phases of early awakening.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Psychologic",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although psychologic abnormalities have been considered to play a role in nocturnal enuresis, this relationship has not been proven. Children whose enuresis has resolved do not develop substitute symptoms, which would be expected if there was ongoing psychopathology [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/21/40281/abstract/18,19,70\">",
"     18,19,70",
"    </a>",
"    ]. In addition, perceived adjustment problems tend to improve after resolution of enuresis, suggesting that the behavioral abnormalities are a result, rather than a cause, of the enuresis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/21/40281/abstract/18-20\">",
"     18-20",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H611494174\">",
"    <span class=\"h1\">",
"     ASSOCIATED CONDITIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Nocturnal enuresis may be associated with neuropsychiatric problems, including cognitive problems, low self-esteem, and attention deficit hyperactivity disorder [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/21/40281/abstract/71-73\">",
"     71-73",
"    </a>",
"    ]. Disturbed sleep may contribute to or exacerbate these problems [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/21/40281/abstract/74\">",
"     74",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?43/38/44649?source=see_link&amp;anchor=H8#H8\">",
"     \"Evaluation of suspected obstructive sleep apnea in children\", section on 'Daytime'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h1\">",
"     DIFFERENTIAL DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Other causes of nocturnal enuresis that may require additional evaluation",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    treatment should be considered in children with enuresis. These include [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/21/40281/abstract/37,75-77\">",
"     37,75-77",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Unrecognized underlying medical disorders (eg, sickle cell disease, seizures, diabetes mellitus, diabetes insipidus, hyperthyroidism) (see appropriate topic reviews)",
"     </li>",
"     <li>",
"      Encopresis or constipation (see",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?43/9/44182?source=see_link&amp;anchor=H6#H6\">",
"       \"Definition, clinical manifestations, and evaluation of functional fecal incontinence in infants and children\", section on 'Clinical manifestations'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?14/63/15354?source=see_link&amp;anchor=H17#H17\">",
"       \"Constipation in children: Etiology and diagnosis\", section on 'Constipation and enuresis'",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Bladder dysfunction (usually associated with daytime symptoms) (see",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?28/7/28793?source=see_link&amp;anchor=H6#H6\">",
"       \"Etiology and clinical features of bladder dysfunction in children\", section on 'Daytime urinary incontinence'",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Urinary tract infection (see",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?20/40/21129?source=see_link&amp;anchor=H2#H2\">",
"       \"Clinical features and diagnosis of urinary tract infections in infants and children older than one month\", section on 'Clinical presentation'",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Chronic kidney disease (see",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?11/9/11418?source=see_link&amp;anchor=H3#H3\">",
"       \"Clinical presentation and evaluation of chronic kidney disease in children\", section on 'Clinical presentation'",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Spinal dysraphism (see",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?32/62/33767?source=see_link&amp;anchor=H17#H17\">",
"       \"Pathophysiology and clinical manifestations of myelomeningocele (spina bifida)\", section on 'Spinal cord'",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Upper airway obstruction (ie, obstructive sleep apnea) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/21/40281/abstract/78-81\">",
"       78-81",
"      </a>",
"      ] (see",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?43/38/44649?source=see_link&amp;anchor=H4#H4\">",
"       \"Evaluation of suspected obstructive sleep apnea in children\", section on 'Diagnostic evaluation'",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Pinworms [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/21/40281/abstract/82,83\">",
"       82,83",
"      </a>",
"      ] (see",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?2/33/2583?source=see_link&amp;anchor=H6#H6\">",
"       \"Enterobiasis and trichuriasis\", section on 'Clinical manifestations'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?2/33/2583?source=see_link&amp;anchor=H10#H10\">",
"       \"Enterobiasis and trichuriasis\", section on 'Diagnosis'",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Psychogenic polydipsia (see",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?23/47/24312?source=see_link&amp;anchor=H3#H3\">",
"       \"Diagnosis of polyuria and diabetes insipidus\", section on 'Primary polydipsia'",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h1\">",
"     EVALUATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The evaluation of the child with monosymptomatic nocturnal enuresis includes history, physical examination, and urinalysis. The history, including a voiding diary, is the mainstay of the evaluation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/21/40281/abstract/3,39,84\">",
"     3,39,84",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The main goal of the evaluation is to determine whether the child has bowel and bladder dysfunction or enuresis as a manifestation of an underlying medical problem (eg, posterior urethral valves or other anatomic abnormality, spinal dysraphism, diabetes, etc) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/21/40281/abstract/3\">",
"     3",
"    </a>",
"    ]. Additional evaluation may be necessary to exclude these disorders. (See",
"    <a class=\"local\" href=\"#H12\">",
"     'Differential diagnosis'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     History",
"    </span>",
"    &nbsp;&mdash;&nbsp;Important issues to be considered in the history include (",
"    <a class=\"graphic graphic_table graphicRef68994 \" href=\"mobipreview.htm?29/10/29868\">",
"     table 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/21/40281/abstract/3,37,39,75,84,85\">",
"     3,37,39,75,84,85",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Presence of daytime wetting or symptoms, including urgency, holding maneuvers, interrupted micturition, weak stream, and straining (see",
"      <a class=\"local\" href=\"#H540528631\">",
"       'Terminology'",
"      </a>",
"      above); urologic and neurologic disorders are more common among children with daytime symptoms",
"     </li>",
"     <li>",
"      Any prolonged period of dryness",
"     </li>",
"     <li>",
"      Frequency and trend of nocturnal enuresis (eg, number of wet nights per week or month, number of episodes per night, time of episodes, approximate volume of each episode)",
"     </li>",
"     <li>",
"      Fluid intake diary (does the majority of fluid intake occur during the late afternoon and evening?); this may help to identify children with diabetes, kidney disease, or psychogenic polydipsia",
"     </li>",
"     <li>",
"      Stooling history and history of soiling (to determine whether there is associated constipation or encopresis, an important cause of secondary enuresis) (see",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?14/63/15354?source=see_link\">",
"       \"Constipation in children: Etiology and diagnosis\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Determination of which interventions the family has tried",
"     </li>",
"     <li>",
"      Medical history (eg, review of systems for symptoms of sleep apnea, diabetes, sickle cell disease or trait, urinary tract infection, gait or neurologic abnormalities)",
"     </li>",
"     <li>",
"      Family history of nocturnal enuresis",
"     </li>",
"     <li>",
"      Social history (particularly important in secondary enuresis because somatic and psychologic comorbidities are more common among children with secondary enuresis) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/21/40281/abstract/2,86\">",
"       2,86",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Assessment of how the problem has affected the child and family; the risk of treatment resistance is increased in children who are not bothered by their enuresis. Postponement of therapy until the child is motivated may be warranted.",
"     </li>",
"     <li>",
"      Behavioral history or behavior screening questionnaire (to screen for psychiatric comorbidity) (see",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?19/29/19928?source=see_link&amp;anchor=H7#H7\">",
"       \"Developmental and behavioral screening tests in primary care\", section on 'Behavioral screening tests'",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H704514100\">",
"    <span class=\"h3\">",
"     Voiding diary",
"    </span>",
"    &nbsp;&mdash;&nbsp;A voiding diary is helpful in identifying children with non-monosymptomatic enuresis or other conditions that may require additional evaluation or referral. The diary should include [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/21/40281/abstract/3,39,85\">",
"     3,39,85",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      The number of daytime voids",
"     </li>",
"     <li>",
"      Usual volume of voided urine (to estimate bladder capacity)",
"     </li>",
"     <li>",
"      Maximum length of time between voids",
"     </li>",
"     <li>",
"      Lower urinary tract symptoms (eg, difficulty starting or stopping stream; dribbling; sensation of incomplete emptying)",
"     </li>",
"     <li>",
"      Timing of voids in relation to events such as meals, school breaks, play activities, etc",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Sample frequency-volume charts are available from the",
"    <a class=\"external\" href=\"file://www.i-c-c-s.org/\">",
"     International Children's Continence Society",
"    </a>",
"    .",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Physical examination",
"    </span>",
"    &nbsp;&mdash;&nbsp;The physical examination of the child with primary monosymptomatic nocturnal enuresis usually is normal. Aspects of the physical examination that may indicate an underlying medical etiology for enuresis include (",
"    <a class=\"graphic graphic_table graphicRef80638 \" href=\"mobipreview.htm?33/28/34251\">",
"     table 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/21/40281/abstract/3,39,85\">",
"     3,39,85",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Poor growth",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      hypertension (",
"      <a class=\"calc calc_professional\" href=\"mobipreview.htm?9/15/9463?source=see_link\">",
"       calculator 1",
"      </a>",
"      and",
"      <a class=\"calc calc_professional\" href=\"mobipreview.htm?9/33/9751?source=see_link\">",
"       calculator 2",
"      </a>",
"      ) may indicate renal disease.",
"     </li>",
"     <li>",
"      Evidence of adenotonsillar hypertrophy or other signs of sleep apnea. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?43/38/44649?source=see_link&amp;anchor=H9#H9\">",
"       \"Evaluation of suspected obstructive sleep apnea in children\", section on 'Examination'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Detection of wetness in the undergarments is a sign of daytime incontinence.",
"     </li>",
"     <li>",
"      Palpation of stool in the abdomen suggests constipation or encopresis.",
"     </li>",
"     <li>",
"      Perianal excoriation or vulvovaginitis may indicate pinworm infection. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?2/33/2583?source=see_link\">",
"       \"Enterobiasis and trichuriasis\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Presence of abnormalities of the lumbosacral spine (eg, abnormal tuft of hair or an abnormality in the gluteal fold)",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      abnormalities on neurologic examination of the perineum and lower extremities may indicate occult spinal cord abnormalities. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?32/62/33767?source=see_link\">",
"       \"Pathophysiology and clinical manifestations of myelomeningocele (spina bifida)\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Detection of incomplete bladder emptying by percussion",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      palpation or observation of voiding that demonstrates slow urinary stream, dribbling, or intermittent stream may indicate urologic abnormalities (eg, posterior urethral valves, ectopic ureter). (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?11/0/11271?source=see_link&amp;anchor=H6#H6\">",
"       \"Clinical presentation and diagnosis of posterior urethral valves\", section on 'Clinical manifestations'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?39/3/39989?source=see_link&amp;anchor=H6#H6\">",
"       \"Ectopic ureter\", section on 'Clinical presentation'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Undescended testicles, underdeveloped scrotum, and abnormal location or characteristics of the urethral meatus also may indicate urologic abnormalities. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?16/44/17098?source=see_link\">",
"       \"Undescended testes (cryptorchidism) in children and adolescents\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?25/42/26280?source=see_link\">",
"       \"Hypospadias\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Urinalysis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Urinalysis should be performed in all children with monosymptomatic enuresis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/21/40281/abstract/3\">",
"     3",
"    </a>",
"    ]. The urinalysis (including specific gravity) is obtained as a screen for diabetic ketoacidosis, diabetes insipidus, water intoxication,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    occult urinary tract infection [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/21/40281/abstract/39\">",
"     39",
"    </a>",
"    ]. Urine culture is not necessary unless indicated by the presence of white blood cells or nitrites on urinalysis. (See appropriate topic reviews).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Imaging",
"    </span>",
"    &nbsp;&mdash;&nbsp;Urologic imaging (renal sonogram and voiding cystourethrogram) is reserved for children who have significant daytime complaints, a history of urinary tract infection(s) not previously evaluated,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    signs and symptoms of structural urologic abnormalities [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/21/40281/abstract/3,39,87\">",
"     3,39,87",
"    </a>",
"    ]. Ultrasonography may be helpful in estimating bladder capacity, post-void residual volume, and bladder wall thickness.",
"   </p>",
"   <p>",
"    An abdominal radiograph may be useful in determining the presence",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    extent of stool retention. Treatment of stool retention has been associated with resolved enuresis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/21/40281/abstract/88\">",
"     88",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?14/63/15354?source=see_link&amp;anchor=H24#H24\">",
"     \"Constipation in children: Etiology and diagnosis\", section on 'Diagnostic testing'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Neurologic imaging (usually magnetic resonance imaging of the spine) is indicated in children who are noted to have abnormalities of the lower lumbosacral spine on neurologic examination of the perineum and lower extremities [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/21/40281/abstract/89\">",
"     89",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h1\">",
"     REFERRAL",
"    </span>",
"    &nbsp;&mdash;&nbsp;Children who have clinical or radiographic findings suggestive of",
"    <span class=\"nowrap\">",
"     renal/urologic",
"    </span>",
"    abnormality or bladder overactivity should be referred to a pediatric",
"    <span class=\"nowrap\">",
"     nephrologist/urologist",
"    </span>",
"    for further evaluation. Such findings include [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/21/40281/abstract/3\">",
"     3",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Daytime incontinence; urgency; holding measures; increased (&ge;8",
"      <span class=\"nowrap\">",
"       times/day)",
"      </span>",
"      or decreased (&le;3",
"      <span class=\"nowrap\">",
"       times/day)",
"      </span>",
"      voiding frequency (possible bladder dysfunction)",
"     </li>",
"     <li>",
"      Weak stream, use of abdominal pressure, continuous incontinence, micturition in more than one phase (possible neurogenic bladder or anatomic abnormalities)",
"     </li>",
"     <li>",
"      Proteinuria, nausea, weight loss, or fatigue (possible kidney disease)",
"     </li>",
"     <li>",
"      Excessive thirst, need for nighttime drinking (possible polydipsia or kidney disease)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Referral to an enuresis specialist may be warranted for children who have nightly enuresis since the prognosis in such children is unfavorable [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/21/40281/abstract/3,90\">",
"     3,90",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Referral to a pediatric neurosurgeon may be warranted for children with clinical or radiographic findings suggestive of occult spinal dysraphism (eg, abnormalities of the lower lumbosacral spine).",
"   </p>",
"   <p>",
"    Referral to a sleep specialist may be warranted for children with evidence of adenotonsillar hypertrophy or sleep disordered breathing. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?27/51/28473?source=see_link&amp;anchor=H27172953#H27172953\">",
"     \"Sleepwalking and other parasomnias in children\", section on 'Sleep enuresis'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?43/38/44649?source=see_link&amp;anchor=H4#H4\">",
"     \"Evaluation of suspected obstructive sleep apnea in children\", section on 'Diagnostic evaluation'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H540528665\">",
"    <span class=\"h1\">",
"     RESOURCES",
"    </span>",
"    &nbsp;&mdash;&nbsp;The",
"    <a class=\"external\" href=\"file://www.i-c-c-s.org/\">",
"     International Children's Continence Society",
"    </a>",
"    provides guidelines for the evaluation and treatment of monosymptomatic enuresis, as well as information for the general public.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topic (see",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?36/39/37489?source=see_link\">",
"       \"Patient information: Bedwetting in children (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Beyond the Basics topic (see",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?7/9/7315?source=see_link\">",
"       \"Patient information: Bedwetting in children (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H692664099\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Enuresis refers to discrete episodes of urinary incontinence during sleep in children who are &ge;5 years of age. Monosymptomatic enuresis refers to enuresis in children without any other lower urinary tract symptoms and without a history of bladder dysfunction. (See",
"      <a class=\"local\" href=\"#H540528631\">",
"       'Terminology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Monosymptomatic nocturnal enuresis has a high rate of spontaneous resolution: the prevalence decreases from 15 percent among five-year-old children to 1 to 2 percent among those &ge;15 years (",
"      <a class=\"graphic graphic_figure graphicRef58087 \" href=\"mobipreview.htm?39/7/40061\">",
"       figure 1",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Epidemiology and natural history'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Monosymptomatic nocturnal enuresis may result from one or a combination of several possible factors. The major pathogenetic mechanisms include nocturnal polyuria, detrusor overactivity, and disturbed sleep. Other factors may include maturational delay, genetics, and abnormal secretion of antidiuretic hormone. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Causes'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The evaluation of children with nocturnal enuresis should include a complete history (",
"      <a class=\"graphic graphic_table graphicRef68994 \" href=\"mobipreview.htm?29/10/29868\">",
"       table 1",
"      </a>",
"      ), voiding diary, physical examination (",
"      <a class=\"graphic graphic_table graphicRef80638 \" href=\"mobipreview.htm?33/28/34251\">",
"       table 2",
"      </a>",
"      ), and urinalysis. The main purpose of the evaluation is to determine whether the child has complex enuresis or enuresis as a manifestation of an underlying medical problem. (See",
"      <a class=\"local\" href=\"#H12\">",
"       'Differential diagnosis'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H13\">",
"       'Evaluation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Children who have clinical or radiographic findings suggestive of",
"      <span class=\"nowrap\">",
"       renal/urologic",
"      </span>",
"      abnormality or bladder overactivity should be referred to a pediatric",
"      <span class=\"nowrap\">",
"       nephrologist/urologist",
"      </span>",
"      for further evaluation. Referral to a pediatric neurosurgeon may be warranted for children with clinical or radiographic findings suggestive of occult spinal dysraphism. (See",
"      <a class=\"local\" href=\"#H18\">",
"       'Referral'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21595985\">",
"    <span class=\"h1\">",
"     ACKNOWLEDGMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;The editorial staff at UpToDate, Inc. would like to acknowledge Dr. Edmond Gonzales, who contributed to an earlier version of this topic review.",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/21/40281/abstract/1\">",
"      Nev&eacute;us T, von Gontard A, Hoebeke P, et al. The standardization of terminology of lower urinary tract function in children and adolescents: report from the Standardisation Committee of the International Children's Continence Society. J Urol 2006; 176:314.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/21/40281/abstract/2\">",
"      von Gontard A, Mauer-Mucke K, Pl&uuml;ck J, et al. Clinical behavioral problems in day- and night-wetting children. Pediatr Nephrol 1999; 13:662.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/21/40281/abstract/3\">",
"      Neveus T, Eggert P, Evans J, et al. Evaluation of and treatment for monosymptomatic enuresis: a standardization document from the International Children's Continence Society. J Urol 2010; 183:441.",
"     </a>",
"    </li>",
"    <li>",
"     Koff S. Enuresis. In: Campbell's Urology, 7th ed, Walsh P, Retik A Jr, et al (Eds), WB Saunders, Philadelphia 1998. p.2055.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/21/40281/abstract/5\">",
"      Rushton HG. Wetting and functional voiding disorders. Urol Clin North Am 1995; 22:75.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/21/40281/abstract/6\">",
"      Fergusson DM, Horwood LJ, Shannon FT. Factors related to the age of attainment of nocturnal bladder control: an 8-year longitudinal study. Pediatrics 1986; 78:884.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/21/40281/abstract/7\">",
"      Bakker E, van Sprundel M, van der Auwera JC, et al. Voiding habits and wetting in a population of 4,332 Belgian schoolchildren aged between 10 and 14 years. Scand J Urol Nephrol 2002; 36:354.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/21/40281/abstract/8\">",
"      Howe AC, Walker CE. Behavioral management of toilet training, enuresis, and encopresis. Pediatr Clin North Am 1992; 39:413.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/21/40281/abstract/9\">",
"      Forsythe WI, Redmond A. Enuresis and spontaneous cure rate. Study of 1129 enuretis. Arch Dis Child 1974; 49:259.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/21/40281/abstract/10\">",
"      Klackenberg G. Nocturnal enuresis in a longitudinal perspective. A primary problem of maturity and/or a secondary environmental reaction? Acta Paediatr Scand 1981; 70:453.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/21/40281/abstract/11\">",
"      Esperanca M, Gerrard JW. Nocturnal enuresis: studies in bladder function in normal children and enuretics. Can Med Assoc J 1969; 101:324.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/21/40281/abstract/12\">",
"      Bloom DA, Seeley WW, Ritchey ML, McGuire EJ. Toilet habits and continence in children: an opportunity sampling in search of normal parameters. J Urol 1993; 149:1087.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/21/40281/abstract/13\">",
"      Michel RS. Toilet training. Pediatr Rev 1999; 20:240.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/21/40281/abstract/14\">",
"      Stadtler AC, Gorski PA, Brazelton TB. Toilet training methods, clinical interventions, and recommendations. American Academy of Pediatrics. Pediatrics 1999; 103:1359.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/21/40281/abstract/15\">",
"      Wille S. Primary nocturnal enuresis in children. Background and treatment. Scand J Urol Nephrol Suppl 1994; 156:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/21/40281/abstract/16\">",
"      N&oslash;rgaard JP, Djurhuus JC. The pathophysiology of enuresis in children and young adults. Clin Pediatr (Phila) 1993; Spec No:5.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/21/40281/abstract/17\">",
"      N&oslash;rgaard JP. Pathophysiology of nocturnal enuresis. Scand J Urol Nephrol Suppl 1991; 140:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/21/40281/abstract/18\">",
"      Baker BL. Symptom treatment and symptom substitution in enuresis. J Abnorm Psychol 1969; 74:42.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/21/40281/abstract/19\">",
"      Young GC, Morgan RT. Conditioning techniques and enuresis. Med J Aust 1973; 2:329.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/21/40281/abstract/20\">",
"      Longstaffe S, Moffatt ME, Whalen JC. Behavioral and self-concept changes after six months of enuresis treatment: a randomized, controlled trial. Pediatrics 2000; 105:935.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/21/40281/abstract/21\">",
"      J&auml;rvelin MR. Developmental history and neurological findings in enuretic children. Dev Med Child Neurol 1989; 31:728.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/21/40281/abstract/22\">",
"      Light L. Children with enuresis. Most cases of primary nocturnal enuresis are caused by isolated developmental immaturity. BMJ 1998; 316:777.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/21/40281/abstract/23\">",
"      Koff SA. Cure of nocturnal enuresis: why isn't desmopressin very effective? Pediatr Nephrol 1996; 10:667.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/21/40281/abstract/24\">",
"      J&auml;rvelin MR, Moilanen I, Kangas P, et al. Aetiological and precipitating factors for childhood enuresis. Acta Paediatr Scand 1991; 80:361.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/21/40281/abstract/25\">",
"      von Gontard A, Freitag CM, Seifen S, et al. Neuromotor development in nocturnal enuresis. Dev Med Child Neurol 2006; 48:744.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/21/40281/abstract/26\">",
"      Iscan A, Ozkul Y, Unal D, et al. Abnormalities in event-related potential and brainstem auditory evoked response in children with nocturnal enuresis. Brain Dev 2002; 24:681.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/21/40281/abstract/27\">",
"      Freitag CM, R&ouml;hling D, Seifen S, et al. Neurophysiology of nocturnal enuresis: evoked potentials and prepulse inhibition of the startle reflex. Dev Med Child Neurol 2006; 48:278.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/21/40281/abstract/28\">",
"      Watanabe H, Azuma Y. A proposal for a classification system of enuresis based on overnight simultaneous monitoring of electroencephalography and cystometry. Sleep 1989; 12:257.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/21/40281/abstract/29\">",
"      Bakwin H. Enuresis in twins. Am J Dis Child 1971; 121:222.",
"     </a>",
"    </li>",
"    <li>",
"     Bakwin H. The genetics of enuresis. In: Bladder Control and Enuresis, Kolvin RM, Meadows SR (Eds), Medical Books Ltd, London 1973. p.73.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/21/40281/abstract/31\">",
"      Eiberg H, Berendt I, Mohr J. Assignment of dominant inherited nocturnal enuresis (ENUR1) to chromosome 13q. Nat Genet 1995; 10:354.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/21/40281/abstract/32\">",
"      Loeys B, Hoebeke P, Raes A, et al. Does monosymptomatic enuresis exist? A molecular genetic exploration of 32 families with enuresis/incontinence. BJU Int 2002; 90:76.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/21/40281/abstract/33\">",
"      Koff SA. Estimating bladder capacity in children. Urology 1983; 21:248.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/21/40281/abstract/34\">",
"      MUELLNER SR. Development of urinary control in children: some aspects of the cause and treatment of primary enuresis. J Am Med Assoc 1960; 172:1256.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/21/40281/abstract/35\">",
"      Starfield B. Functional bladder capacity in enuretic and nonenuretic children. J Pediatr 1967; 70:777.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/21/40281/abstract/36\">",
"      Wu HH, Chen MY, Lee YH, et al. Urodynamic studies in primary nocturnal enuresis. Zhonghua Yi Xue Za Zhi (Taipei) 1988; 41:227.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/21/40281/abstract/37\">",
"      Jalkut MW, Lerman SE, Churchill BM. Enuresis. Pediatr Clin North Am 2001; 48:1461.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/21/40281/abstract/38\">",
"      VULLIAMY D. The day and night output of urine in enuresis. Arch Dis Child 1956; 31:439.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/21/40281/abstract/39\">",
"      Robson WL. Clinical practice. Evaluation and management of enuresis. N Engl J Med 2009; 360:1429.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/21/40281/abstract/40\">",
"      Troup CW, Hodgson NB. Nocturnal functional bladder capacity in enuretic children. Wis Med J 1971; 70:171.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/21/40281/abstract/41\">",
"      Kawauchi A, Tanaka Y, Naito Y, et al. Bladder capacity at the time of enuresis. Urology 2003; 61:1016.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/21/40281/abstract/42\">",
"      POULTON EM. Relative nocturnal polyuria as a factor in enuresis. Lancet 1952; 2:906.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/21/40281/abstract/43\">",
"      Rasmussen PV, Kirk J, Borup K, et al. Enuresis nocturna can be provoked in normal healthy children by increasing the nocturnal urine output. Scand J Urol Nephrol 1996; 30:57.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/21/40281/abstract/44\">",
"      Aikawa T, Kasahara T, Uchiyama M. The arginine-vasopressin secretion profile of children with primary nocturnal enuresis. Eur Urol 1998; 33 Suppl 3:41.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/21/40281/abstract/45\">",
"      Rittig S, Knudsen UB, N&oslash;rgaard JP, et al. Diurnal variation of plasma atrial natriuretic peptide in normals and patients with enuresis nocturna. Scand J Clin Lab Invest 1991; 51:209.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/21/40281/abstract/46\">",
"      Pomeranz A, Abu-Kheat G, Korzets Z, Wolach B. Night-time polyuria and urine hypo-osmolality in enuretics identified by nocturnal sequential urine sampling--do they represent a subset of relative ADH-deficient subjects? Scand J Urol Nephrol 2000; 34:199.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/21/40281/abstract/47\">",
"      Aceto G, Penza R, Delvecchio M, et al. Sodium fraction excretion rate in nocturnal enuresis correlates with nocturnal polyuria and osmolality. J Urol 2004; 171:2567.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/21/40281/abstract/48\">",
"      Rittig S, Schaumburg HL, Siggaard C, et al. The circadian defect in plasma vasopressin and urine output is related to desmopressin response and enuresis status in children with nocturnal enuresis. J Urol 2008; 179:2389.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/21/40281/abstract/49\">",
"      Yeung CK, Sit FK, To LK, et al. Reduction in nocturnal functional bladder capacity is a common factor in the pathogenesis of refractory nocturnal enuresis. BJU Int 2002; 90:302.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/21/40281/abstract/50\">",
"      George CP, Messerli FH, Genest J, et al. Diurnal variation of plasma vasopressin in man. J Clin Endocrinol Metab 1975; 41:332.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/21/40281/abstract/51\">",
"      Rittig S, Matthiesen TB, Pedersen EB, Djurhuus JC. Circadian variation of angiotensin II and aldosterone in nocturnal enuresis: relationship to arterial blood pressure and urine output. J Urol 2006; 176:774.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/21/40281/abstract/52\">",
"      Kawauchi A, Watanabe H, Nakagawa S, Miyoshi K. [Development of bladder capacity, nocturnal urinary volume and urinary behavior in nonenuretic and enuretic children]. Nihon Hinyokika Gakkai Zasshi 1993; 84:1811.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/21/40281/abstract/53\">",
"      Kawauchi A, Watanabe H, Miyoshi K. Early morning urine osmolality in nonenuretic and enuretic children. Pediatr Nephrol 1996; 10:696.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/21/40281/abstract/54\">",
"      Yeung CK, Chiu HN, Sit FK. Bladder dysfunction in children with refractory monosymptomatic primary nocturnal enuresis. J Urol 1999; 162:1049.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/21/40281/abstract/55\">",
"      N&oslash;rgaard JP, Hansen JH, Nielsen JB, et al. Simultaneous registration of sleep-stages and bladder activity in enuresis. Urology 1985; 26:316.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/21/40281/abstract/56\">",
"      Norgaard J. Urodynamic in enuretics: I. Reservoir function. Neurourol Urodynamics 1989; 8:199.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/21/40281/abstract/57\">",
"      Norgaard J. Urodynamics in enuretics: II. A pressure-flow study. Neurourol Urodynamics 1989; 8:213.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/21/40281/abstract/58\">",
"      Van Hoeck K, Bael A, Lax H, et al. Urine output rate and maximum volume voided in school-age children with and without nocturnal enuresis. J Pediatr 2007; 151:575.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/21/40281/abstract/59\">",
"      N&oslash;rgaard JP, Hansen JH, Nielsen JB, et al. Nocturnal studies in enuretics. A polygraphic study of sleep-EEG and bladder activity. Scand J Urol Nephrol Suppl 1989; 125:73.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/21/40281/abstract/60\">",
"      N&oslash;rgaard JP, Hansen JH, Wildschi&oslash;tz G, et al. Sleep cystometries in children with nocturnal enuresis. J Urol 1989; 141:1156.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/21/40281/abstract/61\">",
"      Broughton RJ. Sleep disorders: disorders of arousal? Enuresis, somnambulism, and nightmares occur in confusional states of arousal, not in \"dreaming sleep\". Science 1968; 159:1070.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/21/40281/abstract/62\">",
"      Wille S. Nocturnal enuresis: sleep disturbance and behavioural patterns. Acta Paediatr 1994; 83:772.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/21/40281/abstract/63\">",
"      Nev&eacute;us T, Hetta J, Cnattingius S, et al. Depth of sleep and sleep habits among enuretic and incontinent children. Acta Paediatr 1999; 88:748.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/21/40281/abstract/64\">",
"      Wolfish NM, Pivik RT, Busby KA. Elevated sleep arousal thresholds in enuretic boys: clinical implications. Acta Paediatr 1997; 86:381.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/21/40281/abstract/65\">",
"      Hunsballe JM. Increased delta component in computerized sleep electroencephalographic analysis suggests abnormally deep sleep in primary monosymptomatic nocturnal enuresis. Scand J Urol Nephrol 2000; 34:294.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/21/40281/abstract/66\">",
"      Yeung CK, Diao M, Sreedhar B. Cortical arousal in children with severe enuresis. N Engl J Med 2008; 358:2414.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/21/40281/abstract/67\">",
"      Ritvo ER, Ornitz EM, Gottlieb F, et al. Arousal and nonarousal enuretic events. Am J Psychiatry 1969; 126:77.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/21/40281/abstract/68\">",
"      Bader G, Nev&eacute;us T, Kruse S, Sill&eacute;n U. Sleep of primary enuretic children and controls. Sleep 2002; 25:579.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/21/40281/abstract/69\">",
"      Nev&eacute;us T, Stenberg A, L&auml;ckgren G, et al. Sleep of children with enuresis: a polysomnographic study. Pediatrics 1999; 103:1193.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/21/40281/abstract/70\">",
"      Wille S, Anveden I. Social and behavioural perspectives in enuretics, former enuretics and non-enuretic controls. Acta Paediatr 1995; 84:37.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/21/40281/abstract/71\">",
"      Joinson C, Heron J, Butler R, et al. A United Kingdom population-based study of intellectual capacities in children with and without soiling, daytime wetting, and bed-wetting. Pediatrics 2007; 120:e308.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/21/40281/abstract/72\">",
"      H&auml;ggl&ouml;f B, Andr&eacute;n O, Bergstr&ouml;m E, et al. Self-esteem before and after treatment in children with nocturnal enuresis and urinary incontinence. Scand J Urol Nephrol Suppl 1997; 183:79.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/21/40281/abstract/73\">",
"      Baeyens D, Roeyers H, Hoebeke P, et al. Attention deficit/hyperactivity disorder in children with nocturnal enuresis. J Urol 2004; 171:2576.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/21/40281/abstract/74\">",
"      Nev&eacute;us T. Diagnosis and management of nocturnal enuresis. Curr Opin Pediatr 2009; 21:199.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/21/40281/abstract/75\">",
"      Ullom-Minnich MR. Diagnosis and management of nocturnal enuresis. Am Fam Physician 1996; 54:2259.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/21/40281/abstract/76\">",
"      Robson WL, Leung AK. Secondary nocturnal enuresis. Clin Pediatr (Phila) 2000; 39:379.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/21/40281/abstract/77\">",
"      Readett DR, Morris JS, Serjeant GR. Nocturnal enuresis in sickle cell haemoglobinopathies. Arch Dis Child 1990; 65:290.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/21/40281/abstract/78\">",
"      Cinar U, Vural C, Cakir B, et al. Nocturnal enuresis and upper airway obstruction. Int J Pediatr Otorhinolaryngol 2001; 59:115.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/21/40281/abstract/79\">",
"      Firoozi F, Batniji R, Aslan AR, et al. Resolution of diurnal incontinence and nocturnal enuresis after adenotonsillectomy in children. J Urol 2006; 175:1885.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/21/40281/abstract/80\">",
"      Brooks LJ, Topol HI. Enuresis in children with sleep apnea. J Pediatr 2003; 142:515.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/21/40281/abstract/81\">",
"      Basha S, Bialowas C, Ende K, Szeremeta W. Effectiveness of adenotonsillectomy in the resolution of nocturnal enuresis secondary to obstructive sleep apnea. Laryngoscope 2005; 115:1101.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/21/40281/abstract/82\">",
"      Mayers CP, Purvis RJ. Manifestations of pinworms. Can Med Assoc J 1970; 103:489.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/21/40281/abstract/83\">",
"      Sachdev YV, Howards SS. Enterobius vermicularis infestation and secondary enuresis. J Urol 1975; 113:143.",
"     </a>",
"    </li>",
"    <li>",
"     National Institute for Health and Clinical Excellence. Nocturnal enuresis - the management of bedwetting in children and young people. file://www.nice.org.uk/guidance/index.jsp?action=download&amp;o=51367 (Accessed on February 28, 2011).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/21/40281/abstract/85\">",
"      Vande Walle J, Rittig S, Bauer S, et al. Practical consensus guidelines for the management of enuresis. Eur J Pediatr 2012; 171:971.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/21/40281/abstract/86\">",
"      Robson WL, Leung AK, Van Howe R. Primary and secondary nocturnal enuresis: similarities in presentation. Pediatrics 2005; 115:956.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/21/40281/abstract/87\">",
"      Rushton HG. Evaluation of the enuretic child. Clin Pediatr (Phila) 1993; Spec No:14.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/21/40281/abstract/88\">",
"      Hodges SJ, Anthony EY. Occult megarectum--a commonly unrecognized cause of enuresis. Urology 2012; 79:421.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/21/40281/abstract/89\">",
"      Pippi Salle JL, Capolicchio G, Houle AM, et al. Magnetic resonance imaging in children with voiding dysfunction: is it indicated? J Urol 1998; 160:1080.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/21/40281/abstract/90\">",
"      Yeung CK, Sreedhar B, Sihoe JD, et al. Differences in characteristics of nocturnal enuresis between children and adolescents: a critical appraisal from a large epidemiological study. BJU Int 2006; 97:1069.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 2862 Version 13.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-60.18.131.125-8F74BD76B3-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f39_21_40281=[""].join("\n");
var outline_f39_21_40281=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H692664099\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H540528631\">",
"      TERMINOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      EPIDEMIOLOGY AND NATURAL HISTORY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      BLADDER MATURATION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      CAUSES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Maturational delay",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Genetics",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Small bladder capacity",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Nocturnal polyuria",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H634204340\">",
"      - Role of ADH",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Detrusor overactivity",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Disturbed sleep",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Psychologic",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H611494174\">",
"      ASSOCIATED CONDITIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      DIFFERENTIAL DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      EVALUATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      History",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H704514100\">",
"      - Voiding diary",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Physical examination",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Urinalysis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Imaging",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      REFERRAL",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H540528665\">",
"      RESOURCES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H692664099\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H21595985\">",
"      ACKNOWLEDGMENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PEDS/2862\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PEDS/2862|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?39/7/40061\" title=\"figure 1\">",
"      Monosymptomatic enuresis epidemiology",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?10/55/11125\" title=\"figure 2\">",
"      Normal urinary voiding",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PEDS/2862|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?29/10/29868\" title=\"table 1\">",
"      Enuresis history",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?33/28/34251\" title=\"table 2\">",
"      Enuresis examination",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   CALCULATORS",
"  </h1>",
"  <div id=\"relatedCalculators\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"calc calc_professional\" href=\"mobipreview.htm?9/15/9463?source=related_link\" title=\"calculator 1\">",
"      Calculator: Blood pressure percentiles for boys (2 to 17 years)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"calc calc_professional\" href=\"mobipreview.htm?9/33/9751?source=related_link\" title=\"calculator 2\">",
"      Calculator: Blood pressure percentiles for girls (2 to 17 years)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?20/40/21129?source=related_link\">",
"      Clinical features and diagnosis of urinary tract infections in infants and children older than one month",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?11/0/11271?source=related_link\">",
"      Clinical presentation and diagnosis of posterior urethral valves",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?11/9/11418?source=related_link\">",
"      Clinical presentation and evaluation of chronic kidney disease in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?14/63/15354?source=related_link\">",
"      Constipation in children: Etiology and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?43/9/44182?source=related_link\">",
"      Definition, clinical manifestations, and evaluation of functional fecal incontinence in infants and children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?19/29/19928?source=related_link\">",
"      Developmental and behavioral screening tests in primary care",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?23/47/24312?source=related_link\">",
"      Diagnosis of polyuria and diabetes insipidus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?39/3/39989?source=related_link\">",
"      Ectopic ureter",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?2/33/2583?source=related_link\">",
"      Enterobiasis and trichuriasis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?28/7/28793?source=related_link\">",
"      Etiology and clinical features of bladder dysfunction in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?24/50/25384?source=related_link\">",
"      Evaluation and diagnosis of bladder dysfunction in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?43/38/44649?source=related_link\">",
"      Evaluation of suspected obstructive sleep apnea in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?25/42/26280?source=related_link\">",
"      Hypospadias",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?40/51/41785?source=related_link\">",
"      Management of bladder dysfunction in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?7/0/7178?source=related_link\">",
"      Management of nocturnal enuresis in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?32/62/33767?source=related_link\">",
"      Pathophysiology and clinical manifestations of myelomeningocele (spina bifida)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?7/9/7315?source=related_link\">",
"      Patient information: Bedwetting in children (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?36/39/37489?source=related_link\">",
"      Patient information: Bedwetting in children (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?27/51/28473?source=related_link\">",
"      Sleepwalking and other parasomnias in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?16/44/17098?source=related_link\">",
"      Undescended testes (cryptorchidism) in children and adolescents",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f39_21_40282="Overview of the complications of peptic ulcer disease";
var content_f39_21_40282=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"6\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Overview of the complications of peptic ulcer disease",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?39/21/40282/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?39/21/40282/contributors\">",
"     Andrew H Soll, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?39/21/40282/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?39/21/40282/contributors\">",
"     Mark Feldman, MD, MACP, AGAF, FACG",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?39/21/40282/contributors\">",
"     David I Soybel, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?39/21/40282/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?39/21/40282/contributors\">",
"     Shilpa Grover, MD, MPH",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?39/21/40282/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jun 1, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H62849741\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Complications of peptic ulcer disease (PUD) include bleeding, perforation, penetration, and gastric outlet obstruction. With time, there have been major shifts in the etiologies of complicated peptic ulcers and in the affected patient populations. In addition, management has undergone dramatic changes. Management now includes the early use of high-dose intravenous proton pump inhibitors (PPIs), treatment to eradicate Helicobacter pylori (H. pylori), improved endoscopic methods for control of hemorrhage, and changes in surgical indications and procedures. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?22/32/23049?source=see_link\">",
"     \"Treatment regimens for Helicobacter pylori\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?24/28/25034?source=see_link\">",
"     \"Overview and comparison of the proton pump inhibitors for the treatment of acid-related disorders\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?24/15/24826?source=see_link\">",
"     \"Overview of the treatment of bleeding peptic ulcers\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    This topic will provide an overview of the major complications of PUD. The approach to patients with complicated PUD, the endoscopic management of peptic ulcer bleeding, and the surgical approaches to complications of PUD are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?24/21/24919?source=see_link\">",
"     \"Diagnosis of peptic ulcer disease\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?41/18/42281?source=see_link\">",
"     \"Overview of the natural history and treatment of peptic ulcer disease\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?24/15/24826?source=see_link\">",
"     \"Overview of the treatment of bleeding peptic ulcers\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?32/57/33688?source=see_link\">",
"     \"Role of surgery in the management of peptic ulcer disease\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?39/5/40025?source=see_link\">",
"     \"Surgical management of complications of peptic ulcer disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H73185785\">",
"    <span class=\"h1\">",
"     INCIDENCE",
"    </span>",
"    &nbsp;&mdash;&nbsp;With time, there has been a dramatic fall in the prevalence of peptic ulcer disease (PUD) in developed countries. While older studies suggested that hospitalizations for potentially life-threatening ulcer complications were stable or even increasing [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/21/40282/abstract/1-7\">",
"     1-7",
"    </a>",
"    ], a more recent analysis using a large database from the United States found an approximate 30 to 40 percent fall in hospitalizations for PUD complications between 1993 and 2006 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/21/40282/abstract/8\">",
"     8",
"    </a>",
"    ]. A study from a large regional hospital in Sweden confirmed these trends [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/21/40282/abstract/9\">",
"     9",
"    </a>",
"    ]. A large systematic review estimated that the annual incidence of peptic ulcer hemorrhage is on the order of 19 to 57 cases per 100,000 individuals, and that the annual incidence of ulcer perforation is on the order of 4 to 14 cases per 100,000 individuals [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/21/40282/abstract/10\">",
"     10",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?18/42/19113?source=see_link&amp;anchor=H2#H2\">",
"     \"Epidemiology and etiology of peptic ulcer disease\", section on 'Epidemiology'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Peptic ulcer bleeding is seen most commonly in older patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/21/40282/abstract/1,2,5-7,9\">",
"     1,2,5-7,9",
"    </a>",
"    ]. Sixty percent of patients are above the age of 60 years and 20 percent are over the age of 80 years [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/21/40282/abstract/11\">",
"     11",
"    </a>",
"    ]. This age distribution likely reflects increasing nonsteroidal antiinflammatory drug (NSAID) use among older adults, combined with decreasing prevalence of H. pylori infection among younger patients.",
"   </p>",
"   <p>",
"    Complications of PUD vary in frequency geographically. In the United States, hemorrhage is the most common complication of PUD (73 percent), followed by perforation (9 percent), and obstruction (3 percent) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/21/40282/abstract/8\">",
"     8",
"    </a>",
"    ]. The mortality rate from complications of PUD is more than 10 times that of acute appendicitis or acute cholecystitis. Perforation has the highest mortality rate, followed by obstruction and hemorrhage. By contrast, a 13-year review of all surgical procedures for peptic ulcer complications at a Nigerian hospital found that obstruction was the most common complication (56 percent), followed by perforation (30 percent), and bleeding (10 percent) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/21/40282/abstract/12\">",
"     12",
"    </a>",
"    ]. Some regional factors that may account for these differences include the rates of NSAID use, the prevalence of H. pylori infection, and the distribution and extent of gastritis. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?18/42/19113?source=see_link&amp;anchor=H5#H5\">",
"     \"Epidemiology and etiology of peptic ulcer disease\", section on 'Regional and other demographic variation'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H56805017\">",
"    <span class=\"h1\">",
"     ETIOLOGY AND RISK FACTORS FOR COMPLICATED PUD",
"    </span>",
"    &nbsp;&mdash;&nbsp;Complications can occur in patients with peptic ulcer disease (PUD) due to any etiology. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?18/42/19113?source=see_link\">",
"     \"Epidemiology and etiology of peptic ulcer disease\"",
"    </a>",
"    .) Although controversial in early studies because of difficulty detecting H. pylori in the setting of acute bleeding, evidence now clearly implicates both H. pylori and nonsteroidal antiinflammatory drugs (NSAIDs), including low-dose",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    , as the primary causes of ulcer bleeding and perforation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/21/40282/abstract/13-16\">",
"     13-16",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?36/59/37817?source=see_link&amp;anchor=H6#H6\">",
"     \"Indications and diagnostic tests for Helicobacter pylori infection\", section on 'Recently bleeding gastric or duodenal ulcers'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H56805158\">",
"    <span class=\"h2\">",
"     NSAIDs",
"    </span>",
"    &nbsp;&mdash;&nbsp;The use of NSAIDs is the most commonly identified risk factor for peptic ulcer bleeding, especially in the elderly. Studies have found relative risks for bleeding ranging from 2.7 to 33.9 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/21/40282/abstract/10\">",
"     10",
"    </a>",
"    ]. Studies have also shown that the risk is drug-specific and dose-dependent. As an example, in a study of 2777 patients, the overall relative risk (RR) of bleeding associated with NSAID use was 5.3 (95% CI 4.5-6.2). However, the risk varied by drug and was lowest for aceclofenac (RR 3.1, 95% CI 2.3-4.2) and was highest for",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?34/62/35808?source=see_link\">",
"     ketorolac",
"    </a>",
"    (RR 14.4, 95% CI 5.2-39.9) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/21/40282/abstract/17\">",
"     17",
"    </a>",
"    ]. The risk was higher in patients taking high-dose NSAIDs compared with those taking medium- or low-dose NSAIDs (RR 6.8, 95% CI 5.3-8.8 versus 4.0, 95% CI 3.2-5.0). There was also an increased risk of bleeding with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    use (RR 5.3) that again was dose-dependent (RR 7.5 with 500 mg per day versus 2.7 with 100 mg per day). The concurrent use of aspirin and NSAIDs conferred an even greater risk of bleeding than was seen with either agent alone (RR 12.7). Finally, the risk was highest in the first 30 days of NSAID use, with a RR of 7.6 (95% CI 6.0-9.5). The risk remained high between days 31 and 90 days (RR 7.3, 95% CI 4.0-13.2), but dropped after 91 days (RR 2.6, 95% CI 1.6-4.1).",
"   </p>",
"   <p>",
"    NSAID use has also been identified as a risk factor for ulcer perforation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/21/40282/abstract/15,18\">",
"     15,18",
"    </a>",
"    ]. In a study of 176 patients from Spain, NSAID use was the only risk factor that was significantly associated with perforation (odds ratio [OR] 3.6) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/21/40282/abstract/15\">",
"     15",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H56805165\">",
"    <span class=\"h2\">",
"     H. pylori infection",
"    </span>",
"    &nbsp;&mdash;&nbsp;Multiple studies have identified H. pylori infection as a risk factor for complicated PUD [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/21/40282/abstract/19-21\">",
"     19-21",
"    </a>",
"    ]. In one study with 370 patients with peptic ulcers, patients with H. pylori were at significantly increased risk for bleeding from duodenal (RR 6.0, 95% CI 2.9-12.3) but not gastric ulcers (RR 1.7, 95% CI 0.7-4.1) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/21/40282/abstract/20\">",
"     20",
"    </a>",
"    ]. However, identifying H. pylori can be difficult in the setting of acute bleeding or in patients receiving PPIs. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?36/59/37817?source=see_link&amp;anchor=H6#H6\">",
"     \"Indications and diagnostic tests for Helicobacter pylori infection\", section on 'Recently bleeding gastric or duodenal ulcers'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    With regard to testing for H. pylori, it should be kept in mind that:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Biopsy-based tests for H. pylori, such as the rapid urease test, are less sensitive in a patient with recent bleeding [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/21/40282/abstract/13\">",
"       13",
"      </a>",
"      ]. However, specificity remains high.",
"     </li>",
"     <li>",
"      A stool H. pylori antigen test provides a useful adjunct to diagnosis; however, the sensitivity and specificity of this test may be compromised by the presence of blood [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/21/40282/abstract/22,23\">",
"       22,23",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      A urea breath test for H. pylori performed as soon as the patient has resumed oral feedings is a reasonably sensitive predictor of H. pylori infection, even following initiation of PPIs. In one study, 113 of 131 patients (86 percent) had positive urea breath tests performed the day after resuming oral feeding [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/21/40282/abstract/24\">",
"       24",
"      </a>",
"      ]. The sensitivity was better early in the hospitalization. Of the 18 patients who were initially negative, 15 had positive urea breath tests two weeks after stopping the PPI.",
"     </li>",
"     <li>",
"      Any H. pylori test dependent upon the number of organisms present may be falsely negative with recent use of PPIs, antibiotics, or",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?34/29/35285?source=see_link\">",
"       bismuth",
"      </a>",
"      . Two weeks off of these agents provides adequate time for recovery of test sensitivity.",
"     </li>",
"     <li>",
"      Serology is a useful test for complicated ulcers [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/21/40282/abstract/25\">",
"       25",
"      </a>",
"      ], especially when there is concern about false-negative results on other tests due to the presence of blood or medication use. Although a positive serology when other H. pylori tests are negative may be a false-positive, it may be a true-positive if there has been suppression of organism number or if there is isolated duodenal H. pylori colonization [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/21/40282/abstract/26\">",
"       26",
"      </a>",
"      ], an important cause of apparent H. pylori-negative, NSAID-negative ulcer. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?19/0/19466?source=see_link\">",
"       \"Unusual causes of peptic ulcer disease\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In the face of a demonstrated peptic ulcer the pretest probability of H. pylori is high, so any positive test has high predictive value for H. pylori infection. However, a single negative test has low predictive value, so two tests must be performed under appropriate conditions to confirm that H. pylori is absent. For tests dependent upon the number of organisms (eg, biopsy urease test, urea breath test, stool antigen test, or histology), the patient must have been off of PPIs, antibiotics, or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?34/29/35285?source=see_link\">",
"     bismuth",
"    </a>",
"    for at least two weeks before negative results can be interpreted as reflecting a true absence of organisms. Some patients are very reluctant to stop PPIs, in particular, so it is important to confirm that the drugs have been stopped. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?36/59/37817?source=see_link\">",
"     \"Indications and diagnostic tests for Helicobacter pylori infection\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H56806405\">",
"    <span class=\"h2\">",
"     NSAID use in patients with H. pylori",
"    </span>",
"    &nbsp;&mdash;&nbsp;Studies looking at the relationship between H. pylori and NSAID use in patients with peptic ulcer complications have had variable results [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/21/40282/abstract/20,27,28\">",
"     20,27,28",
"    </a>",
"    ]. A meta-analysis that identified nine case-control studies that assessed the prevalence of H. pylori infection and NSAID use in patients with peptic ulcer bleeding suggested that the H. pylori infection combined with NSAID use increases the risk of bleeding above that seen with either risk factor alone [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/21/40282/abstract/29\">",
"     29",
"    </a>",
"    ]. The analysis found that individually, the odds ratios for bleeding peptic ulcers associated with H. pylori and NSAIDs use were 1.8 (95% CI 0.97-3.3) and 4.9 (95% CI 3.8-6.2), respectively, whereas the odds ratio increased to 6.1 when both H. pylori and NSAID were present (95% CI 3.9-9.6).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H56805613\">",
"    <span class=\"h2\">",
"     Non-H. pylori, non-NSAID ulcers",
"    </span>",
"    &nbsp;&mdash;&nbsp;The development of complications in patients with non-H. pylori, non-NSAID ulcers is an increasing problem, with a high incidence of recurrent ulcer bleeding. Many H. pylori negative, non-NSAID ulcers are associated with medical comorbidity. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?19/0/19466?source=see_link&amp;anchor=H28#H28\">",
"     \"Unusual causes of peptic ulcer disease\", section on 'Comorbid peptic ulcers'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Once H. pylori and NSAIDs have been confidently excluded, acid hypersecretion should be considered in patients with complicated ulcers. While acid hypersecretion leading to complicated PUD may be due to gastrinoma, idiopathic acid hypersecretion has also been seen [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/21/40282/abstract/30,31\">",
"     30,31",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?14/10/14504?source=see_link\">",
"     \"Clinical manifestations and diagnosis of Zollinger-Ellison syndrome (gastrinoma)\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H56805506\">",
"    <span class=\"h2\">",
"     Ulcer characteristics",
"    </span>",
"    &nbsp;&mdash;&nbsp;Certain ulcer characteristics are associated with an increased risk of complications. Refractory, giant (&gt;2 cm), and pyloric channel ulcers are associated with higher complications rates. In addition, most complicated ulcers are chronic and fibrosed. Chronic ulcers may penetrate deeply into the wall to form a dense fibrotic scar that is slow to heal, erodes blood vessels, or reaches the serosa. However, some complicated ulcers, especially in new NSAID users or in hospitalized patients (stress ulcers), are acute and occur without dense fibrosis or a prolonged ulcer history. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?13/18/13609?source=see_link\">",
"     \"Clinical manifestations of peptic ulcer disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H56805513\">",
"    <span class=\"h2\">",
"     Pregnancy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Complicated peptic ulcers are very uncommon during pregnancy, with fewer than 100 cases reported in the literature [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/21/40282/abstract/32\">",
"     32",
"    </a>",
"    ]. However, peptic ulcers are in the differential diagnosis for the very common dyspeptic symptoms of pregnancy and for the very uncommon events of upper gastrointestinal bleeding or gastrointestinal perforation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/21/40282/abstract/32\">",
"     32",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H73184944\">",
"    <span class=\"h1\">",
"     PREDICTORS OF POOR OUTCOMES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Risk factors associated with poor outcomes in patients with complicated peptic ulcer disease (PUD) include comorbid disease, older age, and the patient's physiological status at the time of presentation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18360489\">",
"    <span class=\"h2\">",
"     Comorbid disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;Comorbid disease is a consistent risk factor for poor outcomes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/21/40282/abstract/8,33-44\">",
"     8,33-44",
"    </a>",
"    ]. For example:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a study of 96 patients with perforated peptic ulcers, there was a ninefold increase in postoperative complications in patients with concomitant medical illness [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/21/40282/abstract/35\">",
"       35",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In a study of 9375 patients with peptic ulcer bleeding, overall mortality was 6.2 percent; 80 percent of the deaths were associated with comorbid disease, primarily multiorgan failure, pulmonary conditions, and advanced malignancy [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/21/40282/abstract/40\">",
"       40",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In a large population study, diabetic patients had significantly increased 30-day mortality from ulcer bleeding (RR 1.40, 95% CI 1.15-1.70) and perforation (RR 1.51, 95% CI 1.15-1.98) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/21/40282/abstract/34\">",
"       34",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18360751\">",
"    <span class=\"h2\">",
"     Advanced age",
"    </span>",
"    &nbsp;&mdash;&nbsp;Age is clearly linked to comorbid disease. However, a population-based study of 7232 patients hospitalized for bleeding ulcers indicated that age was also an independent risk factor for poor outcomes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/21/40282/abstract/45\">",
"     45",
"    </a>",
"    ], as have other studies [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/21/40282/abstract/38,44\">",
"     38,44",
"    </a>",
"    ]. Increased age has also been shown to be associated with increased mortality after ulcer perforation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/21/40282/abstract/10\">",
"     10",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18360758\">",
"    <span class=\"h2\">",
"     The magnitude of the physiological insult",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hypotension upon admission [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/21/40282/abstract/38,39,46,47\">",
"     38,39,46,47",
"    </a>",
"    ], metabolic acidosis, acute renal failure, or hypoalbuminemia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/21/40282/abstract/38,47\">",
"     38,47",
"    </a>",
"    ] predicts poor outcomes. In a study of 101 patients who underwent surgery for gastric ulcer bleeding after failing endoscopic treatment, mortality was 5 percent with Apache II scores (",
"    <a class=\"calc calc_professional\" href=\"mobipreview.htm?3/8/3205?source=see_link\">",
"     calculator 1",
"    </a>",
"    ) less than 15 and 58 percent with scores of 15 or greater [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/21/40282/abstract/48\">",
"     48",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18360773\">",
"    <span class=\"h2\">",
"     Complication-specific risk factors",
"    </span>",
"    &nbsp;&mdash;&nbsp;Factors that delay ulcer healing, large ulcer size, and dense fibrosis are also risk factors for poor outcomes. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?3/36/3658?source=see_link\">",
"     \"Peptic ulcer disease: Genetic, environmental, and psychological risk factors and pathogenesis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Bleeding &ndash;",
"      <strong>",
"      </strong>",
"      Active bleeding at presentation, hematemesis, rebleeding, and the need for surgery all predict increased overall risk [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/21/40282/abstract/37\">",
"       37",
"      </a>",
"      ]. Certain factors predict failure of endoscopic therapy, such as hypotension and ulcers larger than 2 cm.",
"     </li>",
"     <li>",
"      Perforation &ndash; Persisting or advancing signs of peritonitis and a preoperative delay of greater than 12 hours increase risk [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/21/40282/abstract/38,39,47,49,50\">",
"       38,39,47,49,50",
"      </a>",
"      ]. Perforated gastric ulcers appear to have a poorer prognosis than duodenal ulcers [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/21/40282/abstract/50\">",
"       50",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Obstruction &ndash; Poor nutritional status predicts poor outcomes. Preoperative gastric atony predicts postoperative emptying problems.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4460443\">",
"    <span class=\"h1\">",
"     PRECEDING SYMPTOMS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although a careful history will reveal typical ulcer symptoms in many patients with complications [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/21/40282/abstract/51\">",
"     51",
"    </a>",
"    ], there is an important subset of patients with &ldquo;silent&rdquo; ulcers in whom complications develop with no or insufficient heralding dyspeptic symptoms to bring them to timely medical attention [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/21/40282/abstract/52-55\">",
"     52-55",
"    </a>",
"    ]. One study using gastric distension with a nutrient meal suggested that patients with bleeding ulcers have lower visceral sensitivity compared with patients with uncomplicated ulcers [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/21/40282/abstract/56\">",
"     56",
"    </a>",
"    ], providing a possible mechanism for the absence of symptoms. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?13/18/13609?source=see_link\">",
"     \"Clinical manifestations of peptic ulcer disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In particular, older patients with complicated ulcers related to nonsteroidal antiinflammatory drugs (NSAIDs) or medical comorbidity tend to not report antecedent dyspeptic symptoms. This point was underlined in an autopsy study of 2121 individuals over age 70 years who died suddenly; acute abdominal causes were found in 111 cases and peptic ulcer perforation and hemorrhage accounted for one-fourth of these 111 deaths [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/21/40282/abstract/57\">",
"     57",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4460472\">",
"    <span class=\"h1\">",
"     GENERAL APPROACH TO PATIENTS WITH COMPLICATED ULCERS",
"    </span>",
"    &nbsp;&mdash;&nbsp;All patients with complicated peptic ulcer disease (PUD) require appropriate supportive care, such as taking in nothing by mouth and fluid resuscitation. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?27/55/28538?source=see_link&amp;anchor=H4#H4\">",
"     \"Approach to acute upper gastrointestinal bleeding in adults\", section on 'General management'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In addition,",
"    <strong>",
"    </strong>",
"    certain management principles apply to all patients with complicated ulcers, regardless of the type of complication (bleeding, perforation, penetration, or gastric outlet obstruction). These principles include coordination of care among the medical, surgical, and radiologic teams, administration of acid suppressive therapy, treatment of H. pylori if present, and discontinuation of NSAIDs if possible (",
"    <a class=\"graphic graphic_table graphicRef65479 \" href=\"mobipreview.htm?34/57/35740\">",
"     table 1",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4460481\">",
"    <span class=\"h2\">",
"     Coordination of care",
"    </span>",
"    &nbsp;&mdash;&nbsp;The importance of early collaboration among the medical, surgical, and radiologic teams for patients with ulcer complications cannot be overemphasized. In addition to aiding in resuscitation of an unstable patient, collaboration between the",
"    <span class=\"nowrap\">",
"     gastroenterologist/endoscopist,",
"    </span>",
"    the intensive care unit team, the surgical team, and the radiologist permits the establishment of goals and limits for initial nonoperative therapy. Early surgical consultation also allows more time for preoperative preparation and evaluation and for education of patients and families, should urgent surgical intervention become necessary.",
"    <br/>",
"    <br/>",
"    If surgery is indicated, it should be done as soon as the indication is clear and the patient is appropriately resuscitated. Excellent results are possible with well coordinated, skilled, timely decision-making and implementation. For example, with skilled, timely care, in one study all 66 high-risk patients with ulcer bleeding (shock on admission, age older than 65 years, an ulcer size greater than 2 cm, stigmata of recent bleeding, or a history of prior gastric surgery) survived five years [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/21/40282/abstract/58\">",
"     58",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4460489\">",
"    <span class=\"h2\">",
"     Acid suppressive therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;All patients with complicated peptic ulcers should receive acid suppressive therapy with an intravenous proton pump inhibitor (PPI). Although",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?25/62/26601?source=see_link\">",
"     omeprazole",
"    </a>",
"    has been the most extensively studied intravenous PPI, other intravenous formulations given in doses that are known to inhibit gastric acid secretion are probably acceptable alternatives.",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/16/32009?source=see_link\">",
"     Pantoprazole",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?15/39/15993?source=see_link\">",
"     esomeprazole",
"    </a>",
"    are the only intravenous formulations available in the United States, and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?3/14/3305?source=see_link\">",
"     lansoprazole",
"    </a>",
"    , which was previously available, has been removed from the world market. For patients with bleeding ulcers, the suggested doses of intravenous pantoprazole, omeprazole, and esomeprazole are all 80 mg bolus followed by 8",
"    <span class=\"nowrap\">",
"     mg/hr",
"    </span>",
"    infusion. However, considerable evidence is accumulating that lower-dose continuous infusions and bolus intravenous dosing may produce comparable results [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/21/40282/abstract/59-62\">",
"     59-62",
"    </a>",
"    ]. Frequent, high-dose oral PPI use may also be comparable in effectiveness [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/21/40282/abstract/63\">",
"     63",
"    </a>",
"    ]. In light of the currently available evidence (and the inability to identify rapid metabolizers who are likely to benefit from higher dosing), use of either continuous infusions or intravenous bolus dosing appears reasonable. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?27/55/28538?source=see_link&amp;anchor=H5079756#H5079756\">",
"     \"Approach to acute upper gastrointestinal bleeding in adults\", section on 'Acid suppression'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Intravenous PPIs have a dramatic impact on ulcer bleeding, which starts to take effect within hours [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/21/40282/abstract/64\">",
"     64",
"    </a>",
"    ]. Starting intravenous PPI therapy before endoscopy decreased the rate of active bleeding, the need for endoscopic treatment, and the number of patients with clean based ulcers [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/21/40282/abstract/65\">",
"     65",
"    </a>",
"    ]. These findings suggest a very rapid effect of profound acid inhibition on fibrin formation and ulcer healing.",
"   </p>",
"   <p>",
"    Once patients are tolerating oral medications, they should be switched to an oral PPI. Initially, high-dose twice daily treatment is reasonable to enhance healing (eg,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?25/62/26601?source=see_link\">",
"     omeprazole",
"    </a>",
"    40 mg twice daily), but dosing should generally be reduced to once daily after four weeks. However, for patients with giant ulcers, it is reasonable to continue twice daily dosing until a repeat endoscopy has been performed and confirmed ulcer healing (see",
"    <a class=\"local\" href=\"#H56806712\">",
"     'Follow-up'",
"    </a>",
"    below).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H193856680\">",
"    <span class=\"h2\">",
"     Treatment of H. pylori",
"    </span>",
"    &nbsp;&mdash;&nbsp;Early diagnosis of H. pylori is important to guide management. Since curing H. pylori dramatically reduces recurrent ulcers and complications, management must include careful investigation for H. pylori infection, appropriate antibiotic treatment, and a confirmation of cure after antibiotic treatment. As noted above, H. pylori testing in the setting of bleeding or PPI use may result in false-negative results, so repeat testing is required for patients whose initial tests are negative [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/21/40282/abstract/13\">",
"     13",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?36/59/37817?source=see_link\">",
"     \"Indications and diagnostic tests for Helicobacter pylori infection\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?22/32/23049?source=see_link\">",
"     \"Treatment regimens for Helicobacter pylori\"",
"    </a>",
"    and",
"    <a class=\"local\" href=\"#H56805165\">",
"     'H. pylori infection'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    The efficacy of intravenous antibiotics for the treatment of H. pylori has not been established. Therefore, it is appropriate to wait until patients are tolerating oral feedings to start oral antibiotics. Interrupted treatment may encourage resistance and should be avoided.",
"   </p>",
"   <p>",
"    We emphasize that because curing H. pylori reduces the recurrence of complications, following treatment for H. pylori it is critical to confirm successful eradication of the organism. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?22/32/23049?source=see_link&amp;anchor=H2834839008#H2834839008\">",
"     \"Treatment regimens for Helicobacter pylori\", section on 'Eradication confirmation'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4460572\">",
"    <span class=\"h2\">",
"     Discontinue NSAIDs",
"    </span>",
"    &nbsp;&mdash;&nbsp;If",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    or non-aspirin NSAIDs can be discontinued, even complicated ulcers readily heal and uncommonly recur. If non-aspirin NSAIDs must be continued, the incidence of recurrent PUD can be decreased by switching to a COX-2 inhibitor with concomitant therapy with a PPI or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?0/41/662?source=see_link\">",
"     misoprostol",
"    </a>",
"    (for patients who are unable to take PPIs or have contraindications to PPI use). Likewise, when continued low-dose aspirin is justified, concomitant co-therapy with a PPI is indicated. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?11/58/12197?source=see_link\">",
"     \"NSAIDs (including aspirin): Secondary prevention of gastroduodenal toxicity\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H193858137\">",
"    <span class=\"h2\">",
"     Urgent or emergent surgery",
"    </span>",
"    &nbsp;&mdash;&nbsp;Urgent or emergent surgery is necessary in patients with uncontrolled hemorrhage or with a perforated ulcer with continued leakage [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/21/40282/abstract/66\">",
"     66",
"    </a>",
"    ]. The specifics of the surgery depend on the complication, ulcer location and characteristics, and the patient's overall status. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?39/5/40025?source=see_link\">",
"     \"Surgical management of complications of peptic ulcer disease\"",
"    </a>",
"    and",
"    <a class=\"local\" href=\"#H4460451\">",
"     'Bleeding'",
"    </a>",
"    below and",
"    <a class=\"local\" href=\"#H73184426\">",
"     'Operative versus nonoperative management'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4460451\">",
"    <span class=\"h1\">",
"     BLEEDING",
"    </span>",
"    &nbsp;&mdash;&nbsp;Upper gastrointestinal bleeding secondary to peptic ulcer disease (PUD) is a common medical condition that results in high morbidity and medical care costs. Patients often present with hematemesis, melena, or both. However, in the setting of massive bleeding, hematochezia may be seen. The diagnosis of a bleeding ulcer is typically made with upper endoscopy. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?27/55/28538?source=see_link\">",
"     \"Approach to acute upper gastrointestinal bleeding in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Most patients with bleeding ulcers can be managed acutely with fluid resuscitation, blood transfusions, proton pump inhibitor (PPI) therapy, and endoscopic intervention, as appropriate. As noted above, early intravenous PPI treatment promotes rapid ulcer healing and reduces rebleeding rates. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?24/15/24826?source=see_link\">",
"     \"Overview of the treatment of bleeding peptic ulcers\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    However, in a minority of patients with bleeding ulcers, surgery will be required.",
"    <strong>",
"    </strong>",
"    Surgery for peptic ulcer hemorrhage is indicated in the following circumstances:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Failed endoscopic therapy.",
"     </li>",
"     <li>",
"      Hemodynamic instability despite vigorous volume resuscitation (&gt;3 unit transfusion during initial resuscitation).",
"     </li>",
"     <li>",
"      Recurrent hemorrhage following initial hemostasis, especially with hypotension, after a second attempt at endoscopic treatment. Repeat endoscopic treatment is suggested in most cases of recurrent hemorrhage because a second attempt has a reasonable chance of success and lower risk than surgery [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/21/40282/abstract/67\">",
"       67",
"      </a>",
"      ]. However, if two attempts have failed to achieve permanent hemostasis, additional attempts at endoscopy are unlikely to be successful.",
"     </li>",
"     <li>",
"      Continued slow bleeding with a transfusion requirement exceeding three units per day.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Secondary or relative indications for surgery include rare blood type or difficult crossmatch, or refusal of transfusion.",
"   </p>",
"   <p>",
"    An alternative to surgery for some patients is angiography (see",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?24/2/24616?source=see_link\">",
"     \"Angiographic control of nonvariceal gastrointestinal bleeding in adults\"",
"    </a>",
"    ). Indications for angiography for acute nonvariceal upper gastrointestinal bleeding have been suggested in a consensus statement from the American College of Radiology [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/21/40282/abstract/68\">",
"     68",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Endoscopy is the best initial diagnostic and therapeutic procedure.",
"     </li>",
"     <li>",
"      Surgery and transcatheter",
"      <span class=\"nowrap\">",
"       arteriography/intervention",
"      </span>",
"      (TAI) are equally effective following failed therapeutic endoscopy and the choice of procedure should be based upon local experience and expertise. However, TAI should be considered in patients at high risk for surgery.",
"     </li>",
"     <li>",
"      TAI is less likely to be successful in patients with impaired coagulation.",
"     </li>",
"     <li>",
"      TAI is the best technique for treatment of bleeding into the biliary tree or pancreatic duct.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Delaying surgery for high-risk patients compromises outcomes. Prolonged resuscitation, large volume transfusion, and periods of hypotension are poorly tolerated in high-risk patients. Therefore, risks such as giant ulcers, very rapid bleeding rates, shock on presentation, advanced age, severe comorbid disease, acute coronary syndromes, and transient ischemic attacks are relative indications for early surgery. As noted above, urgent surgery may be appropriate when hemodynamic instability persists after 3 units of rapid resuscitation. However, continued management with transfusion and pressors may be necessary while comorbidities are being evaluated or consent obtained, and in patients who refuse surgery.",
"   </p>",
"   <p>",
"    The specifics of the surgery depend upon the ulcer location, ulcer characteristics, and the patient's overall status. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?39/5/40025?source=see_link&amp;anchor=H493274237#H493274237\">",
"     \"Surgical management of complications of peptic ulcer disease\", section on 'Bleeding ulcers'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4460621\">",
"    <span class=\"h1\">",
"     PERFORATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Ulcer perforation should be suspected in patients who suddenly develop severe, diffuse abdominal pain. Perforations complicate 2 to 10 percent of peptic ulcers [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/21/40282/abstract/69\">",
"     69",
"    </a>",
"    ]. Duodenal, antral, and gastric body ulcers account for 60, 20, and 20 percent of perforations due to peptic ulcer disease (PUD), respectively [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/21/40282/abstract/70,71\">",
"     70,71",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H66923600\">",
"    <span class=\"h2\">",
"     Clinical manifestations",
"    </span>",
"    &nbsp;&mdash;&nbsp;The following three phases have been described when there is free perforation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/21/40282/abstract/72\">",
"     72",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In the initial phase (within two hours of onset), abdominal pain is usually sudden, sometimes producing collapse or syncope. Localization is usually epigastric, but it quickly becomes generalized. This catastrophic onset reflects bathing of the peritoneal cavity with acidic fluid, which likely results in the release of the vasoactive mediators that underlie the physiologic response. Tachycardia, a weak pulse, cool extremities, and a low temperature are characteristic features. The stage may last only a few minutes or up to two hours. The severity of the onset depends upon how much fluid is released. Pain may radiate to the top of the right shoulder or to both shoulders. As this phase progresses, abdominal rigidity begins to develop.",
"     </li>",
"     <li>",
"      In the second phase (usually 2 to 12 hours after onset), abdominal pain may lessen and an inexperienced observer may be led to believe that the patient is getting better. Pain is usually generalized, often markedly worse upon movement, and the abdomen consistently displays marked board-like rigidity. There may be obliteration of liver dullness to percussion due to peritoneal air. The pelvic peritoneum, palpated at rectal examination, is often tender due to irritation from collected inflammatory fluid. Right lower quadrant tenderness may develop from fluid moving down the pericolic gutter.",
"     </li>",
"     <li>",
"      In the third phase (usually &gt;12 hours after onset), increasing abdominal distention is noted, but abdominal pain, tenderness, and rigidity may be less evident. Temperature elevation and hypovolemia due to \"third-spacing\" into the peritoneal cavity develop and acute cardiovascular collapse may occur as peritonitis advances. Persisting or advancing signs of peritonitis and a preoperative delay greater than 12 hours increase the risk of a poor outcome [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/21/40282/abstract/38,39,47,49,50,73\">",
"       38,39,47,49,50,73",
"      </a>",
"      ]. In addition, perforated gastric ulcers appear to have a poorer prognosis than duodenal ulcers [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/21/40282/abstract/50\">",
"       50",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    If the perforation is walled off or if the gastric fluid is confined by fibrosis, symptoms may be much less severe and these phases may not be apparent. Posterior (retroperitoneal) perforation is another situation where symptoms are less dramatic. Compared to free intraperitoneal perforations, the upper abdominal pain is more insidious, the presentation often delayed, and the abdominal examination is frequently equivocal [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/21/40282/abstract/74\">",
"     74",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H66923362\">",
"    <span class=\"h2\">",
"     Diagnosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Rapid diagnosis is essential, since the prognosis is excellent within the first six hours, but deteriorates with more than a 12-hour delay [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/21/40282/abstract/49,72\">",
"     49,72",
"    </a>",
"    ]. Perforation is largely a clinical diagnosis with the history and physical examination providing essential clues (see",
"    <a class=\"local\" href=\"#H66923600\">",
"     'Clinical manifestations'",
"    </a>",
"    above).",
"   </p>",
"   <p>",
"    If imaging is required, plain x-rays are typically obtained first. Careful interpretation of upright chest and abdominal films can detect diagnostic free air in many cases of perforated gastric and duodenal ulcers [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/21/40282/abstract/75\">",
"     75",
"    </a>",
"    ]. The presence of free air on abdominal imaging is highly indicative of a perforated viscus (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef76267 \" href=\"mobipreview.htm?17/53/18259\">",
"     image 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_diagnosticimage graphicRef55270 \" href=\"mobipreview.htm?8/59/9143\">",
"     image 2",
"    </a>",
"    and",
"    <a class=\"graphic graphic_diagnosticimage graphicRef70824 \" href=\"mobipreview.htm?16/59/17331\">",
"     image 3",
"    </a>",
"    ), although about 10 to 20 percent of patients with a perforated duodenal ulcer will not have free air [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/21/40282/abstract/75\">",
"     75",
"    </a>",
"    ]. If free air is found, no other diagnostic studies are necessary. Leakage of water soluble oral contrast may be useful in selected cases. Once the oral contrast is given, the patient should be rotated 360 degrees and placed on the right side to fill the antrum and duodenum with contrast. However, many perforations have already sealed spontaneously by the time of presentation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/21/40282/abstract/76\">",
"     76",
"    </a>",
"    ], so the absence of a leak does not exclude the diagnosis of a perforated ulcer.",
"   </p>",
"   <p>",
"    If there is no free air on the plain film, computed tomography (CT) or ultrasound can be useful to detect small amounts of free air or fluid. In a small proportion of cases, free fluid will be the only clue indicating perforation on imaging studies and a few percent of cases will have neither free air nor fluid [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/21/40282/abstract/75\">",
"     75",
"    </a>",
"    ]. Spiral and multidetector-row CTs, especially 64 slice scanners, allow the entire abdomen to be examined on a single breath-hold and improve detection of small amounts of air and indirect findings (eg, fluid, phlegmon, abscess, wall pathology and adjacent inflammation) and can provide very useful indirect clues to pathology (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef70824 \" href=\"mobipreview.htm?16/59/17331\">",
"     image 3",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/21/40282/abstract/77,78\">",
"     77,78",
"    </a>",
"    ]. Spiral CTs are undoubtedly much more sensitive than ultrasound for detecting fluid, air, or other clues to perforation. Spiral CT with oral contrast sensitively detects persisting leaks across perforated ulcers.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H66923472\">",
"    <span class=\"h2\">",
"     Management",
"    </span>",
"    &nbsp;&mdash;&nbsp;Once the diagnosis of an ulcer perforation has been made, initial management includes insertion of a nasogastric tube, intravenous volume replacement, treatment with an intravenous proton pump inhibitor (PPI), and broad spectrum antibiotics. A decision is then made about whether the patient requires surgery. (See",
"    <a class=\"local\" href=\"#H73184426\">",
"     'Operative versus nonoperative management'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H66923940\">",
"    <span class=\"h3\">",
"     Intravenous PPI",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although high-dose intravenous PPIs given at presentation promote the cessation of bleeding and healing of ulcers, the impact of such early treatment on perforated ulcers has not yet been reported. Based on the experience with bleeding, it is reasonable to anticipate that intravenous PPIs will enhance fibrin formation and promote rapid sealing of perforations. Therefore, we recommend starting an intravenous PPI as early as possible, with an 80 mg loading dose and 8 mg per hour of the PPI; however, lower doses and twice daily bolus dosing may be equally effective, as noted above. (See",
"    <a class=\"local\" href=\"#H4460489\">",
"     'Acid suppressive therapy'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H66923520\">",
"    <span class=\"h3\">",
"     Antibiotics",
"    </span>",
"    &nbsp;&mdash;&nbsp;The antibiotic regimen for a patient with a perforated ulcer should cover enteric gram negative rods, anaerobes, and mouth flora. The antimicrobial susceptibility patterns for gram negative rods such as Escherichia coli have changed, with increasing resistance to antibiotics. Thus, knowledge of local and regional susceptibility patterns for Enterobacteriaceae is essential in selecting empiric therapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/21/40282/abstract/79-81\">",
"     79-81",
"    </a>",
"    ].&nbsp;",
"   </p>",
"   <p>",
"    Reasonable choices for initial empiric antibiotic therapy in the setting of perforated ulcer include a combination beta",
"    <span class=\"nowrap\">",
"     lactam/beta",
"    </span>",
"    lactamase inhibitor (such as",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?1/8/1160?source=see_link\">",
"     ampicillin-sulbactam",
"    </a>",
"    , ticarcillin-clavulanic acid, or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?23/41/24216?source=see_link\">",
"     piperacillin-tazobactam",
"    </a>",
"    ), or a combination of a third-generation cephalosporin and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?19/38/20065?source=see_link\">",
"     metronidazole",
"    </a>",
"    . In areas where the local prevalence of extended spectrum beta-lactamase (ESBL) producing organisms and pathogenic E. coli is common, empiric monotherapy with a carbapenem such as",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?40/36/41542?source=see_link\">",
"     ertapenem",
"    </a>",
"    , imipenem, or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/38/32359?source=see_link\">",
"     meropenem",
"    </a>",
"    is appropriate. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?37/4/37960?source=see_link\">",
"     \"Pathogenic Escherichia coli\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?29/53/30553?source=see_link\">",
"     \"Extended-spectrum beta-lactamases\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The importance of administering an appropriate initial empiric antibiotic regimen was illustrated in a review of 425 patients who required surgery for community-acquired secondary peritonitis, including patients with perforated peptic ulcers [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/21/40282/abstract/82\">",
"     82",
"    </a>",
"    ]. In 13 percent of patients, the initial antibiotic regimen was inappropriate, defined as not covering all bacteria subsequently isolated or not covering both aerobic and anaerobic organisms in the absence of culture results. Resolution of the infection after primary surgery was significantly less likely with an inappropriate regimen (53 versus 79 percent) and failure to achieve clinical success was associated with a six-day prolongation in hospitalization (20 versus 14 days).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H73184426\">",
"    <span class=\"h3\">",
"     Operative versus nonoperative management",
"    </span>",
"    &nbsp;&mdash;&nbsp;A major decision when treating patients with ulcer perforation is whether and when to operate. After resuscitation, emergent operation and closure with a piece of omentum (Graham patch) is the standard of care for patients with an acute perforation and a rigid abdomen with free intraperitoneal air. If the patient is stable or improving, especially if spontaneous sealing of the perforation has been demonstrated, nonoperative management with close monitoring is a reasonable option. With any free perforation, regardless of the presence or size of the leak, if the patient&rsquo;s status is deteriorating, urgent surgery is indicated. Prolonged efforts to establish a diagnosis or pursue nonoperative care despite worsening status can be counterproductive, since a needed operation will be delayed. In addition, surgery is indicated in circumstances where the cause of an acute abdomen has not been established or the patient&rsquo;s status cannot be closely monitored. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?39/5/40025?source=see_link&amp;anchor=H493274985#H493274985\">",
"     \"Surgical management of complications of peptic ulcer disease\", section on 'Perforated ulcers'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The management of patients with small to moderate leaks who are clinically stable is less clear. Currently, the standard of care for such patients is surgery, but some studies suggest that these patients can be managed nonoperatively:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The efficacy of initial conservative therapy with a nasogastric tube, antibiotics, and H2 blockers was compared with immediate laparoscopic surgical repair in a randomized trial of 83 patients with a perforated peptic ulcer [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/21/40282/abstract/83\">",
"       83",
"      </a>",
"      ]. Surgery was required in 11 of 40 patients (28 percent) in the conservative therapy group because of failure to improve clinically after 12 hours. The other 29 patients in the conservative therapy arm were successfully managed without surgery. The two groups did not differ significantly in terms of morbidity or mortality. However, the hospital stay was 35 percent longer in the group treated conservatively. Also, patients over 70 years old were less likely to respond to conservative treatment. The authors concluded that an initial period of nonoperative treatment with careful observation was safe in patients under age 70 years.",
"     </li>",
"     <li>",
"      A prospective study of 82 patients with perforated peptic ulcers treated patients with nasogastric suction and intravenous H2 receptor antagonists [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/21/40282/abstract/84\">",
"       84",
"      </a>",
"      ]. If patients did not show clinical improvement after 24 hours, surgery was performed. With this approach, surgery was avoided in 44 patients (54 percent). Factors associated with surgery included the size of the pneumoperitoneum, abdominal distension, heart rate &gt;94 beats per minute, pain on digital rectal examination, and age &gt;59 years. Overall mortality in the study was 1 percent.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Data also suggest that if spontaneous sealing occurs, patients do well without surgery. A study of 152 patients whose perforations sealed spontaneously found re-leakage in only two patients, comparing favorably with postoperative re-leak rates [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/21/40282/abstract/76\">",
"     76",
"    </a>",
"    ]. The probability of sealing with nonoperative care and intravenous PPIs or H2 receptor antagonists has not been studied; however, over 50 percent of patients with perforated duodenal ulcers have sealed spontaneously when first examined.",
"   </p>",
"   <p>",
"    Some patients require nonoperative management because severe comorbid illnesses preclude surgery [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/21/40282/abstract/85,86\">",
"     85,86",
"    </a>",
"    ]. In a retrospective series of 30 high-risk patients treated nonoperatively, 11 patients were treated with H2 receptor antagonists (prior to 1996) and 19 were treated with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?25/62/26601?source=see_link\">",
"     omeprazole",
"    </a>",
"    40 mg daily (1996 and later) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/21/40282/abstract/85\">",
"     85",
"    </a>",
"    ]. Mortality was 64 percent in the early period and 11 percent in the later period. Hypotension upon presentation was a major risk factor for a poor outcome. These data raise the hypothesis that PPI treatment promotes sealing of perforations. However, a low mortality rate (3.5 percent) was also seen in a series of 84 high-risk patients treated with percutaneous drainage and H2 receptor antagonists [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/21/40282/abstract/86\">",
"     86",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Nonoperative management may also be considered for patients with delayed presentations. If the patient has a persistent leak across the perforation, surgery may be indicated, but can be complicated by peritoneal contamination. Other options in this setting include nonoperative care with percutaneous peritoneal drainage, especially for patients who are not good surgical candidates [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/21/40282/abstract/86\">",
"     86",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Patients with perforated ulcers should have an upper endoscopy to look for evidence of malignancy, to biopsy for H. pylori, and to assess for ulcer healing. To allow the perforation to heal, we suggest waiting at least two weeks prior to performing an upper endoscopy. If the procedure does not need to be done urgently, we prefer to wait six to eight weeks to allow for ulcer healing. At that time, biopsies can be obtained to look for infection with H. pylori and to rule out malignancy (particularly in the case of a nonhealing gastric ulcer). (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?41/18/42281?source=see_link&amp;anchor=H14#H14\">",
"     \"Overview of the natural history and treatment of peptic ulcer disease\", section on 'Follow-up after initial therapy for peptic ulcer'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4460658\">",
"    <span class=\"h3\">",
"     Surgical approach",
"    </span>",
"    &nbsp;&mdash;&nbsp;For patients who require surgery for a perforated ulcer, the surgical approach depends upon the location of the ulcer. This topic is discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?39/5/40025?source=see_link&amp;anchor=H493274985#H493274985\">",
"     \"Surgical management of complications of peptic ulcer disease\", section on 'Perforated ulcers'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4460706\">",
"    <span class=\"h1\">",
"     PENETRATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Ulcer penetration refers to penetration of the ulcer through the bowel wall without free perforation or leakage of luminal contents into the peritoneal cavity. A longstanding ulcer history is common, but not invariable, in patients who develop penetration. Penetration often comes to attention because of a change in symptoms or involvement of adjacent structures. The change in symptom pattern may be gradual or sudden; it usually involves a loss of cyclicity of the pain with meals, and loss of food and antacid relief. The pain typically becomes more intense, of longer duration, and is frequently referred to the lower thoracic or upper lumbar region.",
"   </p>",
"   <p>",
"    Surgical series suggest that penetration occurs in 20 percent of ulcers, but only a small proportion of penetrating ulcers become clinically evident [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/21/40282/abstract/87\">",
"     87",
"    </a>",
"    ]. Penetration occurs in descending order of frequency into the pancreas, lesser omentum, biliary tract, liver, greater omentum, mesocolon, colon, and vascular structures. Antral and duodenal ulcers can penetrate into the pancreas. Pyloric or prepyloric ulcers can penetrate the duodenum, eventually leading to a gastroduodenal fistula evident as a \"double\" pylorus.",
"   </p>",
"   <p>",
"    Penetration can be associated with a wide array of uncommon complications including perivisceral abscess (evident on computed tomography or ultrasonography) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/21/40282/abstract/88\">",
"     88",
"    </a>",
"    ], erosion into vascular structures leading to exsanguinating hemorrhage (aortoenteric fistula) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/21/40282/abstract/89\">",
"     89",
"    </a>",
"    ], or erosion into the cystic artery [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/21/40282/abstract/90\">",
"     90",
"    </a>",
"    ]. Rare biliary tract complications include erosion into the biliary tree with choledochoduodenal fistula, extrahepatic obstruction, or hemobilia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/21/40282/abstract/91\">",
"     91",
"    </a>",
"    ]. Fistulization into the pancreatic duct has also been reported with penetrating duodenal ulcers [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/21/40282/abstract/92\">",
"     92",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Gastrocolic fistulae are seen with greater curvature gastric ulcers, particularly marginal ulcers [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/21/40282/abstract/71,93\">",
"     71,93",
"    </a>",
"    ]. Typical features of this complication include pain, weight loss, and diarrhea; feculent vomiting is an uncommon, but diagnostic, symptom. A duodenocolic fistula can also occur.",
"   </p>",
"   <p>",
"    A penetrating ulcer is suspected clinically when an ulcer in the proper region is found (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef81661 \" href=\"mobipreview.htm?9/34/9762\">",
"     image 4",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/21/40282/abstract/67\">",
"     67",
"    </a>",
"    ]. Mild hyperamylasemia can develop with posterior penetration of either a gastric or duodenal ulcer, but clinical pancreatitis is uncommon.",
"   </p>",
"   <p>",
"    No rigorous studies are available to guide the management of penetrating ulcers. Management should follow the intensive measures outlined for refractory ulcers. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?15/61/16345?source=see_link\">",
"     \"Refractory or recurrent peptic ulcer disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4460714\">",
"    <span class=\"h1\">",
"     GASTRIC OUTLET OBSTRUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Gastric outlet obstruction is the least frequent complication of peptic ulcer disease (PUD) in developed countries. Most cases are associated with duodenal or pyloric channel ulceration. As peptic ulcers have become less frequent, malignancy has emerged as a predominant cause of gastric outlet obstruction despite the lower overall rates of gastric cancer. Peptic ulcer disease accounts for only about 5 percent of gastric outlet obstructions [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/21/40282/abstract/71,94,95\">",
"     71,94,95",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?43/47/44793?source=see_link&amp;anchor=H3#H3\">",
"     \"Gastric outlet obstruction in adults\", section on 'Etiology'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4460722\">",
"    <span class=\"h2\">",
"     Epidemiology and pathogenesis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Obstruction accounted for 10 to 30 percent of patients undergoing ulcer surgery in past series, but this proportion appears to be dropping relative to bleeding and perforation. Some of this decrease may be due to more effective endoscopic and medical management, including the ability to identify and reverse underlying causes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/21/40282/abstract/71,96\">",
"     71,96",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    No distinct pathophysiologic factors have been identified that promote obstruction, though several elements can contribute to the development of gastric outlet obstruction:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Rapidly reversible elements include spasm, edema, inflammation, and pyloric dysmotility related to the ulcer or inflammatory changes",
"     </li>",
"     <li>",
"      Fibrosis, scarring, and deformity underlie slowly reversible or irreversible obstruction",
"     </li>",
"     <li>",
"      Gastric atony, which develops after prolonged obstruction, contributes to gastric retention",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4460730\">",
"    <span class=\"h2\">",
"     Clinical manifestations",
"    </span>",
"    &nbsp;&mdash;&nbsp;Symptoms of gastric retention include early satiety, bloating, indigestion, anorexia, nausea, vomiting, epigastric pain, and weight loss [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/21/40282/abstract/71,97\">",
"     71,97",
"    </a>",
"    ]. In a surgical series, vomiting was the presenting symptom in 80 percent of cases; it occurred more frequently than once daily in 41 percent of patients, once daily in 34 percent, and less often in 25 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/21/40282/abstract/98\">",
"     98",
"    </a>",
"    ]. The presence of recognizable food more than 8 to 12 hours after eating was uncommon, but highly suggestive of gastric retention. The presence of a succussion splash on abdominal examination several hours after eating or drinking is a useful clue if present. The average duration of symptoms was one month, although one-third had symptoms for longer than three months.",
"   </p>",
"   <p>",
"    Patterns drawn from surgical series are useful, but the presentation in a general medical setting may be different. Important variables include the patient's response to these symptoms, age, comorbid conditions, and general health status. Some patients with chronic organic disease (peptic ulcers in particular) have visceral hyposensitization (see",
"    <a class=\"local\" href=\"#H4460443\">",
"     'Preceding symptoms'",
"    </a>",
"    above). In such patients, high-grade outlet obstruction may be present without perceived gastric distress. Appetite and food intake may be preserved in association with delayed, large volume vomiting of undigested food. Conversely, some patients may have minimal or intermittent obstruction, but complain of considerable nausea, pain, and indigestion.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4460738\">",
"    <span class=\"h2\">",
"     Diagnosis and differential diagnosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;The first step is to determine whether the symptoms are due to gastric retention and, if so, whether outlet obstruction is the underlying cause. Measuring gastric residual volumes and performing a saline load test (",
"    <a class=\"graphic graphic_table graphicRef63196 \" href=\"mobipreview.htm?26/29/27099\">",
"     table 2",
"    </a>",
"    ) can establish the diagnosis of mechanical outlet obstruction.",
"   </p>",
"   <p>",
"    Definitive diagnosis of gastric pathology must await gastric cleansing, decompression, and correction of fluid and electrolyte abnormalities. Endoscopic inspection and biopsy are indicated in suspected cases of gastric outlet obstruction and usually provide a definitive diagnosis of the underlying pathology, especially for excluding malignancy. Conventional upper gastrointestinal radiography can provide useful information, but is often not definitive [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/21/40282/abstract/99\">",
"     99",
"    </a>",
"    ]. A computed tomographic scan",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    surgery may be required if there is a heightened suspicion for malignancy and biopsies are unrevealing.",
"   </p>",
"   <p>",
"    A number of entities must be excluded in the differential diagnosis of gastric outlet obstruction, which is described separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?43/47/44793?source=see_link&amp;anchor=H3#H3\">",
"     \"Gastric outlet obstruction in adults\", section on 'Etiology'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4460746\">",
"    <span class=\"h2\">",
"     Management",
"    </span>",
"    &nbsp;&mdash;&nbsp;After correction of fluid and electrolyte abnormalities, the initial step in the management of presumed gastric outlet obstruction is to confirm the diagnosis of gastric retention. If gastric retention is confirmed, the nasogastric tube should be replaced by a large bore Ewald tube and the stomach lavaged to remove debris. The nasogastric tube should then be reinserted, good function confirmed, and intermittent suction continued for three to five days to decompress the stomach while intravenous fluid and electrolytes are administered.",
"   </p>",
"   <p>",
"    Prolonged vomiting and poor fluid intake may lead to prerenal azotemia, hyponatremia, and a hypokalemic, hypochloremic metabolic alkalosis. Intravenous saline will restore the volume status and urine output;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?33/57/34711?source=see_link\">",
"     potassium chloride",
"    </a>",
"    should also be administered as indicated. Intravenous proton pump inhibitors (PPIs) are used, as considered below. Careful assessment of nutritional status is required and intravenous hyperalimentation should be considered in malnourished patients. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?13/32/13831?source=see_link\">",
"     \"Nutrition support in critically ill patients: An overview\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In the past, patients with gastric outlet obstruction due to PUD traditionally were sent to surgery if they failed to respond to three days of nasogastric suction. However, in cases where the cause can be reversed (eg, H. pylori or NSAIDs), a more conservative approach deserves consideration. Approximately one-half of cases of gastric outlet obstruction due to peptic ulcer and associated spasm, edema, inflammation, or pyloric dysmotility respond initially to medical treatment, although some initial responders may eventually require surgery [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/21/40282/abstract/100\">",
"     100",
"    </a>",
"    ] or endoscopic dilatation. Repeating the saline load test can gauge progress (",
"    <a class=\"graphic graphic_table graphicRef63196 \" href=\"mobipreview.htm?26/29/27099\">",
"     table 2",
"    </a>",
"    ); a residual volume below 200 mL suggests resolution. However, even cases with a good clinical response require endoscopy and biopsy to exclude malignancy, diagnose ulcer disease, and determine if H. pylori is present.",
"   </p>",
"   <p>",
"    Gastric outlet obstruction is not an emergency; in patients who fail to respond to medical therapy, both endoscopic and surgical intervention should be delayed until the patient has been stabilized and fluid and electrolyte balance restored. Delays are also appropriate if the patient's nutritional status is compromised (a serum albumin level",
"    <strong>",
"    </strong>",
"    less than 2.8",
"    <span class=\"nowrap\">",
"     g/dL",
"    </span>",
"    is a strong predictor of a poor surgical outcome) or if the stomach is markedly dilated (postoperative gastric atony is more likely and may be prevented by preoperative decompression).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4460754\">",
"    <span class=\"h3\">",
"     Identifying and treating underlying causes",
"    </span>",
"    &nbsp;&mdash;&nbsp;Once the patient has been stabilized and gastric outlet obstruction has been confirmed, the next steps are to identify and treat the underlying cause of the obstruction. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?43/47/44793?source=see_link&amp;anchor=H17#H17\">",
"     \"Gastric outlet obstruction in adults\", section on 'Diagnosis'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    There is evidence for [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/21/40282/abstract/101-103\">",
"     101-103",
"    </a>",
"    ] and against [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/21/40282/abstract/104\">",
"     104",
"    </a>",
"    ] an association between H. pylori and obstruction, probably due to the low frequency of the complication, the small size of the studies, and patient selection. There are case reports and small series which indicate that cure of H. pylori infection heals the ulcers, resolves the outlet obstruction, and prevents recurrence of obstruction in most, but not all, cases [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/21/40282/abstract/101,105-107\">",
"     101,105-107",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Although data are limited, there is sufficient evidence to indicate that nonsteroidal antiinflammatory drugs (NSAIDs) are an important cause of obstruction. Furthermore, a substantial proportion of patients with outlet obstruction due to NSAID-induced PUD respond to medical therapy as long as NSAID use is discontinued [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/21/40282/abstract/108\">",
"     108",
"    </a>",
"    ]. In a study of 119 elderly patients undergoing endoscopy for PUD, 12 cases with obstruction were found, 11 of whom were consuming NSAIDs [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/21/40282/abstract/109\">",
"     109",
"    </a>",
"    ]. All cases responded to medical management alone. If NSAID use is continued, there is a risk of recurrent obstruction [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/21/40282/abstract/108\">",
"     108",
"    </a>",
"    ]. In particular, great caution should be exercised in using surgical intervention in patients who are likely to continue NSAID use, since continued use predicts postoperative ulcer recurrence [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/21/40282/abstract/110\">",
"     110",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?6/37/6745?source=see_link\">",
"     \"NSAIDs (including aspirin): Pathogenesis of gastroduodenal toxicity\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4460762\">",
"    <span class=\"h3\">",
"     Antisecretory agents",
"    </span>",
"    &nbsp;&mdash;&nbsp;Even though the benefit of antisecretory therapy has not been formally established for the acute or long-term management of ulcer obstruction, these agents are the mainstay of initial treatment. Intravenous PPI therapy is warranted during the initial gastric decompression phase to reduce intravenous fluid requirements, control gastric pH, and facilitate ulcer healing. Based on the precedent for the acute management of bleeding peptic ulcers, a high-dose PPI regimen using an 80 mg loading dose, followed by 8 mg per hour of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?25/62/26601?source=see_link\">",
"     omeprazole",
"    </a>",
"    or equivalent PPI, seems appropriate until the obstruction has resolved; however, lower doses and twice daily bolus dosing may be equally effective, as noted above (see",
"    <a class=\"local\" href=\"#H4460489\">",
"     'Acid suppressive therapy'",
"    </a>",
"    above).",
"   </p>",
"   <p>",
"    After the patient resumes oral intake and is emptying liquids, a liquid antisecretory preparation is needed, such as",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?25/62/26601?source=see_link\">",
"     omeprazole",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?0/52/840?source=see_link\">",
"     sodium bicarbonate",
"    </a>",
"    powder. Since standard preparations of the five proton pump inhibitors (omeprazole,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?15/39/15993?source=see_link\">",
"     esomeprazole",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?3/14/3305?source=see_link\">",
"     lansoprazole",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?43/18/44327?source=see_link\">",
"     rabeprazole",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/16/32009?source=see_link\">",
"     pantoprazole",
"    </a>",
"    ) use enteric-coated formulations, good emptying of solids is required for effective drug delivery; their oral use is therefore limited until the obstruction has resolved and motility has recovered. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?12/47/13049?source=see_link\">",
"     \"Pharmacology of antiulcer medications\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Oral antisecretory therapy with PPIs or H2 receptor antagonists is appropriate for long-term management of patients who have had a gastric outlet obstruction due to PUD. After H. pylori infection is treated (if present), full dose oral antisecretory medication should probably be continued until successful cure of the infection has been confirmed and antral-duodenal deformities have resolved. Although only documented anecdotally, the combination of curing H. pylori infection, continued antisecretory therapy, and time will eventually reverse antral-duodenal deformity and tendency for recurrent obstruction.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4460770\">",
"    <span class=\"h3\">",
"     Endoscopic balloon dilation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients who fail to respond to medical therapy may require endoscopic dilation or surgery. Before surgery is contemplated, endoscopy with biopsy is required to identify the cause of the obstruction and to rule out malignancy, which has been reported in as many as 66 percent of patients in this setting [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/21/40282/abstract/94,111\">",
"     94,111",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    If the pyloric channel can be identified and a balloon passed, dilation is an appropriate option in experienced hands. A Gastrografin study may be helpful to define the anatomy of the pylorus before dilation. If the pylorus can be opened sufficiently to allow the patient to tolerate a liquid diet, especially when an underlying cause can be reversed, then continuing medical treatment is a reasonable option as long as the patient is carefully monitored to ensure that retention does not recur. Monitoring symptoms is important, but it is advisable to also check a gastric residual or perform a saline load test (",
"    <a class=\"graphic graphic_table graphicRef63196 \" href=\"mobipreview.htm?26/29/27099\">",
"     table 2",
"    </a>",
"    ), especially in patients who were previously asymptomatic despite large gastric residuals. Cases that clearly warrant surgery are ones where the pylorus is obstructed and cannot be safely dilated, or where the obstruction persists or recurs during medical and endoscopic management.",
"   </p>",
"   <p>",
"    Dilation can be accomplished by using endoscopy and a through-the-scope (TTS) balloon dilator, or by using a balloon placed over a guidewire positioned under fluoroscopic guidance. While fluoroscopy may not be required for dilation using a TTS balloon in the case of mild strictures (eg, strictures that allow passage of an endoscope), most other stricture dilations are carried out using fluoroscopic guidance. The amount of dilation in a single session is determined by the initial diameter of the stricture. Narrow strictures may require stepwise dilation performed over multiple sessions, as is done with esophageal strictures. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?38/24/39305?source=see_link&amp;anchor=H13#H13\">",
"     \"Management of benign esophageal strictures\", section on 'Technique'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Balloon dilation should be monitored by a pressure gauge. The balloon is inflated to the chosen diameter and inflation is sustained for thirty to sixty seconds. The dilation may then be repeated at the same diameter, though it is not certain that repeated dilations to the same diameter yield better results. Using dilute contrast medium to fill the balloon allows progress to be followed fluoroscopically; a waist forms initially during dilation, but is effaced during balloon distention. Successful dilation is usually confirmed by pulling the balloon through the strictured segment, although failure to accomplish this does not preclude a successful procedure. Symptoms are usually considerably improved with successful dilation to 12 mm. There may be an advantage to postponing dilation beyond 15 mm until after a period of medical management [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/21/40282/abstract/71\">",
"     71",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Long duodenal strictures are the most difficult to dilate. Multiple sessions using stepwise dilation for tight obstructions will likely lower the risk of perforation. Nevertheless, because of the risk of perforation, patients should be appropriately prepared for surgery before duodenal dilation and monitored closely after dilation before resuming oral intake. If there is concern about a possible perforation or if the dilation is unusually difficult to perform, an immediate postprocedure Gastrografin study should be obtained.",
"   </p>",
"   <p>",
"    Multiple sessions of endoscopic balloon dilation are necessary in some cases [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/21/40282/abstract/97,108,112,113\">",
"     97,108,112,113",
"    </a>",
"    ]. In one study, for example, 24 of 30 patients (80 percent) achieved sustained symptom relief; 17 had a single procedure, while seven required multiple sessions [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/21/40282/abstract/97\">",
"     97",
"    </a>",
"    ]. Dilation failed in four patients with long duodenal strictures, while two dilated to 18 mm suffered perforation; both recovered uneventfully after surgery. A good long-term response following dilation is achieved when H. pylori can be cured or NSAID use discontinued [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/21/40282/abstract/108\">",
"     108",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11767029\">",
"    <span class=\"h3\">",
"     Surgery",
"    </span>",
"    &nbsp;&mdash;&nbsp;For patients who require surgery, the choice of procedure is usually made during the operation. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?39/5/40025?source=see_link&amp;anchor=H493273644#H493273644\">",
"     \"Surgical management of complications of peptic ulcer disease\", section on 'Surgery'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H56806712\">",
"    <span class=\"h1\">",
"     FOLLOW-UP",
"    </span>",
"    &nbsp;&mdash;&nbsp;Upper endoscopy is indicated for most patients after four to six weeks to exclude neoplasia and other diagnoses and to establish healing. In addition, biopsies should be obtained to look for H. pylori or to confirm H. pylori eradication in those who have been treated. To increase the yield for diagnosing H. pylori, patients should be switched to H2 receptor antagonists for the two weeks prior to the endoscopy. In addition, they should be off of antibiotics and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?34/29/35285?source=see_link\">",
"     bismuth",
"    </a>",
"    for two weeks. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?41/18/42281?source=see_link&amp;anchor=H14#H14\">",
"     \"Overview of the natural history and treatment of peptic ulcer disease\", section on 'Follow-up after initial therapy for peptic ulcer'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?22/32/23049?source=see_link&amp;anchor=H2834839008#H2834839008\">",
"     \"Treatment regimens for Helicobacter pylori\", section on 'Eradication confirmation'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H193857306\">",
"    <span class=\"h1\">",
"     PREVENTION OF RECURRENCE",
"    </span>",
"    &nbsp;&mdash;&nbsp;The natural history of complicated peptic ulcer disease (PUD) is for the recurrence of complications unless the underlying cause can be treated.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H56805934\">",
"    <span class=\"h2\">",
"     Stop NSAIDs",
"    </span>",
"    &nbsp;&mdash;&nbsp;The recurrence of ulcer complications with continuing nonsteroidal antiinflammatory drug (NSAID) use is well established [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/21/40282/abstract/114,115\">",
"     114,115",
"    </a>",
"    ] and is an indication for co-therapy with antisecretory agents, which reduces recurrences. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?11/58/12197?source=see_link\">",
"     \"NSAIDs (including aspirin): Secondary prevention of gastroduodenal toxicity\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Although we are unaware of rigorous studies, when NSAIDs are the cause of ulceration and are stopped, complicated and refractory ulcers tend to heal rapidly and do not recur [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/21/40282/abstract/116\">",
"     116",
"    </a>",
"    ]. Important exceptions are giant or densely fibrosed ulcers for which healing may be delayed.",
"   </p>",
"   <p>",
"    <br/>",
"    It is important to recall that a subset of patients who consume NSAIDs fail to disclose their use even when directly asked [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/21/40282/abstract/117\">",
"     117",
"    </a>",
"    ]. Such patients are also likely to continue NSAID use even in the face of ulcer complications, clear instructions to stop the medication, and even failed ulcer surgery [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/21/40282/abstract/99,118,119\">",
"     99,118,119",
"    </a>",
"    ]. Therefore, particularly with complicated ulcers, a diligent search for NSAID use is critical. In addition, some patients with a history of complicated ulcers are prescribed NSAIDs. In a study of 26,618 NSAID prescriptions, 2244 patients reported a prior peptic ulcer and 489 reported upper gastrointestinal tract bleeding. However, among patients with a history of bleeding, physicians recorded the history of prior bleeding in only 8 percent of cases [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/21/40282/abstract/120\">",
"     120",
"    </a>",
"    ], suggesting that NSAIDs are frequently prescribed when they are contraindicated in the absence of proton pump inhibitor (PPI) cotherapy or careful monitoring.",
"   </p>",
"   <p>",
"    Ulcers can recur despite definitive ulcer surgery (eg, vagotomy) in the setting of continued NSAID use. Uncontrolled series and case reports highlight problematic recurrences following definitive ulcer surgery when NSAIDs, and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    in particular, are continued [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/21/40282/abstract/110,118,119,121\">",
"     110,118,119,121",
"    </a>",
"    ]. Therefore, every effort should be made to discover NSAID use in patients with complicated ulcers, especially before surgery; a careful history from the patient and family and, in selected cases, measuring salicylate levels and platelet function may be justified [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/21/40282/abstract/110\">",
"     110",
"    </a>",
"    ]. Any role of definitive ulcer surgery in patients with continued NSAID use remains to be elucidated.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H56805976\">",
"    <span class=\"h2\">",
"     Treat H. pylori",
"    </span>",
"    &nbsp;&mdash;&nbsp;A confident diagnosis of H. pylori is essential because treatment can prevent life-threatening recurrences. However, as noted above, making a diagnosis of H. pylori in the setting of acute bleeding may be difficult. (See",
"    <a class=\"local\" href=\"#H56805165\">",
"     'H. pylori infection'",
"    </a>",
"    above and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?36/59/37817?source=see_link\">",
"     \"Indications and diagnostic tests for Helicobacter pylori infection\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    With H. pylori-associated ulcer bleeding, successful cure of the infection dramatically reduces recurrent ulceration and recurrent complications [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/21/40282/abstract/122,123\">",
"     122,123",
"    </a>",
"    ]. Although much less extensively studied, in two randomized trials with a total of 173 patients with perforated ulcers, H. pylori antibiotic treatment reduced the recurrence rate of duodenal, prepyloric, and pyloric ulcers after simple surgical closure of the perforation from 30 to 6.1 percent in the first study and from 38 percent to 4.8 percent in the second [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/21/40282/abstract/14,124\">",
"     14,124",
"    </a>",
"    ]. Three other case series support similar conclusions [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/21/40282/abstract/52,125,126\">",
"     52,125,126",
"    </a>",
"    ]. Following treatment for H. pylori, patients should be tested to confirm successful eradication of the organism. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?22/32/23049?source=see_link&amp;anchor=H2834839008#H2834839008\">",
"     \"Treatment regimens for Helicobacter pylori\", section on 'Eradication confirmation'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The role of H. pylori in ulcer recurrences following acid reducing surgery remains controversial [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/21/40282/abstract/121\">",
"     121",
"    </a>",
"    ]. Postoperative ulcer recurrences can clearly result from incomplete vagotomy and continued NSAID use. No studies resolve the question of whether curing H. pylori reduces recurrences following definitive ulcer surgery in the subset of patients with H. pylori. However, two reports indicated that persistent postoperative H. pylori infection is associated with advancing atrophic gastritis or precursor lesions that may underlie the increased rate of gastric cancer observed after definitive peptic ulcer surgery [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/21/40282/abstract/127,128\">",
"     127,128",
"    </a>",
"    ]. Considering these factors and the weight of evidence implicating H. pylori in ulcer recurrence, we suggest that the organism be eradicated (if present) even in patients who have undergone definitive ulcer surgery [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/21/40282/abstract/121\">",
"     121",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18363529\">",
"    <span class=\"h2\">",
"     Non-H. pylori, non-NSAID ulcers",
"    </span>",
"    &nbsp;&mdash;&nbsp;While less common, ulcers not due to H. pylori infection or NSAIDs are prone to frequent recurrences that often require continued maintenance medical therapy or surgery. This point was illustrated in a prospective study that compared 120 patients with a history of H. pylori-negative, NSAID-negative bleeding ulcers to 213 patients with a history of H. pylori positive bleeding ulcers who were treated successfully with eradication therapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/21/40282/abstract/129\">",
"     129",
"    </a>",
"    ]. At follow-up of up to seven years, the H. pylori negative patients had a significantly higher rate of recurrent bleeding (42 versus 11 percent). (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?18/42/19113?source=see_link&amp;anchor=H7#H7\">",
"     \"Epidemiology and etiology of peptic ulcer disease\", section on 'H. pylori'",
"    </a>",
"    .)",
"    <br/>",
"    <br/>",
"    In patients with presumed non-H. pylori, non-NSAID ulcers, every effort must be made to exclude H. pylori infection and NSAID use and to determine the cause of the ulcer. A cause for most non-H. pylori, non-NSAID ulcers can be established (",
"    <a class=\"graphic graphic_table graphicRef75002 \" href=\"mobipreview.htm?11/34/11820\">",
"     table 3",
"    </a>",
"    ). For example, crack cocaine use can cause perforated ulcers. The ulcers should be diligently treated and reversible factors contributing to ulcer development should be addressed to decrease the risk of recurrent complications. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?19/0/19466?source=see_link\">",
"     \"Unusual causes of peptic ulcer disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H73186734\">",
"    <span class=\"h2\">",
"     Maintenance acid suppressive therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with complicated PUD due to an identifiable cause that can be addressed (eg, treatment for H. pylori or discontinuation of NSAIDs) generally do not require maintenance acid suppressive therapy. Such patients are typically treated with a PPI for at least four to six weeks. The duration of therapy depends upon the etiology and characteristics of the ulcer (particularly size and presence of dense scarring):",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In patients with H. pylori infection, eradication should be confirmed prior to stopping antisecretory treatment (see",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?22/32/23049?source=see_link&amp;anchor=H2834839008#H2834839008\">",
"       \"Treatment regimens for Helicobacter pylori\", section on 'Eradication confirmation'",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      In patients requiring endoscopic confirmation of ulcer healing (eg, gastric ulcers at high-risk of malignancy, giant duodenal ulcers, or deformed ulcers with dense scarring), the PPI should be continued until healing has been demonstrated (see",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?41/18/42281?source=see_link&amp;anchor=H14#H14\">",
"       \"Overview of the natural history and treatment of peptic ulcer disease\", section on 'Follow-up after initial therapy for peptic ulcer'",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      For patients with NSAID-associated ulcer complications where NSAIDs have been stopped (and H. pylori excluded or eradicated), it is reasonable to stop maintenance therapy after healing has been confirmed",
"     </li>",
"     <li>",
"      Although the natural history of complicated non-NSAID, non-H. pylori ulcers has received only limited study, recurrence rates are likely to be high and sustained maintenance therapy is probably indicated",
"     </li>",
"     <li>",
"      Any patient who has had a prior ulcer complication should be carefully educated about the ways recurrent complications can present and about the critical importance of immediately seeking emergent medical attention for any suspicion of recurrent complications",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In patients requiring maintenance therapy, once the ulcer has healed, the PPI can be tapered by cutting the dose by 50 percent every week until the patient is on a low dose of the medication (eg,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?25/62/26601?source=see_link\">",
"     omeprazole",
"    </a>",
"    20 mg daily). The patient can then either continue the low-dose PPI, or after a week on the low-dose PPI, switch to an H2 receptor antagonist. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?41/18/42281?source=see_link&amp;anchor=H17#H17\">",
"     \"Overview of the natural history and treatment of peptic ulcer disease\", section on 'Maintenance therapy'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?41/18/42281?source=see_link&amp;anchor=H6#H6\">",
"     \"Overview of the natural history and treatment of peptic ulcer disease\", section on 'Antisecretory therapy after H. pylori eradication'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?41/18/42281?source=see_link&amp;anchor=H11#H11\">",
"     \"Overview of the natural history and treatment of peptic ulcer disease\", section on 'Antisecretory therapy'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H193856781\">",
"    <span class=\"h2\">",
"     Definitive ulcer surgery",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although definitive acid-reducing surgical procedures (parietal cell vagotomy or vagotomy with drainage or partial gastrectomy) have the potential of decreasing recurrent complications, their performance (especially during emergency ulcer surgery) adds operative time, perioperative risk, and long-term adverse side effects, such as dumping syndrome. Most large studies of definitive ulcer surgery were performed prior to the recognition of H. pylori, the role of NSAIDs, and potent antisecretory agents [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/21/40282/abstract/130-133\">",
"     130-133",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?32/57/33688?source=see_link\">",
"     \"Role of surgery in the management of peptic ulcer disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    An illustrative report included 159 patients who were followed more than 10 years after vagotomy and pyloroplasty for perforated duodenal ulcer [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/21/40282/abstract/132\">",
"     132",
"    </a>",
"    ]. The perioperative mortality was 5.5 percent, ulcers recurred in 8.8 percent, and postoperative digestive sequelae, notably diarrhea and dumping, developed in 16 percent. Similar recurrence rates (but with less morbidity) have been described in patients who underwent parietal cell vagotomy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/21/40282/abstract/133\">",
"     133",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Even though no data are available to compare the risks of definitive ulcer surgery to current medical treatment, a few points are relevant:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In light of the demonstrated benefits of medical treatment (curing H. pylori, eliminating NSAIDs, and using potent antisecretory agents) for decreasing complicated ulcer recurrence, the rates of performing definitive ulcer procedures during emergency surgery have fallen dramatically, without any obvious deleterious impact on outcomes [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/21/40282/abstract/37,55,134,135\">",
"       37,55,134,135",
"      </a>",
"      ]. As a result, there is a decline in surgical expertise for performing these definitive procedures, especially in the community, which inevitably further compromises the outcomes of surgery.",
"     </li>",
"     <li>",
"      If patients who require emergency surgery for ulcer complications have failed all forms of medical management, definitive surgery deserves consideration.",
"     </li>",
"     <li>",
"      By contrast, definitive surgery is generally not appropriate if medical management has not been tried. Although the cause of the ulcer disease may not be known at the time of surgery, all forms respond quite well to medical management. However, the proportion of patients who will not tolerate, be adherent with, or respond to medical treatment is likely to be very small and elective definitive ulcer surgery can be reserved for this subset [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/21/40282/abstract/136\">",
"       136",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In patients with acid hypersecretion, definitive ulcer surgery (eg, vagotomy) should be avoided because there is a high risk of postoperative ulcer recurrence. This approach is well established for patients with gastrinomas, but also appears to pertain to patients with nongastrinoma acid hypersecretion [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/21/40282/abstract/137\">",
"       137",
"      </a>",
"      ]. On the other hand, in patients undergoing surgery to resect a gastrinoma, a parietal cell (highly selective) vagotomy performed at the time of tumor resection has been advocated to reduce the need for postoperative medical therapy, particularly when complete resection of the gastrinoma tissue cannot be accomplished [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/21/40282/abstract/138,139\">",
"       138,139",
"      </a>",
"      ]. However, relatively few surgeons currently perform this procedure. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?6/51/6968?source=see_link\">",
"       \"Management and prognosis of the Zollinger-Ellison syndrome (gastrinoma)\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11767021\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The major complications of peptic ulcer disease (PUD) include perforation, gastric outlet obstruction, penetration, and bleeding. For reasons that have not been defined, the relative prominence of these complications varies in different regions. (See",
"      <a class=\"local\" href=\"#H62849741\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Although a history of preceding ulcer symptoms is common, many patients have no preceding typical peptic ulcer symptoms or known disease. (See",
"      <a class=\"local\" href=\"#H4460443\">",
"       'Preceding symptoms'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Certain management principles apply to all patients with complicated ulcers, regardless of type (",
"      <a class=\"graphic graphic_table graphicRef65479 \" href=\"mobipreview.htm?34/57/35740\">",
"       table 1",
"      </a>",
"      ). These principles include coordination of care among the surgical and medical teams, early administration of intravenous proton pump inhibitors (PPIs) for acid suppression, treatment of H. pylori if present (after the patient resumes oral feedings), and discontinuation of nonsteroidal antiinflammatory drugs (NSAIDs), at least until healing has been established. (See",
"      <a class=\"local\" href=\"#H4460472\">",
"       'General approach to patients with complicated ulcers'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Appropriate treatment for patients with bleeding ulcers generally includes fluid resuscitation to correct hypovolemia; blood transfusions as necessary; early, high-dose intravenous PPI (80 mg loading and 8 mg per hour of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?25/62/26601?source=see_link\">",
"       omeprazole",
"      </a>",
"      or equivalent is usually recommended, though lower doses administered by intravenous bolus appear equally effective); and endoscopic intervention for ulcers with stigmata of active bleeding. Surgery or angiography is required when two endoscopic treatment sessions have failed or bleeding recurs after these interventions, especially in hemodynamically unstable patients. (See",
"      <a class=\"local\" href=\"#H4460451\">",
"       'Bleeding'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H4460489\">",
"       'Acid suppressive therapy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Ulcer perforation should be suspected in patients with or without a history of peptic ulcer symptoms or disease who develop the sudden onset of severe epigastric or diffuse abdominal pain or, especially in elderly patients, sudden decompensation. Once the diagnosis of an ulcer perforation has been made, initial management includes insertion of a nasogastric tube, intravenous volume replacement, treatment with an intravenous PPI, and appropriate antibiotics. A decision then is made about whether the patient requires surgery. (See",
"      <a class=\"local\" href=\"#H4460621\">",
"       'Perforation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For patients with an acute perforation and a rigid abdomen with free intraperitoneal air, emergent operation and closure with a piece of omentum (Graham patch) is the standard of care. Furthermore, with an established ulcer perforation, regardless of the presence or size of the leak, if the patient&rsquo;s status is deteriorating, urgent surgery is indicated. Lastly, surgery is indicated in circumstances where the cause of an acute abdomen has not been established or the patient&rsquo;s status cannot be carefully monitored. (See",
"      <a class=\"local\" href=\"#H66923472\">",
"       'Management'",
"      </a>",
"      above.)",
"      <br/>",
"      <br/>",
"      Despite this standard of care, there are several situations where continuing nonoperative care appears justifiable, especially because there are no rigorous data available to guide treatment decisions. If the patient is stable or improving, especially if imaging studies show spontaneous sealing of the perforation, then continued nonoperative management with close monitoring is a reasonable option. Furthermore, for patients with small to moderate leaks who are clinically stable, some studies suggest that nonoperative management with close monitoring is reasonable. Lastly, patients who are at very high risk for surgery because of comorbidity can have surprisingly low mortality with rigorous, nonoperative management. There are two critical unknowns: the ability of intravenous PPIs to accelerate sealing of the perforation and the role for percutaneous drainage. The latter appears to be very useful for patients with persisting leaks across perforated ulcers who are adequately stable to tolerate nonoperative care. (See",
"      <a class=\"local\" href=\"#H73184426\">",
"       'Operative versus nonoperative management'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Ulcer penetration refers to penetration of the ulcer through the bowel wall without free perforation and leakage of luminal contents into the peritoneal cavity. Penetration often comes to attention because of a change in symptoms or involvement of adjacent structures. Patients are typically managed in a manner similar to patients with refractory peptic ulcers. (See",
"      <a class=\"local\" href=\"#H4460706\">",
"       'Penetration'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?15/61/16345?source=see_link&amp;anchor=H14#H14\">",
"       \"Refractory or recurrent peptic ulcer disease\", section on 'Treatment'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Gastric outlet obstruction is the least common ulcer complication. Most cases are associated with duodenal or pyloric channel ulceration. Symptoms of gastric outlet obstruction include early satiety, bloating, indigestion, anorexia, nausea, vomiting, epigastric pain, and weight loss. Malignancy is a more common cause of gastric outlet obstruction and must be excluded. Some patients can be managed medically, whereas others require endoscopic balloon dilation or surgery. (See",
"      <a class=\"local\" href=\"#H4460714\">",
"       'Gastric outlet obstruction'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/21/40282/abstract/1\">",
"      Ohmann C, Imhof M, Ruppert C, et al. Time-trends in the epidemiology of peptic ulcer bleeding. Scand J Gastroenterol 2005; 40:914.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/21/40282/abstract/2\">",
"      Kang JY, Elders A, Majeed A, et al. Recent trends in hospital admissions and mortality rates for peptic ulcer in Scotland 1982-2002. Aliment Pharmacol Ther 2006; 24:65.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/21/40282/abstract/3\">",
"      Post PN, Kuipers EJ, Meijer GA. Declining incidence of peptic ulcer but not of its complications: a nation-wide study in The Netherlands. Aliment Pharmacol Ther 2006; 23:1587.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/21/40282/abstract/4\">",
"      Lassen A, Hallas J, Schaffalitzky de Muckadell OB. Complicated and uncomplicated peptic ulcers in a Danish county 1993-2002: a population-based cohort study. Am J Gastroenterol 2006; 101:945.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/21/40282/abstract/5\">",
"      Bardhan KD, Royston C. Time, change and peptic ulcer disease in Rotherham, UK. Dig Liver Dis 2008; 40:540.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/21/40282/abstract/6\">",
"      Thomopoulos KC, Vagenas KA, Vagianos CE, et al. Changes in aetiology and clinical outcome of acute upper gastrointestinal bleeding during the last 15 years. Eur J Gastroenterol Hepatol 2004; 16:177.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/21/40282/abstract/7\">",
"      Sonnenberg A. Time trends of ulcer mortality in Europe. Gastroenterology 2007; 132:2320.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/21/40282/abstract/8\">",
"      Wang YR, Richter JE, Dempsey DT. Trends and outcomes of hospitalizations for peptic ulcer disease in the United States, 1993 to 2006. Ann Surg 2010; 251:51.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/21/40282/abstract/9\">",
"      Sadic J, Borgstr&ouml;m A, Manjer J, et al. Bleeding peptic ulcer - time trends in incidence, treatment and mortality in Sweden. Aliment Pharmacol Ther 2009; 30:392.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/21/40282/abstract/10\">",
"      Lau JY, Sung J, Hill C, et al. Systematic review of the epidemiology of complicated peptic ulcer disease: incidence, recurrence, risk factors and mortality. Digestion 2011; 84:102.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/21/40282/abstract/11\">",
"      Sung JJ, Tsoi KK, Ma TK, et al. Causes of mortality in patients with peptic ulcer bleeding: a prospective cohort study of 10,428 cases. Am J Gastroenterol 2010; 105:84.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/21/40282/abstract/12\">",
"      Irabor DO. An audit of peptic ulcer surgery in Ibadan, Nigeria. West Afr J Med 2005; 24:242.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/21/40282/abstract/13\">",
"      S&aacute;nchez-Delgado J, Gen&eacute; E, Su&aacute;rez D, et al. Has H. pylori prevalence in bleeding peptic ulcer been underestimated? A meta-regression. Am J Gastroenterol 2011; 106:398.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/21/40282/abstract/14\">",
"      Ng EK, Lam YH, Sung JJ, et al. Eradication of Helicobacter pylori prevents recurrence of ulcer after simple closure of duodenal ulcer perforation: randomized controlled trial. Ann Surg 2000; 231:153.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/21/40282/abstract/15\">",
"      Gisbert JP, Legido J, Garc&iacute;a-Sanz I, Pajares JM. Helicobacter pylori and perforated peptic ulcer prevalence of the infection and role of non-steroidal anti-inflammatory drugs. Dig Liver Dis 2004; 36:116.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/21/40282/abstract/16\">",
"      Kumar S, Mittal GS, Gupta S, et al. Prevalence of Helicobactor pylori in patients with perforated duodenal ulcer. Trop Gastroenterol 2004; 25:121.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/21/40282/abstract/17\">",
"      Lanas A, Garc&iacute;a-Rodr&iacute;guez LA, Arroyo MT, et al. Risk of upper gastrointestinal ulcer bleeding associated with selective cyclo-oxygenase-2 inhibitors, traditional non-aspirin non-steroidal anti-inflammatory drugs, aspirin and combinations. Gut 2006; 55:1731.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/21/40282/abstract/18\">",
"      Collier DS, Pain JA. Non-steroidal anti-inflammatory drugs and peptic ulcer perforation. Gut 1985; 26:359.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/21/40282/abstract/19\">",
"      Kuyvenhoven JP, Veenendaal RA, Vandenbroucke JP. Peptic ulcer bleeding: interaction between non-steroidal anti-inflammatory drugs, Helicobacter pylori infection, and the ABO blood group system. Scand J Gastroenterol 1999; 34:1082.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/21/40282/abstract/20\">",
"      Santolaria S, Lanas A, Benito R, et al. Helicobacter pylori infection is a protective factor for bleeding gastric ulcers but not for bleeding duodenal ulcers in NSAID users. Aliment Pharmacol Ther 1999; 13:1511.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/21/40282/abstract/21\">",
"      Labenz J, Peitz U, K&ouml;hl H, et al. Helicobacter pylori increases the risk of peptic ulcer bleeding: a case-control study. Ital J Gastroenterol Hepatol 1999; 31:110.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/21/40282/abstract/22\">",
"      Demiray E, Yilmaz O, Sarkis C, et al. Comparison of invasive methods and two different stool antigen tests for diagnosis of H pylori infection in patients with gastric bleeding. World J Gastroenterol 2006; 12:4206.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/21/40282/abstract/23\">",
"      van Leerdam ME, van der Ende A, ten Kate FJ, et al. Lack of accuracy of the noninvasive Helicobacter pylori stool antigen test in patients with gastroduodenal ulcer bleeding. Am J Gastroenterol 2003; 98:798.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/21/40282/abstract/24\">",
"      Gisbert JP, Esteban C, Jimenez I, Moreno-Otero R. 13C-urea breath test during hospitalization for the diagnosis of Helicobacter pylori infection in peptic ulcer bleeding. Helicobacter 2007; 12:231.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/21/40282/abstract/25\">",
"      Malfertheiner P, Megraud F, O'Morain C, et al. Current concepts in the management of Helicobacter pylori infection: the Maastricht III Consensus Report. Gut 2007; 56:772.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/21/40282/abstract/26\">",
"      Pietroiusti A, Forlini A, Magrini A, et al. Isolated H. pylori duodenal colonization and idiopathic duodenal ulcers. Am J Gastroenterol 2008; 103:55.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/21/40282/abstract/27\">",
"      Okan A, Tankurt E, Aslan BU, et al. Relationship between non-steroidal anti-inflammatory drug use and Helicobacter pylori infection in bleeding or uncomplicated peptic ulcers: A case-control study. J Gastroenterol Hepatol 2003; 18:18.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/21/40282/abstract/28\">",
"      Lanas A, Fuentes J, Benito R, et al. Helicobacter pylori increases the risk of upper gastrointestinal bleeding in patients taking low-dose aspirin. Aliment Pharmacol Ther 2002; 16:779.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/21/40282/abstract/29\">",
"      Huang JQ, Sridhar S, Hunt RH. Role of Helicobacter pylori infection and non-steroidal anti-inflammatory drugs in peptic-ulcer disease: a meta-analysis. Lancet 2002; 359:14.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/21/40282/abstract/30\">",
"      Hirschowitz BI, Simmons J, Mohnen J. Clinical outcome using lansoprazole in acid hypersecretors with and without Zollinger-Ellison syndrome: a 13-year prospective study. Clin Gastroenterol Hepatol 2005; 3:39.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/21/40282/abstract/31\">",
"      Wilcox CM, Seay T, Arcury J, Hirschowitz BI. Presentation, response to lansoprazole therapy, and outcome of Zollinger-Ellison syndrome-like gastric acid hypersecretors. Scand J Gastroenterol 2011; 46:277.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/21/40282/abstract/32\">",
"      Cappell MS. Gastric and duodenal ulcers during pregnancy. Gastroenterol Clin North Am 2003; 32:263.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/21/40282/abstract/33\">",
"      Taha AS, Angerson WJ, Prasad R, et al. Clinical trial: the incidence and early mortality after peptic ulcer perforation, and the use of low-dose aspirin and nonsteroidal anti-inflammatory drugs. Aliment Pharmacol Ther 2008; 28:878.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/21/40282/abstract/34\">",
"      Thomsen RW, Riis A, Christensen S, et al. Diabetes and 30-day mortality from peptic ulcer bleeding and perforation: a Danish population-based cohort study. Diabetes Care 2006; 29:805.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/21/40282/abstract/35\">",
"      Sharma SS, Mamtani MR, Sharma MS, Kulkarni H. A prospective cohort study of postoperative complications in the management of perforated peptic ulcer. BMC Surg 2006; 6:8.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/21/40282/abstract/36\">",
"      Ahsberg K, H&ouml;glund P, Kim WH, von Holstein CS. Impact of aspirin, NSAIDs, warfarin, corticosteroids and SSRIs on the site and outcome of non-variceal upper and lower gastrointestinal bleeding. Scand J Gastroenterol 2010; 45:1404.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/21/40282/abstract/37\">",
"      Chiu PW, Ng EK, Wong SK, et al. Surgical salvage of bleeding peptic ulcers after failed therapeutic endoscopy. Dig Surg 2009; 26:243.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/21/40282/abstract/38\">",
"      M&oslash;ller MH, Adamsen S, Thomsen RW, M&oslash;ller AM. Preoperative prognostic factors for mortality in peptic ulcer perforation: a systematic review. Scand J Gastroenterol 2010; 45:785.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/21/40282/abstract/39\">",
"      Noguiera C, Silva AS, Santos JN, et al. Perforated peptic ulcer: main factors of morbidity and mortality. World J Surg 2003; 27:782.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/21/40282/abstract/40\">",
"      Sung JJ, Lau JY, Ching JY, et al. Continuation of low-dose aspirin therapy in peptic ulcer bleeding: a randomized trial. Ann Intern Med 2010; 152:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/21/40282/abstract/41\">",
"      Klebl FH, Bregenzer N, Sch&ouml;fer L, et al. Comparison of inpatient and outpatient upper gastrointestinal haemorrhage. Int J Colorectal Dis 2005; 20:368.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/21/40282/abstract/42\">",
"      M&uuml;ller T, Barkun AN, Martel M. Non-variceal upper GI bleeding in patients already hospitalized for another condition. Am J Gastroenterol 2009; 104:330.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/21/40282/abstract/43\">",
"      Schemmer P, Decker F, Dei-Anane G, et al. The vital threat of an upper gastrointestinal bleeding: Risk factor analysis of 121 consecutive patients. World J Gastroenterol 2006; 12:3597.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/21/40282/abstract/44\">",
"      Schimke K, Chubb SA, Davis WA, et al. Antiplatelet therapy, Helicobacter pylori infection and complicated peptic ulcer disease in diabetes: the Fremantle Diabetes Study. Diabet Med 2009; 26:70.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/21/40282/abstract/45\">",
"      Christensen S, Riis A, N&oslash;rgaard M, et al. Short-term mortality after perforated or bleeding peptic ulcer among elderly patients: a population-based cohort study. BMC Geriatr 2007; 7:8.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/21/40282/abstract/46\">",
"      Chiu PW, Ng EK, Cheung FK, et al. Predicting mortality in patients with bleeding peptic ulcers after therapeutic endoscopy. Clin Gastroenterol Hepatol 2009; 7:311.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/21/40282/abstract/47\">",
"      Kocer B, Surmeli S, Solak C, et al. Factors affecting mortality and morbidity in patients with peptic ulcer perforation. J Gastroenterol Hepatol 2007; 22:565.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/21/40282/abstract/48\">",
"      Wang BW, Mok KT, Chang HT, et al. APACHE II score: a useful tool for risk assessment and an aid to decision-making in emergency operation for bleeding gastric ulcer. J Am Coll Surg 1998; 187:287.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/21/40282/abstract/49\">",
"      Svanes C, Lie RT, Svanes K, et al. Adverse effects of delayed treatment for perforated peptic ulcer. Ann Surg 1994; 220:168.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/21/40282/abstract/50\">",
"      Hermansson M, Sta&euml;l von Holstein C, Zilling T. Surgical approach and prognostic factors after peptic ulcer perforation. Eur J Surg 1999; 165:566.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/21/40282/abstract/51\">",
"      Jordan PH Jr, Thornby J. Twenty years after parietal cell vagotomy or selective vagotomy antrectomy for treatment of duodenal ulcer. Final report. Ann Surg 1994; 220:283.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/21/40282/abstract/52\">",
"      Rodr&iacute;guez-Sanju&aacute;n JC, Fern&aacute;ndez-Santiago R, Garc&iacute;a RA, et al. Perforated peptic ulcer treated by simple closure and Helicobacter pylori eradication. World J Surg 2005; 29:849.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/21/40282/abstract/53\">",
"      Pounder R. Silent peptic ulceration: deadly silence or golden silence? Gastroenterology 1989; 96:626.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/21/40282/abstract/54\">",
"      Wilcox CM, Clark WS. Features associated with painless peptic ulcer bleeding. Am J Gastroenterol 1997; 92:1289.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/21/40282/abstract/55\">",
"      Sarosi GA Jr, Jaiswal KR, Nwariaku FE, et al. Surgical therapy of peptic ulcers in the 21st century: more common than you think. Am J Surg 2005; 190:775.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/21/40282/abstract/56\">",
"      Gururatsakul M, Holloway RH, Talley NJ, Holtmann GJ. Association between clinical manifestations of complicated and uncomplicated peptic ulcer and visceral sensory dysfunction. J Gastroenterol Hepatol 2010; 25:1162.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/21/40282/abstract/57\">",
"      Ng CY, Squires TJ, Busuttil A. Acute abdomen as a cause of death in sudden, unexpected deaths in the elderly. Scott Med J 2007; 52:20.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/21/40282/abstract/58\">",
"      Bender JS, Bouwman DL, Weaver DW. Bleeding gastroduodenal ulcers: improved outcome from a unified surgical approach. Am Surg 1994; 60:313.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/21/40282/abstract/59\">",
"      Song&uuml;r Y, Balkarli A, Acart&uuml;rk G, Senol A. Comparison of infusion or low-dose proton pump inhibitor treatments in upper gastrointestinal system bleeding. Eur J Intern Med 2011; 22:200.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/21/40282/abstract/60\">",
"      Javid G, Zargar SA, U-Saif R, et al. Comparison of p.o. or i.v. proton pump inhibitors on 72-h intragastric pH in bleeding peptic ulcer. J Gastroenterol Hepatol 2009; 24:1236.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/21/40282/abstract/61\">",
"      Andriulli A, Loperfido S, Focareta R, et al. High- versus low-dose proton pump inhibitors after endoscopic hemostasis in patients with peptic ulcer bleeding: a multicentre, randomized study. Am J Gastroenterol 2008; 103:3011.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/21/40282/abstract/62\">",
"      Wang CH, Ma MH, Chou HC, et al. High-dose vs non-high-dose proton pump inhibitors after endoscopic treatment in patients with bleeding peptic ulcer: a systematic review and meta-analysis of randomized controlled trials. Arch Intern Med 2010; 170:751.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/21/40282/abstract/63\">",
"      Laine L, Shah A, Bemanian S. Intragastric pH with oral vs intravenous bolus plus infusion proton-pump inhibitor therapy in patients with bleeding ulcers. Gastroenterology 2008; 134:1836.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/21/40282/abstract/64\">",
"      Leontiadis GI, Sreedharan A, Dorward S, et al. Systematic reviews of the clinical effectiveness and cost-effectiveness of proton pump inhibitors in acute upper gastrointestinal bleeding. Health Technol Assess 2007; 11:iii.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/21/40282/abstract/65\">",
"      Lau JY, Leung WK, Wu JC, et al. Omeprazole before endoscopy in patients with gastrointestinal bleeding. N Engl J Med 2007; 356:1631.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/21/40282/abstract/66\">",
"      Smith BR, Stabile BE. Emerging trends in peptic ulcer disease and damage control surgery in the H. pylori era. Am Surg 2005; 71:797.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/21/40282/abstract/67\">",
"      Lau JY, Sung JJ, Lam YH, et al. Endoscopic retreatment compared with surgery in patients with recurrent bleeding after initial endoscopic control of bleeding ulcers. N Engl J Med 1999; 340:751.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/21/40282/abstract/68\">",
"      Millward SF. ACR Appropriateness Criteria on treatment of acute nonvariceal gastrointestinal tract bleeding. J Am Coll Radiol 2008; 5:550.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/21/40282/abstract/69\">",
"      Behrman SW. Management of complicated peptic ulcer disease. Arch Surg 2005; 140:201.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/21/40282/abstract/70\">",
"      Gunshefski L, Flancbaum L, Brolin RE, Frankel A. Changing patterns in perforated peptic ulcer disease. Am Surg 1990; 56:270.",
"     </a>",
"    </li>",
"    <li>",
"     Graham DY. Ulcer complications and their nonoperative treatment. In: Gastrointestinal Disease, 5th ed, Sleisenger M, Fordtran J (Eds), WB Saunders, Philadelphia 1993. p.698.",
"    </li>",
"    <li>",
"     Silen W. Cope's Early Diagnosis of the Acute Abdomen, Oxford University Press, New York 1996.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/21/40282/abstract/73\">",
"      Su YH, Yeh CC, Lee CY, et al. Acute surgical treatment of perforated peptic ulcer in the elderly patients. Hepatogastroenterology 2010; 57:1608.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/21/40282/abstract/74\">",
"      Wong CH, Chow PK. Posterior perforation of gastric ulcer. Dig Dis Sci 2004; 49:1882.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/21/40282/abstract/75\">",
"      Grassi R, Romano S, Pinto A, Romano L. Gastro-duodenal perforations: conventional plain film, US and CT findings in 166 consecutive patients. Eur J Radiol 2004; 50:30.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/21/40282/abstract/76\">",
"      Donovan AJ, Berne TV, Donovan JA. Perforated duodenal ulcer: an alternative therapeutic plan. Arch Surg 1998; 133:1166.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/21/40282/abstract/77\">",
"      Furukawa A, Sakoda M, Yamasaki M, et al. Gastrointestinal tract perforation: CT diagnosis of presence, site, and cause. Abdom Imaging 2005; 30:524.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/21/40282/abstract/78\">",
"      Yeung KW, Chang MS, Hsiao CP, Huang JF. CT evaluation of gastrointestinal tract perforation. Clin Imaging 2004; 28:329.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/21/40282/abstract/79\">",
"      Dumont R, Cinotti R, Lejus C, et al. The Microbiology of Community-acquired Peritonitis in Children. Pediatr Infect Dis J 2011; 30:131.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/21/40282/abstract/80\">",
"      Johnson JR, Johnston B, Clabots C, et al. Escherichia coli sequence type ST131 as the major cause of serious multidrug-resistant E. coli infections in the United States. Clin Infect Dis 2010; 51:286.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/21/40282/abstract/81\">",
"      Rogers BA, Sidjabat HE, Paterson DL. Escherichia coli O25b-ST131: a pandemic, multiresistant, community-associated strain. J Antimicrob Chemother 2011; 66:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/21/40282/abstract/82\">",
"      Krobot K, Yin D, Zhang Q, et al. Effect of inappropriate initial empiric antibiotic therapy on outcome of patients with community-acquired intra-abdominal infections requiring surgery. Eur J Clin Microbiol Infect Dis 2004; 23:682.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/21/40282/abstract/83\">",
"      Crofts TJ, Park KG, Steele RJ, et al. A randomized trial of nonoperative treatment for perforated peptic ulcer. N Engl J Med 1989; 320:970.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/21/40282/abstract/84\">",
"      Songne B, Jean F, Foulatier O, et al. [Non operative treatment for perforated peptic ulcer: results of a prospective study]. Ann Chir 2004; 129:578.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/21/40282/abstract/85\">",
"      Bucher P, Oulhaci W, Morel P, et al. Results of conservative treatment for perforated gastroduodenal ulcers in patients not eligible for surgical repair. Swiss Med Wkly 2007; 137:337.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/21/40282/abstract/86\">",
"      Rahman MM, Islam MS, Flora S, et al. Mortality in perforated peptic ulcer patients after selective management of stratified poor risk cases. World J Surg 2007; 31:2341.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/21/40282/abstract/87\">",
"      NORRIS JR, HAUBRICH WS. The incidence and clinical features of pentration in peptic ulceration. JAMA 1961; 178:386.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/21/40282/abstract/88\">",
"      Ranschaert E, Rigauts H. Confined gastric perforation: ultrasound and computed tomographic diagnosis. Abdom Imaging 1993; 18:318.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/21/40282/abstract/89\">",
"      Odze RD, B&eacute;gin LR. Peptic-ulcer-induced aortoenteric fistula. Report of a case and review of the literature. J Clin Gastroenterol 1991; 13:682.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/21/40282/abstract/90\">",
"      Ford GA, Simpson AH, Gear MW, Wilkinson SP. Duodenal ulceration into the cystic artery. Postgrad Med J 1990; 66:144.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/21/40282/abstract/91\">",
"      Van Steenbergen W, Ponette E, Marchal G, et al. Distal common bile duct stenosis secondary to benign duodenal ulceration: report of a case. Gastrointest Radiol 1990; 15:215.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/21/40282/abstract/92\">",
"      Merrill JR. Fistulation to the pancreatic duct complicating duodenal peptic ulcer. Gastroenterology 1984; 87:957.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/21/40282/abstract/93\">",
"      Soybel DI, Kestenberg A, Brunt EM, Becker JM. Gastrocolic fistula as a complication of benign gastric ulcer: report of four cases and update of the literature. Br J Surg 1989; 76:1298.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/21/40282/abstract/94\">",
"      Shone DN, Nikoomanesh P, Smith-Meek MM, Bender JS. Malignancy is the most common cause of gastric outlet obstruction in the era of H2 blockers. Am J Gastroenterol 1995; 90:1769.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/21/40282/abstract/95\">",
"      Johnson CD, Ellis H. Gastric outlet obstruction now predicts malignancy. Br J Surg 1990; 77:1023.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/21/40282/abstract/96\">",
"      Greiser WB, Bruner BW, Shamoun JM, et al. Factors affecting mortality in patients operated upon for complications of peptic ulcer disease. Am Surg 1989; 55:7.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/21/40282/abstract/97\">",
"      DiSario JA, Fennerty MB, Tietze CC, et al. Endoscopic balloon dilation for ulcer-induced gastric outlet obstruction. Am J Gastroenterol 1994; 89:868.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/21/40282/abstract/98\">",
"      KOZOLL DD, MEYER KA. OBSTRUCTING GASTRODUODENAL ULCERS. GENERAL FACTORS INFLUENCING INCIDENCE AND MORTALITY. Arch Surg 1964; 88:793.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/21/40282/abstract/99\">",
"      Shaffer HA Jr. Perforation and obstruction of the gastrointestinal tract. Assessment by conventional radiology. Radiol Clin North Am 1992; 30:405.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/21/40282/abstract/100\">",
"      Weiland D, Dunn DH, Humphrey EW, Schwartz ML. Gastric outlet obstruction in peptic ulcer disease: an indication for surgery. Am J Surg 1982; 143:90.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/21/40282/abstract/101\">",
"      Taskin V, Gurer I, Ozyilkan E, et al. Effect of Helicobacter pylori eradication on peptic ulcer disease complicated with outlet obstruction. Helicobacter 2000; 5:38.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/21/40282/abstract/102\">",
"      Kate V, Ananthakrishnan N, Badrinath S, et al. Helicobacter pylori infection in duodenal ulcer with gastric outlet obstruction. Trop Gastroenterol 1998; 19:75.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/21/40282/abstract/103\">",
"      Misra SP, Misra V, Dwivedi M, Singh PA. Helicobacter pylori-induced lymphonodular hyperplasia: a new cause of gastric outlet obstruction. J Gastroenterol Hepatol 1998; 13:1191.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/21/40282/abstract/104\">",
"      Gibson JB, Behrman SW, Fabian TC, Britt LG. Gastric outlet obstruction resulting from peptic ulcer disease requiring surgical intervention is infrequently associated with Helicobacter pylori infection. J Am Coll Surg 2000; 191:32.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/21/40282/abstract/105\">",
"      Annibale B, Marignani M, Luzzi I, Delle Fave GF. Peptic ulcer and duodenal stenosis: role of Helicobacter pylori infection. Ital J Gastroenterol 1995; 27:26.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/21/40282/abstract/106\">",
"      de Boer WA, Driessen WM. Resolution of gastric outlet obstruction after eradication of Helicobacter pylori. J Clin Gastroenterol 1995; 21:329.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/21/40282/abstract/107\">",
"      Gisbert JP, Pajares JM. Review article: Helicobacter pylori infection and gastric outlet obstruction - prevalence of the infection and role of antimicrobial treatment. Aliment Pharmacol Ther 2002; 16:1203.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/21/40282/abstract/108\">",
"      Boylan JJ, Gradzka MI. Long-term results of endoscopic balloon dilatation for gastric outlet obstruction. Dig Dis Sci 1999; 44:1883.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/21/40282/abstract/109\">",
"      Geraghty RJ, Black D, Bruce SA. The successful medical management of gastric outflow obstruction associated with the use of non-steroidal anti-inflammatory drugs in the elderly. Postgrad Med J 1991; 67:1004.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/21/40282/abstract/110\">",
"      Hirschowitz BI, Lanas A. Intractable upper gastrointestinal ulceration due to aspirin in patients who have undergone surgery for peptic ulcer. Gastroenterology 1998; 114:883.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/21/40282/abstract/111\">",
"      Benjamin SB, Cattau EL, Glass RL. Balloon dilation of the pylorus: therapy for gastric outlet obstruction. Gastrointest Endosc 1982; 28:253.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/21/40282/abstract/112\">",
"      Solt J, Bajor J, Szab&oacute; M, Horv&aacute;th OP. Long-term results of balloon catheter dilation for benign gastric outlet stenosis. Endoscopy 2003; 35:490.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/21/40282/abstract/113\">",
"      Cherian PT, Cherian S, Singh P. Long-term follow-up of patients with gastric outlet obstruction related to peptic ulcer disease treated with endoscopic balloon dilatation and drug therapy. Gastrointest Endosc 2007; 66:491.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/21/40282/abstract/114\">",
"      Cebollero-Santamaria F, Smith J, Gioe S, et al. Selective outpatient management of upper gastrointestinal bleeding in the elderly. Am J Gastroenterol 1999; 94:1242.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/21/40282/abstract/115\">",
"      Godil A, DeGuzman L, Schilling RC 3rd, et al. Recent nonsteroidal anti-inflammatory drug use increases the risk of early recurrence of bleeding in patients presenting with bleeding ulcer. Gastrointest Endosc 2000; 51:146.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/21/40282/abstract/116\">",
"      Lanas A, Remacha B, S&aacute;inz R, Hirschowitz BI. Study of outcome after targeted intervention for peptic ulcer resistant to acid suppression therapy. Am J Gastroenterol 2000; 95:513.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/21/40282/abstract/117\">",
"      Hirschowitz BI, Lanas A. Atypical and aggressive upper gastrointestinal ulceration associated with aspirin abuse. J Clin Gastroenterol 2002; 34:523.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/21/40282/abstract/118\">",
"      H&ouml;lscher AH, Klingele C, Bollschweiler E, et al. [Postoperative recurrent ulcer after gastric resection--results of surgical treatment]. Chirurg 1996; 67:814.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/21/40282/abstract/119\">",
"      Perrault J, Fleming CR, Dozois RR. Surreptitious use of salicylates: a cause of chronic recurrent gastroduodenal ulcers. Mayo Clin Proc 1988; 63:337.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/21/40282/abstract/120\">",
"      Fourrier-R&eacute;glat A, Lacoin L, Pariente A, et al. When patients report diseases that prescribers seem unaware of: discordance between patient and physician reporting of risk-related previous history in NSAID users from the CADEUS study. Clin Pharmacol Ther 2010; 88:668.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/21/40282/abstract/121\">",
"      Turnage RH, Sarosi G, Cryer B, et al. Evaluation and management of patients with recurrent peptic ulcer disease after acid-reducing operations: a systematic review. J Gastrointest Surg 2003; 7:606.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/21/40282/abstract/122\">",
"      Gisbert JP, Khorrami S, Carballo F, et al. Meta-analysis: Helicobacter pylori eradication therapy vs. antisecretory non-eradication therapy for the prevention of recurrent bleeding from peptic ulcer. Aliment Pharmacol Ther 2004; 19:617.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/21/40282/abstract/123\">",
"      Gisbert JP, Calvet X, Feu F, et al. Eradication of Helicobacter pylori for the prevention of peptic ulcer rebleeding. Helicobacter 2007; 12:279.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/21/40282/abstract/124\">",
"      El-Nakeeb A, Fikry A, Abd El-Hamed TM, et al. Effect of Helicobacter pylori eradication on ulcer recurrence after simple closure of perforated duodenal ulcer. Int J Surg 2009; 7:126.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/21/40282/abstract/125\">",
"      Bose AC, Kate V, Ananthakrishnan N, Parija SC. Helicobacter pylori eradication prevents recurrence after simple closure of perforated duodenal ulcer. J Gastroenterol Hepatol 2007; 22:345.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/21/40282/abstract/126\">",
"      Yetkin G, Uluda�� M, Akg&uuml;n I, et al. Late results of a simple closure technique and Helicobacter pylori eradication in duodenal ulcer perforation. Acta Chir Belg 2010; 110:537.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/21/40282/abstract/127\">",
"      Giuliani A, Galati G, Demoro M, et al. Screening of Helicobacter pylori infection after gastrectomy for cancer or peptic ulcer: results of a cohort study. Arch Surg 2010; 145:962.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/21/40282/abstract/128\">",
"      Lindsetmo RO, Eide TJ, Johnsen R, Revhaug A. Helicobacter pylori-induced damage to the gastric mucosa is not modulated by previous vagotomy or medical treatment of peptic ulcer disease: a comparative study of vagotomized patients, medically treated peptic ulcer patients and community control subjects. World J Surg 2008; 32:2267.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/21/40282/abstract/129\">",
"      Wong GL, Wong VW, Chan Y, et al. High incidence of mortality and recurrent bleeding in patients with Helicobacter pylori-negative idiopathic bleeding ulcers. Gastroenterology 2009; 137:525.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/21/40282/abstract/130\">",
"      Tanphiphat C, Tanprayoon T, Na Thalang A. Surgical treatment of perforated duodenal ulcer: a prospective trial between simple closure and definitive surgery. Br J Surg 1985; 72:370.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/21/40282/abstract/131\">",
"      Wara P, Kristensen ES, S&oslash;rensen FH, et al. The value of parietal cell vagotomy compared to simple closure in a selective approach to perforated duodenal ulcer. Operative morbidity and recurrence rate. Acta Chir Scand 1983; 149:585.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/21/40282/abstract/132\">",
"      Robles R, Parrilla P, Lujan JA, et al. Long-term follow-up of bilateral truncal vagotomy and pyloroplasty for perforated duodenal ulcer. Br J Surg 1995; 82:665.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/21/40282/abstract/133\">",
"      Jordan PH Jr, Thornby J. Perforated pyloroduodenal ulcers. Long-term results with omental patch closure and parietal cell vagotomy. Ann Surg 1995; 221:479.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/21/40282/abstract/134\">",
"      Smith BR, Wilson SE. Impact of nonresective operations for complicated peptic ulcer disease in a high-risk population. Am Surg 2010; 76:1143.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/21/40282/abstract/135\">",
"      Abe N, Takeuchi H, Yanagida O, et al. Surgical indications and procedures for bleeding peptic ulcer. Dig Endosc 2010; 22 Suppl 1:S35.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/21/40282/abstract/136\">",
"      Stabile BE. Redefining the role of surgery for perforated duodenal ulcer in the Helicobacter pylori era. Ann Surg 2000; 231:159.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/21/40282/abstract/137\">",
"      Hirschowitz BI, Fineberg N, Wilcox CM, et al. Costs and risks in the management of patients with gastric acid hypersecretion. J Clin Gastroenterol 2010; 44:28.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/21/40282/abstract/138\">",
"      Jensen RT. Should the 1996 citation for Zollinger-Ellison syndrome read: \"Acid-reducing surgery in, aggressive resection out\"? Am J Gastroenterol 1996; 91:1067.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/21/40282/abstract/139\">",
"      McArthur KE, Richardson CT, Barnett CC, et al. Laparotomy and proximal gastric vagotomy in Zollinger-Ellison syndrome: results of a 16-year prospective study. Am J Gastroenterol 1996; 91:1104.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 24 Version 10.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1005-213.131.41.98-64F77B4D5B-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f39_21_40282=[""].join("\n");
var outline_f39_21_40282=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H11767021\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H62849741\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H73185785\">",
"      INCIDENCE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H56805017\">",
"      ETIOLOGY AND RISK FACTORS FOR COMPLICATED PUD",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H56805158\">",
"      NSAIDs",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H56805165\">",
"      H. pylori infection",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H56806405\">",
"      NSAID use in patients with H. pylori",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H56805613\">",
"      Non-H. pylori, non-NSAID ulcers",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H56805506\">",
"      Ulcer characteristics",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H56805513\">",
"      Pregnancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H73184944\">",
"      PREDICTORS OF POOR OUTCOMES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18360489\">",
"      Comorbid disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18360751\">",
"      Advanced age",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18360758\">",
"      The magnitude of the physiological insult",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18360773\">",
"      Complication-specific risk factors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4460443\">",
"      PRECEDING SYMPTOMS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4460472\">",
"      GENERAL APPROACH TO PATIENTS WITH COMPLICATED ULCERS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4460481\">",
"      Coordination of care",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4460489\">",
"      Acid suppressive therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H193856680\">",
"      Treatment of H. pylori",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4460572\">",
"      Discontinue NSAIDs",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H193858137\">",
"      Urgent or emergent surgery",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4460451\">",
"      BLEEDING",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4460621\">",
"      PERFORATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H66923600\">",
"      Clinical manifestations",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H66923362\">",
"      Diagnosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H66923472\">",
"      Management",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H66923940\">",
"      - Intravenous PPI",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H66923520\">",
"      - Antibiotics",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H73184426\">",
"      - Operative versus nonoperative management",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H4460658\">",
"      - Surgical approach",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4460706\">",
"      PENETRATION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4460714\">",
"      GASTRIC OUTLET OBSTRUCTION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4460722\">",
"      Epidemiology and pathogenesis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4460730\">",
"      Clinical manifestations",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4460738\">",
"      Diagnosis and differential diagnosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4460746\">",
"      Management",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H4460754\">",
"      - Identifying and treating underlying causes",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H4460762\">",
"      - Antisecretory agents",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H4460770\">",
"      - Endoscopic balloon dilation",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11767029\">",
"      - Surgery",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H56806712\">",
"      FOLLOW-UP",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H193857306\">",
"      PREVENTION OF RECURRENCE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H56805934\">",
"      Stop NSAIDs",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H56805976\">",
"      Treat H. pylori",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18363529\">",
"      Non-H. pylori, non-NSAID ulcers",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H73186734\">",
"      Maintenance acid suppressive therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H193856781\">",
"      Definitive ulcer surgery",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11767021\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"GAST/24\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"GAST/24|DiagnosticImage\">",
"      <a href=\"#\" title=\"DIAGNOSTIC IMAGES\">",
"       DIAGNOSTIC IMAGES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"mobipreview.htm?17/53/18259\" title=\"diagnostic image 1\">",
"      CT with free air from perforated ulcer",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"mobipreview.htm?8/59/9143\" title=\"diagnostic image 2\">",
"      CT with extraluminal contrast from perforated ulcer",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"mobipreview.htm?16/59/17331\" title=\"diagnostic image 3\">",
"      Perforated duodenal ulcer on computed tomography",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"mobipreview.htm?9/34/9762\" title=\"diagnostic image 4\">",
"      Penetrating duodenal ulcer on fluoroscopy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"GAST/24|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?34/57/35740\" title=\"table 1\">",
"      General management of patients with complicated PUD",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?26/29/27099\" title=\"table 2\">",
"      Saline load test",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?11/34/11820\" title=\"table 3\">",
"      Work-up for apparently H pylori-negative NSAID-negative ulcers",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   CALCULATORS",
"  </h1>",
"  <div id=\"relatedCalculators\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"calc calc_professional\" href=\"mobipreview.htm?3/8/3205?source=related_link\" title=\"calculator 1\">",
"      Calculator: APACHE II scoring system",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?24/2/24616?source=related_link\">",
"      Angiographic control of nonvariceal gastrointestinal bleeding in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?27/55/28538?source=related_link\">",
"      Approach to acute upper gastrointestinal bleeding in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?14/10/14504?source=related_link\">",
"      Clinical manifestations and diagnosis of Zollinger-Ellison syndrome (gastrinoma)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?13/18/13609?source=related_link\">",
"      Clinical manifestations of peptic ulcer disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?24/21/24919?source=related_link\">",
"      Diagnosis of peptic ulcer disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?18/42/19113?source=related_link\">",
"      Epidemiology and etiology of peptic ulcer disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?29/53/30553?source=related_link\">",
"      Extended-spectrum beta-lactamases",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?43/47/44793?source=related_link\">",
"      Gastric outlet obstruction in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?36/59/37817?source=related_link\">",
"      Indications and diagnostic tests for Helicobacter pylori infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?6/51/6968?source=related_link\">",
"      Management and prognosis of the Zollinger-Ellison syndrome (gastrinoma)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?38/24/39305?source=related_link\">",
"      Management of benign esophageal strictures",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?6/37/6745?source=related_link\">",
"      NSAIDs (including aspirin): Pathogenesis of gastroduodenal toxicity",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?11/58/12197?source=related_link\">",
"      NSAIDs (including aspirin): Secondary prevention of gastroduodenal toxicity",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?13/32/13831?source=related_link\">",
"      Nutrition support in critically ill patients: An overview",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?24/28/25034?source=related_link\">",
"      Overview and comparison of the proton pump inhibitors for the treatment of acid-related disorders",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?41/18/42281?source=related_link\">",
"      Overview of the natural history and treatment of peptic ulcer disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?24/15/24826?source=related_link\">",
"      Overview of the treatment of bleeding peptic ulcers",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?37/4/37960?source=related_link\">",
"      Pathogenic Escherichia coli",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?3/36/3658?source=related_link\">",
"      Peptic ulcer disease: Genetic, environmental, and psychological risk factors and pathogenesis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?12/47/13049?source=related_link\">",
"      Pharmacology of antiulcer medications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?15/61/16345?source=related_link\">",
"      Refractory or recurrent peptic ulcer disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?32/57/33688?source=related_link\">",
"      Role of surgery in the management of peptic ulcer disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?39/5/40025?source=related_link\">",
"      Surgical management of complications of peptic ulcer disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?22/32/23049?source=related_link\">",
"      Treatment regimens for Helicobacter pylori",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?19/0/19466?source=related_link\">",
"      Unusual causes of peptic ulcer disease",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f39_21_40283="Decision aids";
var content_f39_21_40283=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PC%2F75850&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PC%2F75850&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Decision aids for prostate cancer screening",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tr>",
"      <td class=\"subtitle1\">",
"       Resource",
"      </td>",
"      <td class=\"subtitle1\">",
"       Website",
"      </td>",
"      <td class=\"subtitle1\">",
"       Available from",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       \"Should I be tested for prostate cancer?\"",
"      </td>",
"      <td>",
"       www.cancer.org/prostatemd",
"      </td>",
"      <td>",
"       American Cancer Society",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       \"Prostate cancer screening: A decision guide\"",
"      </td>",
"      <td>",
"       www.cdc.gov/cancer/prostate/pdf/prosguide.pdf",
"      </td>",
"      <td>",
"       Centers for Disease Control and Prevention",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       \"Prostate cancer screening: A decision guide for African Americans\"",
"      </td>",
"      <td>",
"       www.ustoo.org/PDFs/CDC_PCa_Screen_Guide_AA.pdf",
"      </td>",
"      <td>",
"       Centers for Disease Control and Prevention",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       \"La Deteccion del Cancer de Prostata: Una guia para Hispanos en los Estados Unidos\"",
"      </td>",
"      <td>",
"       www.cdc.gov/cancer/prostate/pdf/prostate_cancer_spanish.pdf",
"      </td>",
"      <td>",
"       Centers for Disease Control and Prevention",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       \"Is a PSA test right for you?\"",
"      </td>",
"      <td>",
"       www.healthdialog.com",
"      </td>",
"      <td>",
"       Foundation for Informed Medical Decision Making",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       \"Prostate cancer screening: Should you get a PSA test?\"",
"      </td>",
"      <td>",
"       www.mayoclinic.com/health/prostate-cancer/HQ01273",
"      </td>",
"      <td>",
"       the Mayo Clinic",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       \"PROSDEX: A PSA decision aid\"",
"      </td>",
"      <td>",
"       www.prosdex.com",
"      </td>",
"      <td>",
"       University of Cardiff, UK",
"      </td>",
"     </tr>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Source: Wolf, AMD, Wender, RC, Etzioni, RB, et al. American Cancer Society Guidelines for the Early Detection of Prostate Cancer. Update 2010. CA Cancer J Clin 2010; 60:70.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f39_21_40283=[""].join("\n");
var outline_f39_21_40283=null;
var title_f39_21_40284="High potassium foods";
var content_f39_21_40284=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEPH%2F53492&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEPH%2F53492&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    High potassium content foods",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\" class=\"container\">",
"     <tbody>",
"      <tr>",
"       <td class=\"container\">",
"        <table cellspacing=\"0\">",
"         <tbody>",
"          <tr>",
"           <td class=\"subtitle1_single\">",
"            Highest content (&gt;25 meq/100 g)",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Dried figs",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Molasses",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Seaweed",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"subtitle1_single\">",
"            Very high content (&gt;12.5 meq/100 g)",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Dried fruits (dates, prunes)",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Nuts",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Avocados",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Bran cereals",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Wheat germ",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Lima beans",
"           </td>",
"          </tr>",
"         </tbody>",
"        </table>",
"       </td>",
"       <td class=\"container\">",
"        <table cellspacing=\"0\">",
"         <tbody>",
"          <tr>",
"           <td class=\"subtitle1_single\">",
"            High content (&gt;6.2 meq/100 g)",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"subtitle2_single\">",
"            Vegetables",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Spinach",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Tomatoes",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Broccoli",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Winter squash",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Beets",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Carrots",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Cauliflower",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Potatoes",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"subtitle2_single\">",
"            Fruits",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Bananas",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Cantaloupe",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Kiwis",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Oranges",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Mangos",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"subtitle2_single\">",
"            Meats",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Ground beef",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Steak",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Pork",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Veal",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Lamb",
"           </td>",
"          </tr>",
"         </tbody>",
"        </table>",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Adapted from: Gennari FJ. Hypokalemia. N Engl J Med 1998; 339:451.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f39_21_40284=[""].join("\n");
var outline_f39_21_40284=null;
var title_f39_21_40285="Urinary collections and stones";
var content_f39_21_40285=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEPH%2F72059&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEPH%2F72059&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Increased likelihood of detecting kidney stone risk factors with multiple 24-hour urine collections",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 440px; height: 263px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Among calcium renal stones formers, the number of urinary risk factor abnormalities that are identified increases with the number of 24-hour urine collections and with collections obtained at later time points after the occurence of a stone. In this study of 75 recurrent idiopathic calcium renal stone formers, the relative diagnostic utility of one, two, and three urine collections, as well as variations in timing of collections after a clinically evident stone event was evaluated. U1, U2, and U3 were obtained at a mean period of 105, 116, and 163 days after the stone event, respectively. The largest number of abnormalities were observed with the performance of three urinary collections (U1+2+3).",
"    <div class=\"footnotes\">",
"     ++ P: 0.011 versus U1; &ordm;&ordm; P: 0.011 versus U1+2; &ordm;&ordm;&ordm; P: 0.0001 vs any single urine; *** P: 0.0001 versus any combination of two urines and versus any single urine.",
"    </div>",
"    <div class=\"reference\">",
"     Data from Hess, B, Hasler-Strum U, Ackermann, D, Jaeger, P. Nephrol Dial Transplant 1997; 12:1362.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f39_21_40285=[""].join("\n");
var outline_f39_21_40285=null;
var title_f39_21_40286="Construction of a double barrel loop colostomy - maturing";
var content_f39_21_40286=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=SURG%2F70912&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=SURG%2F70912&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Construction of a double barrel loop colostomy - anchoring and maturing",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 358px; height: 236px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    This figure depicts the loop colostomy anchored to the abdominal wall.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f39_21_40286=[""].join("\n");
var outline_f39_21_40286=null;
var title_f39_21_40287="Ureteral course";
var content_f39_21_40287=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F51215&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F51215&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Ureteral course: laparoscopic view",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 360px; height: 240px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCADwAWgDASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwDxb4OS+XrlwD0MX9a9kSQ/wMo9R2NeIfCo7dblP/TOvW4pgo4JoNIrQ2RIG4k4+vSmS24J/d8NVeKQN8rn86nQkcI3y/yqdCyvJEwyGX5RVaSDJyOorYhILAzIrgcHB61FJCrMSh71NgMKS1NVXgZG3DKv2IrfkiP8Sn8qrS2+e1UropMNK167sDtlY+X3YDmvQ/CfiSRZYbq2dLp04KEkHFeZyW3FFsbiymE1lKYpQf4TWit1NlWdrPVHvOqeI21C4jkggCxKpGGPJz61galqDhAehQ5FcDZeJLmNyLnqf4h0NXptZWVNz9ccHsazlHU7qE4KFoG6bhr+7CO3ydytQzaSLM+YIA6ZzuxVjRUjawRnx5rnJrYhcgESBZIu4pWsKVS78jMsGtmQKyJ/vAdK0D+5XB+ePqGxVS/0ng3OnnC+npVK2vnQeVOvfHNZuzNYQT1R0MjFkBB+QcA1m3luTIpB5Bpn2uSOIiOPcM8Y5qP7a3nHMJQEgCpsaKm1sF55UbO8m0kL8vsaw9Tsv9E+2x9jk+9aOoWtxI5uHX92OOtWLRojaGGT7nvRbQU4pI4uFlJfB+UdOc1XmAM+eq96s65bJpt+TEPkcZH0qirEZPHzc5rnfkYNcoyVMAn8iaqElJWGSSO1TSSZA9ulUGbMxJwc0KDIbJpc7c+3aqDvhj/nNT3D/K9UiecL361tHYzJkYomXPXqaN5MnuRxxTFOTljk9qa3fismrj0H7+CSP6UgJZv6Y6VADjnbyO1KmeSe/U4quUCZ5Ng68VVdyZD606Y5z6+lMXgf/WrRRsSxvJ47DrTPmMo7r7Gm7sL6Meh9KP4P4f8AgNMXKNLEucfKO5qORyU28cHmkPLfIvy+1RPtKlVP14rQzaCQkLjPGKzZiWfjirxRdrlz8o7ZqpcLnPAVe9UYtFdznPNRPndVl07VAUJHy0AZ95D8u9Bz3FUsn1rZK49fxrNuYPLk4+6aaZjOJX59qbzUlNqzMz9SzhKKXU+iUUgOl+GKM2rTbVziOvT0YrjPHavPvg8ca1cEf88v61628NtMcFfn9u1c863JKx6VDDc8LozY5SDirUU2O54om07BPlsSM96rGN4jtdCpFWqqZM6EoGhFOUPX8Knjmy+4HD1lox6CpVYHleau5hymv9oZvvYpHKlslQfwqikxBHPNTLIvUHmiwrD38kqd8XNQXEcO3MIOT2NTZQ/Kwz6GmlPTlfajQWxAmzOHGVra0uys7tDEZFTPYnpWO6jnK8VH8yfcJH07VQ+ZrY23uLnRLwxSv5lv/DJ7VvabrUbsCWHzdq4eS5kki2TMWTpzVWKeS1fdAfkz9ylbudNOr3PXIpoyuYT16iqWoW0EkgTav7zn5a47S9f5EZco/v1roLHVIZ72MTPhypA4qXA66c+qD7Pc2crFGMkXYGpRM0qjeAhrpLa0FzbcqD71Bd6KqgnBwe4rNo2hXi9zOW5b+z54X2mSQYXPaobe2V1iiUF88gCrL6c4H3M4qzaFYI0KKROucDFLcttW0OY8Q6etxbSKw2yx9B/SuEEzCR4pAVMfavUrqJ9xLjljnJFcZ4s0R4j9vgj9nx296zcUmTOPMvM5xhnJJPPtVXcASVz9ccU8nKHuvcU0p8mKtI4npuV5mPB7Z4qNFwP606TAY56jtinLCzAYHWnZEEblUBLelRKxPOMH+dW2t2IHdyeKd5Cj5SP8azdkWinu78ijdxjjNTyRAe341BsO44XPehWKswnZWZSowQOvrVV2IJz/ACp2WfhF5FHlHr6+lWKxF15P86Gfr/CKGjbk4/8Ar0bM8n7vpRoRYidixIwue+aZ5eOSVP8AKnuigY/u9aQnHJFMRA/DZY/Sq83XHI7datOvBqs6EA/pWiZlJET7APvVHGhldVH3j+lOuGTChVwR1Pc1CGI4BI+lMy0Fmj8tnXrg4JFVp4kkiIzyelWHUpjpUL/e/u0AzIZdpIPUVHV29j6SKOvB+tVDWlzna1M/U+iUUan0SikI7b4MrnWrr/rl/WvYHjAwVxz19xXkPwZiaXWLnYcYiz+tewGK4j/1ifIPxz+NeZibuofRYGK9ihyn5cFcipU8qQiKeMOvYmqisVJ6Dv8Ae/xpfM3Jh1ZV9hmppvubTpMkudIjKF4SoHoTWWbd0J2c4rchnZIx1b+4SvWs7UkZJknwTIMZwMV0qTRyOgpblDcR1OPbFSiQ9+tbl7psJ0q11BJYmSZwjxg/NF6E+xrOudMmi5i+ZDyMVrGp3OeWHfQgRyc7RUisPpVM7kOCMYPQ05XrS5zuDW5dU5Hz4zSNGCPlqsJD1HP8qlR880zO1hrx5+XvUJiJ9zVxenPNRunXvmgky5Ij/d/HNTW97LbSqTkqOM1M6buq/pVZ48Mfl+WmjRTa2O98MeLIxsjkbNeiabfW99EBuHPavncxyRtujJRh0I7Vv6F4quNPkRLgnyx/EP603FMpu+x7TJAIZCUClPSlhsLeZgwAD55NYeieJbTUIk+dST0IrfX5lV4GGa55qxtTqvYZeaQzAjywQM7axrnSdkRW7XMbg7s111jdqRsm4f3q7LZQ3KHeoZT2rJm8cTy7nzb4q8Pvpt2ZoYmFtJyp9q59zuyqdf519Ka/4diurZleJWQc4IrxHXPD0mn3UreWdgPPFEJ20Y6nLV95GDaWSkAuMmpViXDqOxxUrTRhMRjJ9Kqb3Q7iOvPNXZnOSxRbpXOPlAwP6mlli5HGfb0p1m+VRWwEJ5bqRSySgSumSoz1qLFlKWIk4HJzzVaSNuFAx64FbD7BCSi8LUUMEbHdJ1Pf0q0g5jIhi4+7kk4HFWlgH3Fj5rUhXS9k8jrIXAwuB1PrTLu8hW2EdtAkCH7xHLn8adhXuYl1bHgLHy3TI7etUDBz8ozk9c1oXMxlnkbbhMYqKZhsGSAANv0oKM5lA+7kD1qMryc8+9Wpz8mU5PbHeqpTIySdpoE0QksrHbkVBIrkn5RmrLgBSPTg8VFnsTiqVzMpOhzyvPvUUw2HH51cuMDPX/Cqbrnhc4rQxaINx29qT7x+7n1qRYQF+fn2odcdFX2xTuLkG3kstzGq3Dlyo2xjPCD0FZBBBIYcrWsU696oX0eJdy9H/nTTMaqMbVeiUUap0SimZHo3wDUnXLzAB/c/1r20wHB+ZYxjPPpXifwEhSfXbpXJH7nscd69x+wRK3Tec8liSf1rx8XU5aup9LgF+5RUjso5LcN5fme+etVpdOQZEIaL6NxXQpgYGEx24pJIQwzjp2rHnOhtnPrBOseNwf03Dn8xTrlDLasGh2SjhvTPrWw9sgUHy8H2NIUclxtLQsuJAePpXTTqXRlKJz9gWigks52baeSg4yK11jQx55I9RVK9szExaNeQRgk8/jVqBDLAk9q2x+hXPP0rVVO4ciYTWMM0ZMkYk9T0NYV7pSxtmAr5Z6Bu9b6rclcPLz7rkU0QQgAzRebL6knH61pcl4e++pyLxSxEiSMg00OoJBrob1pAH2WybOcZrLaMyuqzWuD6CrVYwqYF2uiurjJwdv1p6vnvRNp7DJhOSO1Vn3xHbICPrWykmcNTDyhuTFhk5xUZUdeM1HvHrzSq9MxsJJH7f/qqB48g1bUgmo3T070Ela2uJ9PlWW0kMbA9OxrvPC3jdS6Q37eRL03HoTXDFOKrvDk/d4puz3C59A2+pRXUaurLnsQa09P1R4n2yce9fPmi6/faTIgDGW3HHlnt9DXpGg+K7PUYwgkUSd4z1rCVK2qNVPoz1iC7jmj+tYHiPQbe/ikcKCxFUrPUDDgocoa3LGYXjKkbAFq5plxfJqjwfxPoc2lTyMIz5WevpXPOUP0Ne8+KNLV2khni3Aj06ivMrrwdPLqEq209vb24GfMmOAPb3pU530Zs2pK5yMUmeCeO9TDDDqu3FbMngq/ZR5E9rKSeMEgmqN14d1ew3efaMcZ5iw4/Stk4k2b2M6TMeDnJ+tRzXGxDxz6U6RHi+/GQfQiql1gkkkYHWteZByvsTxbY4gGbPfHvVeV9pJbkdetVPMKfK5JNIWLY35wT0rN3ZSViVOIsnqeSKhdkIJJFOkfIx7d6qSHPTHFJBcSYDY5BwuKhcOPunNLskkBUR5NEkLRrztzjoK0sTcqSOQNuBmq+SCf6VbeNmJ+WhISxGB+NNCsysoLf4Ux4Cu3dhfQVq+UIAM8vVeRc5ZzkmruLkM7YB0pCgz0/+tU8nB+bp3qKQY69qQmrFaRfWmXNqXs5GOMjkCrqR5O+QHb6CtaGL7GyyTqhnIwkWOAKpHPN3PM9T+6lFWvEtpJYajLbTxtG8bdD+lFWctj0D9n4I+u3gdc/uc/rXu+14+vzg/nXhn7O8e/X732h/rXvskLA44IPb7teLjV759Ll/wDBSIYt3XamD0wasBsnYcj61EqmN8Ipwe2KkX5idy49VNcsTscByxoV5+9S+WfKO3ByMUqx7PvfgakRWx/jXRF2MnAzbq0LRAsy5I4Y9/Y1n2m6yuyHjIjf5SK332rkFV9hVHUYsL7d/Wt4PqZ+RpRR288aHcqE+nekvIjGJHQiTHAj6Z981zum3lxBeC25PePcBn6V0cNzDL8rldvcsMAH0xW260NIqxl3cE8saFI41GRjy8k/r1pYtEcAvOpOD97vmuiiKxRZRM+X8ox/SmPOBEHugwXqT1Apcprzt7I5C+s1hJ3xlR2+TI/OsGKP7Q8kcmSnY46V3N6XubmPyo08sDKg8Vh2FoZ97x7N+Spx9aFe4TiuXU5O9sxDKQknNUnVoz86Gus8T6c8ThwF2EfrWGVDQIXHzdM1upnnVcMmroobwfr/ADpRIO4+npTpLdDn+A/Tj8aryRSxcnJQ9COQa2UkzgqUHAscEVG6jBPy/UVXWT3+WpFmB5707HPyjHXknmofmikV4WKOOhBwRVpsHp+lQuv935T2p3sB0/h7xtPZvHBqmZIv+eo6j616Ro+sxSPDdWcqsucgqa8LcDntzmrGnX93pk3mWUhQd1zwazlTUtirn0VqOprcSRi/bMR4EqrwM1zevwJbthyCnUN/KsLwt4zs9UsxpurP9nkzmM+9buyNtsFwnnWZ+7IvVPeuOdNxZvCS2Of+3Pbl1OHPZvWtbw9rDQuVjAJZSCWAOKg13QVt7bdbOJAfuyx9DXMQ3N3a3ISSNnTPOBiknfRluOl0dvFotndh3kjRnY5LEVnat4UtEjMkVshI/CtPRb1GjHINdAlyoiISONiR/GM01FLYISdzyC80izQnbbjJP8NZtzpUGf8AUrtPpXoWt2nmXMkxVckdR/hXOXKfvdmz5yM5NaRO9K+xxr6JGc7MgdvSqL6WyNtRgp75Ga7OSNgMZODziqM8Qj7c46elaGTicv8A2dNyEbAxUZ08AkEFieD71uSDZ90Dn8aY6xoM7V5HBNMmxjm2A4POO1PW3jXk/dq28akZHB7bRUU7BP8AWHao657Uh8hSmjVFJ6AelZdww5+6MetaF3OnlHygQT3NZTpkHJJ+vSmZyViu2TyM4oSFWGXz7ADrViGEsFOCewAHX2rZgtVsFV5Bm9cfKn/PMVaOWo+iK0Nt9jCM6r9pPMcZH3frWjYWn2f/AEy8Ie57DPSp7S1SHNxcKXnbkCkuSXJZ2woouSoHnXxQQvrEd0es8YJ+o4oqX4kSCVLMLjCZUUVUdjlnudT+zaM+Ib//AK4D+dfQ00WRnrXz3+zV/wAjDff9cR/Ovos9z/I15mM+M+gy/wDgoqrEM4200xY5UZIqyQp/hpxT8q4VGx33K2xSPTtTRmMmpnXGaZs/yK1jczIypJ7U8xIRyvFKVA570gOeMn6ZreBlM5/WImikjuIj+9hYOM+1bWq2wlMdzarkyqHIA4INZ+qxdf8AaGMHvWnp7KdGtA77GEWASeuO1dSWgoaO5WsvLmgKQmUuCQNzYP0xTmguSoAm4H8DYxUU6fY54JocbJDygPStJFQ/u1bGRkEnrSOjnsYt6t2LeeOE8kYGBzio7Ga3treJMNHMTmTmtCVmN/8AZlOEI5Yd/wAafPaRMghXyx059KuCCpUVrMzfEBU2injrnNc1FFGY5IiOASR6it3xNE8FuI/NL7eSwGM1jW3zRAqpJPccU1uY200K7WnyEbRn19ay5rV4Jd2cjuMda63TiqWZDxr5hGAWHCfWrTmG9jCyW8EqD5DKoCgH0960t2OaU+jOEubOAxhw6xE9QfWqE1vLbHLqdnZh3rvL3SrSMJ5kkCDsQc4/SqD26xxny7mCbPSNh29MUJtHPUpxnsccsn0/xp2/JPrWtf6dBvffEbN8de35Vk3Nlc2sfm7fMtz0kHSrUjlnRaGttO3+lR8d9v41F5nXp+dO3Z+6cmqMrClecqSDnj2ro/DPiq80yZFkkzGOMnmuaJ/4CPSnKQ/rQ7PcR7RpetxajDJ5eyN2GfKQZ8z6VpW9ra3se5kCyAdMV4np2oT2coMUhAHYV3nhnxKd0csjGTBxKn8X1rmnS7GnM0dY+m+USYwUIqZbxoozFIMH7oNacM0OoWiT2jrJGRyR2PpVC9iQqUYc1le25pTnc526nlEpWRmHPI61UmWJ1OdqH3qbU5/s1yscqkf3WH9aik2zxZBXPqKuJ6UGrGRdQspIhPOehrPuUXI8xtp6ba2XgkjXJVeeQKoXUZlXCBcHue/rWhT1M0xqOXAPoKoysdxyrM56DHWtCXGT3x+tRFVaToFoM7WKtvbsfmdeetVNQibJIRXPvW31TCcr396o6koWMkH5uOcUEcxydyzHPJxngYpLa1acgYzGO/rWi1u1xISq/IDyTU8UYiPlQ5kk9fSmjmrVL7DF/c7Ni5mAwMdFqxbWvltuk5lPPNTRW6w87cyn17U2aVY1OCM1VznSsNckB2lZMdh3rJvblcf7PYYzU08zFjkgyfSqD7YlLO3Oaq1x6nH+NiTHCXXB3c0VH41YkRZ656UVSOOW53n7NS58Q3//AFwH86+iV4yCv4188/syDPiLUB/0wH86+imQeleVi/4h9HgP4KIwuM4o6CgoeccU057j61yWOwV1BGajPNLnPXC0/YprVK5myDAz/wDWpjbAD0J9KldMZqneSlFwQPxrZIyepR1DLfIhye1bWlWePDkOR8w3EcZrEtkZ23t0J4BrurOCNPDybSfMVwuDjkd+K6YR93UmU+Ro5tLFpbNxhSEGeTjFSQwmayMWP3sY3g55FSJOfMazUIRJ8rMV+Zcc4B7U+0L2tx5KwyMT0I7iqUTR3WrM2aKSxZZp1Xy2ONy9qW4m8uInaOPbpW74gszbRmCV98bxh/mXG3J6EVy832jy/LcIif8ALPJ6iq8jNSVVcyMnWJmktyjtktzj0pbfTjFY20qn5y2DnuKiv3JlMckf71O68jH1rqfD0QlsgtxFIUHI9/erS0uE3yo5jUDNa2Eq+XgxdfQ5rHVpHIuHZTIOiY4HtW/4xa1S8SGDYh275ueh7Vg28W4x+Vgo/wCNSmRNpI1ypntUdvl4zn0qu9vAi5kCDP8AFjmtCI+RaHzYySvUGrn9mQzrvxnIBGSeKd9TlcmcuvlMxME2D7jH86mifykw8ROR/B8tdEvh+JlLGEfoaig0exPmeVIsci9VI6VaVzKUjib/AEqzuyWgja3uD1KjIrAv9OurBv38ZMf/AD0XkV6wbOMIyrIee471m3GklELNIpBGArDOfzoSa2M+ZPc8uLD2pyt06V1GpeHo5S7RRtDJ6qPkP4Vzt5p13aKXlgk8of8ALUdBVKSM3TtsMjZSVGfoKs2zTQfvITgg8Vmls9f/ANdTRXLR7dvIHpTITO48O+J59Nn88qTET++iHT6getelo8WpW0Vxaur28q5DLXhdteROMS4Qn3rvPhbqbNqj6JJIiW5jeeAsfusOvNY1afOik7M6i/0lrmOSKQEcZEnvXL3Frc6dJtkz5Y6kdMeor1+G1g1C1LwgC5QfOvr7isTU9MS4gdZFXeBXNFOJ3Uqp5+Jdw+/lDUNzGZVIQ4+lSahZvpV0YPmMXVD7VCrCPnJ2jmtlqdO2pl3MBjBDk7epxVdRvQ5Crj5Rg1r6gkbRHoo9aypYjCgZ12EjOCevvVbA2mhkz+TH84/MVmbDdu2eIh1x3/wqeRfPYvIfLtk6n1qpPObr91GAlsOMf36rc46tS2iEmYynZbD90vGe1SQiOGPgY9zSLthBVcA+npTEjdiXf8CfSi6Oew53OCxGB296pOxkJVE2k/jWh5IJyoOAPvEVRuZxFkR/LnvQtS7FW42Q5OAXPesa6fLHJU4q3eOf4x1/hrPkUyHkYHp61pqJnK+LG3LHjpmipPF64SL60VRxzWp6H+zF/wAjFqH/AFwH86+jHr5z/Zj/AORk1D/rh/Wvo5sntXlYqN6h9BgP4KIP4TkUnA61K8a7c96hU4+U9aw5DrbAop4/lTShjOU59qk3D1qOT25+laQjYzbI3lUff+WsjUpRIcLt5OMg1pT/AOrf2rCuWBvYAR3zWxEErmjpxUSop4xwPSuwtph5DD+4Mg1x0KfvTyXPXg4rotMMrRkJE0qjqc81tDYdRFRYvKaeUjMhkG2tu2gSN/tFyk0cy4MXl4OD6kZrIuGSLUYjKGTGCQRyPqK6B7pHWLy8AsMH1Naw93Uyr3loU9bg1G905tTupLeJVXbsRCWZN3SuXjQSXP76Nip4Getbt9cE3ZiI+U87yOh9KzYSDdOZP9UD8zDsfpSl7zFTjyQs/wDIw9StY47xY4029zx1rorm6XTNCjNpF5tzKRFbxdSzVlanZEXxmDLJE44KnpVu0uNmtxTxHbHY25SI4B+Y9T/n+7QloZ1XszEtvB6W87XOukySNlzbmXnPqSKfb6YJY0nezltogf3aQSeWQM8Hnmul1CKKfT0PmSrJ5hkkyBjPtWFf3xtbd0kflvuo2TvFZa3sRKbmrsxPiVqraH4Yu7tU+2fZmRImkxullYgKML25z9BWLf6R498P6BLrcniC3ubq1jNxPpbWiiFkAyyK4+YkAduvr67Pi7TD4z8AXdlpMy/b1Kz24YABnRgQvPqARzxmqeueNtY17wzcaHZ+D9cj8R3cLW0izW+y2gLDaz+aTgrg5Gev89YwaVzhnO7sxt14ovBrfgvU4pXj8O69D5LQlV/dXDDKfNjOSTtxnHBOPWTV7/Ubn4q2ujaZMVtrWzNzfgKnzljhEyRweh46g/lJ4p8Jzp8I4NEtA8t/pcMUttKgyTcR/Mdo9/mA+tZXwyhvZDrviDXbeW01TVbvPlTRlXjiQYRcHkdSPoBTUrK6D3r2ZQ1WbxNcyXdxq3iGz8N2sMjC3t0SGUlB0d2JySfT+VY9v431W/8Ahtrd5LcRPq1hMYUu4lUK65T5gmNvOT2xWZocenWLXsXifwlqGseJGndjP5e+GUE/KQSdqr+GB+gZpuk6tD4D8YWEukXEd3PcCRIooSQwLKcR4HzAY7dK0v3M2+3mdJf2fiq28KXOtrrgmvGtFu1s47VNsAyGIyQSfkyPrWp4v19Y/h7Zatog23uqGGG1UKCBI/JBB4JADD6iuw02Nf7Es4ZlZALdFdCuz+EAg4rwNL+Pw34sTTdVZ59L8PXEz2kYbO8yEFPyB3ex/WV7wSfLseh6p4cZNPBt4g18qjzXDACRgOTtHyrnrxXMGGSFj58RB785/UVsaV4lt/EyStbDywv+si6VS8UXUWj6ebmZTsZtoQdXNFNNbmknFq5Qc7zwvXsK3PB94+n+I7K4QtIFJ8yJT/rE7iua8Ka5pOsXT21/aXEJIyGgkAbH48V6DLJ4W0/7J/wj6XiSzRFLw3YyQexDf71adDFWeqPZdJ1JDsmsZMK4BGD29K2zLaat8kY8ucHHlSAjn2PevIfBevR219JY3DI0bcwsDt4r0FJFYLKrkFSGDKeQay5VsapnNfEfFn5NqFV71nyq4Kgp3wa49zzt52nqK9N1qNdWZLi72S3ES4RkGw1wWv2KxmW4hY+6d6nksd9KqnFJmYXheJ45Bg46k1lXLt5Rmum22w4TjlqfcbY1S4vlJLf6m1HBkPqfQVm3E7NOZ7o+ZP0CgfJGPQCnYirVtoiOZZLkkylY4h0j/wAaiLeWhCkKOmadnc5D/f8A7uelOSNRz1PrQcw2GJic/wAPXFWYolj+Z14HvRuEUWfuAc5xyarXE5k/uomOCOKCkhl5csxODgDoKyJJGDYT5nx1zVgq052qCo/vVFb2xQyBVz7+tUi7FJYWJJfk9vameRyoO33ya1/sw+UFcA96geLg8dTxV8wrHDeNY9kUX1oqbx59yH60Uzz6nxHa/szBv+Eiv9i5Pkf1r6Kfzxn5BXz3+y4ufEmo/LnEA/nX0odg615+I/iHvYF/uUZhmZPvg9O9V5nVs9BWnc4CHgHPpUSW4wC65/2TWaSOtsy/OIyFIzQt515/Krs9pAPvxriqNxbRRodhx+NaKxDaInu13nkdKx/OibW4EfJXk4XHpWhc2vybkfNeb/FDW28MWEk9lcLDqE67IQY885Xd2xwpJ5qlFOVkQ5xppzeyPT7dGGVyhJ6Ecc1vaTfTWdt5LrGRnPTrXleg+MNPnttNaO8WQXrmCBvJcGR1A3DkcYz1OBXWTeJNPsZLKHULkwyXcvkW3yM+5/TgcfU4FbRuipuEle90dlb2Qvjfxx2UN1dTDOJ3wI+MZ6HNRiwe2twweRpEXBz1JFeS2XjiDw78TfGEms6vPHZQizFpAXd8M0QJEcYzyTycD616X4Z8b6X4utZrnR7tX+fDkAhlPo6nlf644rSUVujjhUfO0vu9NCD7X5zk55xyTVWa/EKoYwqn1Pc1yXiLx/4c0bVp7W61ENPE22ZYYmlVD6MVGAfbrVlb6LVYbe7tJY5LaQAxPG4K4zWSujrThL4XqjtdH0dry5VmDSliHKA8fWti78P6TbO5jkaEnG6SMlgT16dqxrK+/wBGSOBcyIMYzyaZq811aabJNL5NvIvQD5jk9KbOGalKW4a3NbWdq/n3yBDgFchSR6D/APVXD6tdz63rHm2sCgxriMHgVUnRzqXmzsssrDiRu3sKtyNcRRRGL93kfMx4H51LSWprTh0M7Qb250DU2gulMEe7Eig7sP8Ah2+legadr8c03+vAf1xXnOq3Eflz3UzLiNSSwHUCuK8P/EuFNaSKS1f7M7bA5PNbRvJanFVcYT1PouW1tJIpbme7ZFxkRhiMn1PauL164a4dFgJitE6kDHmGpLSVb4KY1YwntjgUanJBa28mcbxwqZBOaxa10NFIp2dmZlBK7UB78VpXls6WxW3dI5MfJjrWPNrdubBCdwuouAgHJ+pqgdZvLl3iRhZxkAhv43H1q7Nmeu5Jq9vdQ6K8a6jJHqEo2xEYO1vXb3Fea678P5TprTLfpc6k0hlnkfCh89h6YrtJGjM/7h0Ld2Jz+VPWGPfm4JkPYE4rSK5SakFLc5HwHoMuhC4nu5EM0ihQifNge9anibShr1gbU5QqdyybeldHus0TGzJ/3qQ3sAGEgH51VzNRSXKcH4U8IjSrt57x2eTBC7BgD3rsdN8q01a3clTHIfKkBHY1ObuHlVh/DNVr67QRAovIIPWgfKoqyOiv7GBSfssaLKnIYJjb+NbfhzxAUi8m6JBT5Gz2rIsbhfKb5V5bJz7CucN6YdSnk58styB/hUx0dgiro9bOpQRqcspjPP8An3rjvE+rRPckQRoZR0B6L7n39q5c6tczI4R/KtkP3s8msuS78wkJt8j+dNlLQsXN1mVijmS5k+9KR/L0qhKHRN0J+71HpTZGCZyVzjOz1qq8pMmSPmAwNtToNK+ois2SzE5znmrtpdb/AL4+YelUFQyKW+X5PWrCWrzYPkhEz97JyaVzTlLk0+Fw5LMfugVDFayO4acY/wBjNaWnWcVsu/bz7+tTpHmYseh5+tK5agyg1sBnanXtmq0tsUIOAeeK12Q+Y5x05rNut0kqRRhcZyx70JmiiIcE5I6D0qjMoBzmtVw23kL+NY140ib/AJQFz1rQlQOL8fcxQH3opPHaBbW0dDkMTiimtjzKy99ne/ss4/4STUQf+eA/nX0lPGMEvXzV+y9Gz+IdSCdfIH86+kn37dkjAkGuarT5mexgnamiK2g8x8yE4+lWJofLUtG5Ydxt6GrAt02gnr70sijyyFxxWLhY6HPmZkXO4yDadv1qjdRtyd2SenvWnIjc/KPyrPkjPmZJ/WqgiHIoKzY/eAbfY1578cEjbwDqLhSHUxDP/bVa9KKDJyfyrmvHGk22reH7myuw3kyAB2QkEYIII98gGtLWaZErzjKK6pnIeI3X/hKfh8H5HnnA6dY1GKm+Jpi/4SfwaqKsbNqSkf3iABkn8xUv/CGWV3o9tYanqGo3QhZZYLoygTwMBxtbHQe/+FXrL4eadJe2F9d6jq19qFrMsqTzzh246Jgjhc9hgk9TVqxThU1Vt7Pftb/IzvCFvZv8a/Fk0wX7TDb25hLDLAGJNxHv90Z96NVf7D8Wddk0PCyv4fae5C/8/Ab5Cf8Aaxt/M1pXvgDT7/xFe6nFd6nZ6lcFAtzazBDFtULheOhA5Bzntit/wl4KsfDpuik1xd3Vywa4u7iTfNKR0yfT2qnJEKjNvlatq3c8w+HNn4vfwZZzaHH4XbT5AxLXPn+Y7biG8wjgtnj6Adq3vh1pNzpFnqf2yfSpVe9Z1g06UvHbsfvR4PK4P8Pata++G+nxT3LaDq2t6TBcuXmtbK52RknqQpB2n6flir2naVp3h/w22k6fAI9hLNubczuerMe5OP09KhzXQ0o4eSaUunn+R0VjdxCJZ8gYHNY17P8AbA1xcSHyhJ8uTkAfSqNq8jWqW4XaTywzU8kAe1uIcZyOPrSbvqEqaTsU9SMcex7eVJIs5ztxg1heJvEVnYRRfb7oRg9FI5I9K3LSKxl0SX7TdSjVEJ225iHlAZ6lv/1V5J8RdFv9TvILqyjM8YUptUYxz1xRFc0rMK83Spc1NXZ29vLaa3pbmKYTW8ylCQ33c1xulfDoQ6tHLLdCS2RtyrtwTjsa1fh1pV5oulTG8YQvKwYIecV1SuZHJOTx/njpW1+XQ832ftrSktR/lzBNqXTRZ6rGeMepqaLYEBRTIv8AekO2qMl0Iwdh57//AF6rPM0ny5yO3ep5jZUye8WMgnzMuO64AqnJIdp2ZK9896WdHkVB90k/d9frTJ3EPEqxiMd/6UrofKOs4ioL7QHbr0FTPtjyXZdvuayZtTk5W1TYnZiKgt5CzZlYsSOpp3IlHqakl5AD1LEdgP60gvVAO2Bge1VtoEZJxikQ88fIv86dyLaF3zpvsxmVYlTdswXG4nGfudce9Ubq7k2bdsYyQOnvV0XeNKnt/s1tIZGBNyYsyRgcYD9hWOY3uJwka5I5Zuyp3JovqJLudNZ3axafczM/yZ2Lx1rEeTe5d8lDzj+//wDWqO5kAxAzZijOAB0c+tQlmY5HX6UxN9CaSd5eXOxAPlTsKjed9gizgIOBjpQGEahVBNDwNLIpXIj9SMUAkVypCnG/r97HWpLe2MvGD+P8P1rRhs4y37kYzz83JPvjsK2F08xxD5eT0J61DZ0Qpt7mdaWcUSb5R5jdBmrqRFsFxj0QVaW1WPOWAIxV2GCP5No5FZ3NlTSM5Imkbaq5HepLiIJH1GT2zWhcqOUTmSsy5RkwT1HAAouOxWuGDIQg/eH7gPaq8MYIAXaX9ccGtaG0jjR5eTIy9aqqnlROXAwAa0Qm+xmSySNK0RjyiHGao3aYVwueO1X0+RSwYHOXJqpcL5hyOS3UU0Qzz74iERyWUPcRlyM9MmiszxrOs+rSFPuIfLT6CitUjyK0vfZ6j+yvkeJNSK9fIH86+lJImlYsq5Yd8V80/st5PiLUgv8AzwH86+mECxg5NZTWp6eGnakJHOhTa5+cdjTDNiT5sVFMsUhJVQPequwhjsbPqDUtGyaZbkkzn+7WVct8x7qfSpZZSi8gp79arXCq480NmouaWK0m8kkYCVBew+bauhOVIqeRiBg8+1MC7o3zlfQUpajRzG9gBCzKJE6Z9O1a1vcHy4y7HKDBwM5rNuVT+0C6naAMED1qaWJoF3J1xk+poUu53U1dHUeSEUPC0M+VBLoOntVvKS264bBx2JFYNneRQW0bSSSR+8q/KT9RVmC5hnyIymcZBPf6VTDkcRLxVjPztvGOM9BWNeo00x2lY0I5GMk471vzQ24UPOu89uazCUvLp/l/doMAA9ahRE6hhPm0mV1yQ/Jz6VopMRHldpJ7DvVPWJN0HlnaADwB/jUbmRLSFEJBKg4x1q76HNUV2Y+oXayxSxbf3hkHP86orMhkLRp04XPpUV1k3kpkPfH+/UakHC55J7DnFVBJanPVqN+6WF3SkueEA+aQnpTDOCdkPAPrUc025QsY/dp6dzSRMoPz4AUZqZszirk6KmeSJH60PPuY7NrY6Be1Qojyuc7hH0C9KddTxwxfIoLdk96i9jSwk8y2g3TkSXB/1ceegrKffNLunYsewxwPpUe75zJIcuTyTSmTqNvPbvS3EBTBIPSoySrkqenWmO2xdxA56UKrEq2wnPIA44q4aEMtwzFkIx07Vo6VZT6pcyQ2oj8yKF5mDNj92vU9OaofZ8kj7pxxg1MVManjg8HPcVoZPyIJriYWxg86RLaVgWTJ2OR0JHfFbVraWel2sWoeIFzbyHzIdP6SXY5QliPu44OMHrWVb3kdpfpMtvHczgFIo5Om88ZP0rSuYrbSJpNU8YML3WSc/YJPnAPQiUfqCB2NBlPfQ559wZ1dGSTOdkgII7jim7meURQgl2/DH1rd1RL7U5o9T8V3M1rEYvLtYjHm4MeMpgHAI96s+GdKW2geaQE3Ev8Ay0xtwKteY1qVdN0pgnrIerAVppp6x/3TnuOgrZS0XywAuU6ZHVjUrxAL0yAOtZykdlOCMiGERvkLyPWrgiYqrFeewz096tw2nzKXT5jzt9K0EtvMfc/NZXNmYa2x346IOT7VYWLYCwPNaHl5l+ZcLTZ12KSOh9ulMVzGeNvM3Lnn8KLj5Ytyc84q35fyHb+PHWqV63lmFeQXPftVRB6kssq/Z/KjwZDxj0rOvCqxOp4OME1oz4jgQKM45LYrG1Lc8UjZxsYOferMkihOojXylYfKOuKoXtylrZXNy5H7qMgf756VoTZLA9FZc1ynja4EVlb2KHMkh82X6DoKtGNaVonnmsElUJ6nmil1rpHRWp5DPWP2X38vxHqR/wCmA/nX0mZ8qa+Y/wBm1iniC/8A+uI/nX0VFP1zms2j0sP/AAy67ZUmoon2NyOtVDcFvug49KZ5jYxwAahtHRZmnMyFDu6H2rEum8hyYvudxV+I7o8eYfwqhexgA/Pn61g9zpp2tqVIpCxJQgmrErCO3dn+/jvWdH+7bMf3/wBKJt8g/fNkeh6U+gmtTMtv3rFierE81rTpCyo0i5Udt1ZiOIJpFKoyfTpV20mC5Lr8poWx1xbG3KyFMWrKUPUE9qNELhX8yRFO47fl4xTb69iiQjHXvVZGgjXPBH3yc9DRF2N27xsauo30UQ/eKr44wM81nfaSEEeP3h7A9K5291mN7oqjnZ2bBxTvtBY7Ub5H6svU1a1OabitCzOTd3u1DlEPJ65q1q9zHBBmQ/PGuF7Ef/WqKzvIdPt2eMIJTwpJOR+Fc7q921xLtPPOW/8A10/I56jb1ZHdNugPmcnOePWq8K7S+euOtKWPDE5x0welN24OFxzz+NTJ2ZypNjzt+4PmPpSQoBLnrgcemaikJJJC9KchAx646+1ZtlpWLDP1ySR9aypJd0pJPA4XPSrFzMUiYZ59M1mqoODmpWpVywGBBVxwccjjFO+xsGRl+dCPl7H8KZbP5dzGxVCUOQCMjPv61M7lpjvXl8k4GBXQloZN9hIYUUbpgwIPRl71cAjxhcEnqapiTGdh+XuFNPVkPG7YvfcOadjNksRxIV3/ACjpn0oeRd3H3e9QFhuwjE49eKYXwcAkk0JAQkyQXKzwSMjqflK9fzq9aONKIv5YFutQbmFp2P7o/wB8DofxqiXyy8HAOeeKdCrXV0Xk+rUFRhfctwrLc3KzzkyysSTxgR/QdK7KwVBbgSck9s15v48mmtPDck9pPJDIskYVomKsoPuK9HsTnb8uT0J7U+YuMbycexr26LKVMn3B+tTbd0pO0FF4CetebeHPETabbeNL3U72UxWuoyRQGQs6xnJCqAM4GcDHSui+F3iax1jw19ovL5ZNQtIy96XQosRZnKnJAXG1e3TFRKLZUa0bpHWrH1j25lbkj0FTy/uEwOSRj/GuYs/iJ4TmvvJTVFEsjbVmeJ0iZvQORj8TxV/xH4i03RJ4l1e7S2Eu7y2IYhtoyegOOPXr9aXKx+0jJXuXTlmJK7SecegqKTZITv5VRWRZeMdEvYbJre6kDXsrQQBoXUs6gEjlfQjk8VY1fU7PT5LWK8l8qe8fyoVUE7nPbgcfjinZjU4tXTLMMeIs9KoXqr9pgXbnJ5qhrni/RdDmFreXeLnYCYkjaRkHq20HFXtLvbLVLQX1lcRXFtJ0kU+nYg8g+xp8pCmm7JlbXbhoAIowT8vJ9BWJct9ogZB/qjjkfxVq6nGscc5yTlepPWsrYBbbT8uevNM00S0KaNGkUrEsMHhjz8gHJrzfWr1tR1Oa5OVRziPPZB0rrPFt6bLT/scLfvbn5SM8hO/51wx4rWJ5uKqXdjM1rpHRTdY6JRVnCeofs4f8jBf/APXEfzr6GJQ/dWvnz9mpFbxDqAP/ADx/rX0WY19Klo9HDy90qeWx52mkMTHNXN+0Y+WkRsn7tYysdSkVPKYdvxrOv1zPtGQprZuGUKemTWJM26Y1zN6nVTvYaiIiBe/55qWC3UnMnWmKoxz+tTQkt9KtIljJtONwf3Y24/iqodNu/N8lQDjvmuo0WCO4uYoXLBHOMgjj86drVu2l30kDo2wKDGZCpJH4VfJbclYhp8iOH1W1mtk3XPluE6Yrlr+5nucqzYj6ADvW74nvTJP5fY9cVzkhAlKqPk/KhRG603oyCSNVj3fxJWlpFxbSAeZtB9T3qg5yxwR6ZzVW8TBBTIx371SkluQ1fY6LULu0gjYFkDMPlBbNYBUOxZ1X6GvI/EU16dbn855d4f5OT07Yr0rQZJ20q2N2T5vlgnPWra6nHCs5ycWti/tCSZ6UibfMO7vTWJL5b86WJlB5H0Fcs3Y6qYOAPv8AU0hU5Oe3apH9V4qN2GzAPSsuY0sULxsA/wAs81VZiY/kP4+lSXzZTnke9Vcj5SK3hsYyLQyibSOoz8tads9t9iQzTs97I3+pMXCR/wB7zM/pj8azbcmTLF9xJ5z3qX5eCn3uv1rXmWxDVzQ8tN3yr156VE8CS/w/TFVEmZc81MlwhwNu315o0FqU3Z4JTG446j2pWkAQ7QSTzz1q3cSLKqRHZsXPO0A81k3LtuIJPp9Kd7hbsTNtRVbqTWxYRNHbjcPvc/UVjwqOp+6ABwK6G3Tag+79PSkzogjn/iNBI3gyd9ufLkQsew5xx+dekaR5VxaxTqwaOVQ64PGD3rEFvFewPb3SLJC6lTGw4I9Kyofh9aBTbRaxrMVifvW0dzhPpjHT61KaaswcZxm5RV7/AKEnw8ZZrHxzdQc2899cGNuzLgnj8CKxb+4kT4F6TFGyBJJkSYuSF2eax5xzjIXOK9O0TTrHS9JGnWMKx2YUqUx9/PUk9yfWsLRvBtnptrfadJc3l7o86+WlpdMGVOScjAGOTnI+tWpK5l7CVkvJr7ylq9n4w1DwzPY3qeC49J8kgnE6rEoHDA9FwOQegrP1SzWS6+HFjfzQXrRzFZJom3pJtVcEE9RwOe9a8vw/skhjs5tZ1q40pMH7A91+6OOi8AHHtW1daBYXVxos2ZIpNMYvCkWAnIAwRjoAO2KfMiPYye67dfMwvHkiyeMvBxACoLqRR7/KKpfEKbd4k8KRnA/4mAYD1HGf5/rXUeKtCsdf06G2ufMjkicTQzQvteIjuDXP2ngyya+tL27vdSu7y0lWUTTyhicdF5HC+wwaE0aThLVJb2/QoXVjqun+JNWv/CV5pt957p9stJmG+NwOBuHTv1I+hxV/wNqNtcJqVkmlLpN7bz77u3DblLv/ABA++3oOnHarOr+E7XUNUm1Gyu77TLuQBZpLSXYswHTcMcmptI0Oz0O0njgM0ssz+ZLNO++SVvVj3p6WMVCSl5DtQkVzleTnv0zWO7+XLJJcOEtIgST6Acmrt85cIFCJsOT61xvj3U1DLplsenz3GP0T+tCRrVqKETmdXvX1LUpbp/lVziNf7qDoKzz1/lT2OCRTDjPStrHkznzGXrHRKKbq38FFBmeqfs1/8jBf/wDXEfzr6MjQ4ya+c/2af+Rh1H/riP519Hr93FSztov3RCqnioQgQ4FTSfInG38aqFyzCuaoztpxEkVieTVG4t+c55rTT7uT1qOTBU8Vz2udKZlbDyNtS26Zk+6alZV/hFWLWJiedq+1VHcbLlvGUjwT7ZrK1yaZ5QS2cDZyegrUkPkxnc2RWDqM4k4xW+pnoc1rEAILHGeua5l2x3rd1y5KOYkOfXNc7Mxbv060rCHI5aTkjrUk2Hic9dnvVOIndjPHel1Cf7Jp08wTcY0Jx64FTcp6K5Sa3jlbLxIzjoSoOKnyyLyuV9a860/xPfnUlMhDRSMAUA6A+ld+kuVxnFXJSiclOpGpdxJt3HpUiH5cdvQ1ULYHGMj3p8b9M1zz1OhFzf7gHHNQSHHB5H1oznnv/Oo5MnO4Z9ayRpYqXSZU8rk8detUyvyfp17VffaSd3I7iqL5GflOelbwkZSQsM2w464P0q1v+XORyazyRu+7U6yHrn/61UzMmyTt4znpS+W54wSAMnAqNZD+OPSgzHoCRk9RxQmFgLtk/wAJ9zVVcPON556mlmP8KjGep9abZ/fkJGeOua1QdS/aAySp1IznnqK3kYEjuvpzWHYL8ytwABWxacnPYe/SobOmnHua9oxNyVT5M9fWtZP3eAp471kWbLGdz8virizqZQSRgGpubWNMyERHhR6k1F9rwRn3OKhdvNX5idntUMuAzk5yBlfQ0gVjRd5ZJIxnJPP0FTLs80lTkY2Csu3nMEX7zh8dahiuDCUzy0hycHpWqM3BmjNIVujg71HFSBQiBR3O4isyKbzbgt05q7vxyOvqaozloK+UL/NhM4rPvHJcsp2DsKmvJNkO1McdSaw9WvobSykvL9sQKMKo/wCWh9BVmUny6mX4i1SPSbaSUbXuZlIiTsPfjsK80kLOxZyS7HJPcmrerX82p3klxcd+FjHRE7AVQNWlY82tV52I/SoyecU9uM81E3WrOdmdq38FFGrfwUUhHqX7Np2+Ib8/9MR/Ovo052/L1r5w/Zxx/wAJDf8AI3CDOM84zX0R5ox1FRNndh9hk03BDnFRK2G/2aSZg2c0yMYrlaPQgWs/LUcroBzUbviqsx3Er2qFFs0ROsiEnbV+G0uvKMzoREv8WOB9ao6VCTKGX14zXQ3+pEaf5Ua7JOh2scOPf1rfkUFczlJt2iYF7MRkHtXO6lcsI3I6/lV+6diSCa5/WJhFERxk96zu2Vsc/MTLKzucn/vmqsgByTt21Oc7Dz7n3qnLJgEE/WmwihkJAbIIx9atMFaJ43AZSMEGqceemO/SpWOYWCbc44xWbLsc3H4f0+2vvPijG7O5QTkL+FaJ+9jhT25rzS6kvv7WkLtL9p8wjHPr0FelxIxgjM339o3fWtpxaSuzjw9SM7qMbWEz77aFODwT+JpjMA2Mjn3pruiDJZEHqxxj86waN9i8jZ+U+lKf9lec5qhFe2uMfarcf9tk/wAal+3WgXH2q3x/11T/ABrFxdy1ND5Cf90dDVZ0JycUr31tnm5gPqPMT/Gq73ttj/j5tx9ZF/xrWKaJbRDN8hJ9aRW3f5xUc95bn7txD7bZR8v601Li3/5+IVx0/ep/jWyvYxbRcQdRjp60E469aq/arf8A5+YP+/if40/7VbH/AJeID/21T/GnysnmQOS3qQafb8CTao54NQm6tyvM8P18wf40kVxbjP8ApEP/AH9H+NGpSsbNsAEHcY5zWxZnMZbJz9KwUu7Tg/abfj/pqn+NaVpfWYJ/0u2/7/J/jU2OqDVtzooXBTPyqoqSFt7E4/Os1L/T2QZvLNcD/nvH/jRDqFkJcm/tPp58f+NLlL5kbyssSYLVVlmy5UYXPaqT6jZE/wDH/a9e88f/AMVTI76xfzGe/swB0Bnj5/WnZiuu5fdkZgDheOarvMplLZUeX6nGKoPfWZQL9vsuepM0fH05qqbqxmkzJf2xA7GaPn9aC7rudDbyK8RfPFWlbp698VzVnqtoWG+9tlTrjzk4H51opqunLHLJNqFnHEgyx85D/I5rVI5as0iTVrlILaSaeRYreMfMx9K8s8RazJrF1uIMdpHkQxeg9T7mpPFniX+27rbG6R2Ef+qj3DLe5rAM0X99P++hWsYHnVq3NoiQnNRE0hkjP/LRP++hTTJH/wA9I/8AvoVZxgaQ0xpI/wC/H/30KTzY/wC+n/fQphcoap0Sik1NlYJgqfoaKQj/2Q==);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Superior view of the ureter during laparoscopy. Dots represent the course of the ureter.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Thomas Lyons, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f39_21_40287=[""].join("\n");
var outline_f39_21_40287=null;
       